<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02055976</url>
  </required_header>
  <id_info>
    <org_study_id>B1481036</org_study_id>
    <nct_id>NCT02055976</nct_id>
  </id_info>
  <brief_title>Dose Ranging Study Of Bococizumab (PF-04950615; RN316) In Hypercholesterolemic Japanese Subjects</brief_title>
  <official_title>A Phase 2 Double Blind, Parallel Group, Placebo Controlled, Randomized, Dose Ranging Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 Following Twice Monthly Subcutaneous Doses In Hypercholesterolemic Japanese Subjects Who Are Receiving A Stable Dose Of Atorvastatin Or Treatment Naïve.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the low density lipoprotein cholesterol (LDL-C)
      lowering effect of Bococizumab (PF-04950615;RN316) administered subcutaneously at every two
      weeks (Q14D) in hypercholesterolemic Japanese subjects whose LDL-C is not controlled by a
      stable dose of atorvastatin, or who are naïve to a treatment by lipid lowering drug and whose
      LDL-C is not controlled.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2014</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change From Baseline in Fasting Low Density Lipoprotein-Cholesterol (LDL-C) at Day 85</measure>
    <time_frame>Baseline, Day 85</time_frame>
    <description>LDL-C is cholesterol in the bloodstream that is carried by low density lipoprotein. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value. Percent change from baseline = ([observed value divided by baseline value] minus 1) multiplied by 100.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent Change From Baseline in Fasting Low Density Lipoprotein-Cholesterol (LDL-C) at Day 113</measure>
    <time_frame>Baseline, Day 113</time_frame>
    <description>LDL-C is cholesterol in the bloodstream that is carried by low density lipoprotein. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value. Percent change from baseline = ([observed value divided by baseline value] minus 1) multiplied by 100.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Low Density Lipoprotein-Cholesterol (LDL-C)</measure>
    <time_frame>Baseline, Day 5, 8, 15, 22, 29, 36, 43, 50, 57, 71, 85, 99, 106, 113, 127, 141, 155, 169</time_frame>
    <description>LDL-C is cholesterol in the bloodstream that is carried by low density lipoprotein. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) at Day 85 and Day 113</measure>
    <time_frame>Baseline, Day 85, 113</time_frame>
    <description>LDL-C is cholesterol in the bloodstream that is carried by low density lipoprotein. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value. Change from baseline = observed value minus baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Cholesterol (TC)</measure>
    <time_frame>Baseline, Day 5, 8, 15, 22, 29, 36, 43, 50, 57, 71, 85, 99, 106, 113, 127, 141, 155, 169</time_frame>
    <description>Total cholesterol is the sum of all the cholesterol within the blood. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Total Cholesterol (TC) at Day 85 and Day 113</measure>
    <time_frame>Baseline, Day 85, 113</time_frame>
    <description>Total cholesterol is the sum of all the cholesterol within the blood. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Total Cholesterol (TC) at Day 85 and Day 113</measure>
    <time_frame>Baseline, Day 85, 113</time_frame>
    <description>Total cholesterol is the sum of all the cholesterol within the blood. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value. Percent change from baseline = ([observed value divided by baseline value] minus 1) multiplied by 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apolipoprotein B (ApoB)</measure>
    <time_frame>Baseline, Day 5, 8, 15, 22, 29, 36, 43, 50, 57, 71, 85, 99, 106, 113, 127, 141, 155, 169</time_frame>
    <description>ApoB is a major protein that makes up LDL cholesterol and is involved in transporting cholesterol and triglycerides to cells and tissues in the body. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Apolipoprotein B (ApoB) at Day 85 and Day 113</measure>
    <time_frame>Baseline, Day 85, 113</time_frame>
    <description>ApoB is a major protein that makes up LDL cholesterol and is involved in transporting cholesterol and triglycerides to cells and tissues in the body. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value. Change from baseline = observed value minus baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Apolipoprotein B (ApoB) at Day 85 and Day 113</measure>
    <time_frame>Baseline, Day 85, 113</time_frame>
    <description>ApoB is a major protein that makes up LDL cholesterol and is involved in transporting cholesterol and triglycerides to cells and tissues in the body. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value. Percent change from baseline = ([observed value divided by baseline value] minus 1) multiplied by 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apolipoprotein A-I (ApoA-I)</measure>
    <time_frame>Baseline, Day 5, 8, 15, 22, 29, 36, 43, 50, 57, 71, 85, 99, 106, 113, 127, 141, 155, 169</time_frame>
    <description>ApoA1 is a major protein that is a component of HDL cholesterol and helps in clearing cholesterol from the blood by removing cholesterol from organs and tissues to be destroyed by the liver. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Apolipoprotein A-I (ApoA-I) at Day 85 and Day 113</measure>
    <time_frame>Baseline, Day 85, 113</time_frame>
    <description>ApoA1 is a major protein that is a component of HDL cholesterol and helps in clearing cholesterol from the blood by removing cholesterol from organs and tissues to be destroyed by the liver. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value. Change from baseline = observed value minus baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Apolipoprotein A-I (ApoA-I) at Day 85 and Day 113</measure>
    <time_frame>Baseline, Day 85, 113</time_frame>
    <description>ApoA1 is a major protein that is a component of HDL cholesterol and helps in clearing cholesterol from the blood by removing cholesterol from organs and tissues to be destroyed by the liver. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value. Percent change from baseline = ([observed value divided by baseline value] minus 1) multiplied by 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apolipoprotein A-II (ApoA-II)</measure>
    <time_frame>Baseline, Day 5, 8, 15, 22, 29, 36, 43, 50, 57, 71, 85, 99, 106, 113, 127, 141, 155, 169</time_frame>
    <description>ApoA-II is the second most abundant component of the HDL cholesterol. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Apolipoprotein A-II (ApoA-II) at Day 85 and Day 113</measure>
    <time_frame>Baseline, Day 85, 113</time_frame>
    <description>ApoA-II is the second most abundant component of the HDL cholesterol. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value. Change from baseline = observed value minus baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Apolipoprotein A-II (ApoA-II) at Day 85 and Day 113</measure>
    <time_frame>Baseline, Day 85, 113</time_frame>
    <description>ApoA-II is the second most abundant component of the HDL cholesterol. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value. Percent change from baseline = ([observed value divided by baseline value] minus 1) multiplied by 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipoprotein (a) (Lp[a])</measure>
    <time_frame>Baseline, Day 5, 8, 15, 22, 29, 36, 43, 50, 57, 71, 85, 99, 106, 113, 127, 141, 155, 169</time_frame>
    <description>Lp(a) is a lipoprotein subclass which consists of an LDL-like particle and the specific apolipoprotein(a). Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Lipoprotein (a) (Lp[a]) at Day 85 and Day 113</measure>
    <time_frame>Baseline, Day 85, 113</time_frame>
    <description>Lp(a) is a lipoprotein subclass which consists of an LDL-like particle and the specific apolipoprotein(a). Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value. Change from baseline = observed value minus baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Lipoprotein (a) (Lp[a]) at Day 85 and Day 113</measure>
    <time_frame>Baseline, Day 85, 113</time_frame>
    <description>Lp(a) is a lipoprotein subclass which consists of an LDL-like particle and the specific apolipoprotein(a). Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value. Percent change from baseline = ([observed value divided by baseline value] minus 1) multiplied by 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High Density Lipoprotein- Cholesterol (HDL-C)</measure>
    <time_frame>Baseline, Day 5, 8, 15, 22, 29, 36, 43, 50, 57, 71, 85, 99, 106, 113, 127, 141, 155, 169</time_frame>
    <description>HDL-C is cholesterol in the bloodstream that is carried by high density lipoprotein. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in High Density Lipoprotein- Cholesterol (HDL-C) at Day 85 and Day 113</measure>
    <time_frame>Baseline, Day 85, 113</time_frame>
    <description>HDL-C is cholesterol in the bloodstream that is carried by high density lipoprotein. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value. Change from baseline = observed value minus baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in High Density Lipoprotein- Cholesterol (HDL-C) at Day 85 and Day 113</measure>
    <time_frame>Baseline, Day 85, 113</time_frame>
    <description>HDL-C is cholesterol in the bloodstream that is carried by high density lipoprotein. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value. Percent change from baseline = ([observed value divided by baseline value] minus 1) multiplied by 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Very Low Density Lipoprotein-Cholesterol (VLDL-C)</measure>
    <time_frame>Baseline, Day 5, 8, 15, 22, 29, 36, 43, 50, 57, 71, 85, 99, 106, 113, 127, 141, 155, 169</time_frame>
    <description>VLDL is a type of lipoprotein made by the liver and one of the five major groups of lipoproteins, that enable fats and cholesterol to move within the water-based solution of the bloodstream. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Very Low Density Lipoprotein-Cholesterol (VLDL-C) at Day 85 and Day 113</measure>
    <time_frame>Baseline, Day 85, 113</time_frame>
    <description>VLDL is a type of lipoprotein made by the liver and one of the five major groups of lipoproteins, that enable fats and cholesterol to move within the water-based solution of the bloodstream. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value. Change from baseline = observed value minus baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Very Low Density Lipoprotein-Cholesterol (VLDL-C) at Day 85 and Day 113</measure>
    <time_frame>Baseline, Day 85, 113</time_frame>
    <description>VLDL is a type of lipoprotein made by the liver and one of the five major groups of lipoproteins, that enable fats and cholesterol to move within the water-based solution of the bloodstream. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value. Percent change from baseline = ([observed value divided by baseline value] minus 1) multiplied by 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglyceride (TG)</measure>
    <time_frame>Baseline, Day 5, 8, 15, 22, 29, 36, 43, 50, 57, 71, 85, 99, 106, 113, 127, 141, 155, 169</time_frame>
    <description>Triglycerides are a type of fat circulating in the blood and account for the majority of the fats circulating in the blood. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Triglyceride (TG) at Day 85 and Day 113</measure>
    <time_frame>Baseline, Day 85, 113</time_frame>
    <description>Triglycerides are a type of fat circulating in the blood and account for the majority of the fats circulating in the blood. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value. Change from baseline = observed value minus baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Triglyceride (TG) at Day 85 and Day 113</measure>
    <time_frame>Baseline, Day 85, 113</time_frame>
    <description>Triglycerides are a type of fat circulating in the blood and account for the majority of the fats circulating in the blood. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value. Percent change from baseline = ([observed value divided by baseline value] minus 1) multiplied by 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)</measure>
    <time_frame>Baseline, Day 5, 8, 15, 22, 29, 36, 43, 50, 57, 71, 85, 99, 106, 113, 127, 141, 155, 169</time_frame>
    <description>Non-HDL-C calculated as total cholesterol minus HDL cholesterol. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Non-High Density Lipoprotein- Cholesterol (Non-HDL-C) at Day 85 and Day 113</measure>
    <time_frame>Baseline, Day 85, 113</time_frame>
    <description>Non-HDL-C calculated as total cholesterol minus HDL cholesterol. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value. Change from baseline = observed value minus baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Non-High Density Lipoprotein- Cholesterol (Non-HDL-C) at Day 85 and Day 113</measure>
    <time_frame>Baseline, Day 85, 113</time_frame>
    <description>Non-HDL-C calculated as total cholesterol minus HDL cholesterol. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value. Percent change from baseline = ([observed value divided by baseline value] minus 1) multiplied by 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio</measure>
    <time_frame>Baseline, Day 5, 8, 15, 22, 29, 36, 43, 50, 57, 71, 85, 99, 106, 113, 127, 141, 155, 169</time_frame>
    <description>Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio at Day 85 and Day 113</measure>
    <time_frame>Baseline, Day 85, 113</time_frame>
    <description>Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value. Change from baseline = observed value minus baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio at Day 85 and Day 113</measure>
    <time_frame>Baseline, Day 85, 113</time_frame>
    <description>Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value. Percent change from baseline = ([observed value divided by baseline value] minus 1) multiplied by 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio</measure>
    <time_frame>Baseline, Day 5, 8, 15, 22, 29, 36, 43, 50, 57, 71, 85, 99, 106, 113, 127, 141, 155, 169</time_frame>
    <description>Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio at Day 85 and Day 113</measure>
    <time_frame>Baseline, Day 85, 113</time_frame>
    <description>Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value. Change from baseline = observed value minus baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio at Day 85 and Day 113</measure>
    <time_frame>Baseline, Day 85, 113</time_frame>
    <description>Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value. Percent change from baseline = ([observed value divided by baseline value] minus 1) multiplied by 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Low-density Lipoprotein Cholesterol (LDL-C) Less Than (&lt;) 10, 25, 40, 70 and 100 Milligram Per Deciliter</measure>
    <time_frame>Baseline up to Day 113</time_frame>
    <description>LDL-C is cholesterol in the bloodstream that is carried by low density lipoprotein. Fasting was required at least 10 hours before blood sample collection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-Emergent Adverse Events (TEAEs) or Serious Adverse Events (SAEs)</measure>
    <time_frame>Baseline up to Day 169</time_frame>
    <description>An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. TEAEs are events between first dose of study drug and up to Day 169 that were absent before treatment or that worsened relative to pretreatment state. Adverse events included treatment emergent injection site adverse events and any clinically significant abnormal laboratory value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Anti-Drug Antibody (ADA) Response</measure>
    <time_frame>Baseline up to Day 169</time_frame>
    <description>Participants tested positive for ADA response on at least one post-baseline visit were reported. Participants with ADA titer level &gt;=6.23 for PF-04950615 were considered ADA positive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of PF-04950615</measure>
    <time_frame>Single dose (Day 1: pre-dose, 24, 48, 72, 96, 120, 144, 168 hour (hr) post-dose), Multiple dose (Day 99: pre-dose, 24, 72, 120, 168, 336, 504, 672, 1008 hr post-dose)</time_frame>
    <description>Area under the plasma concentration time-curve from time zero to end of dosing interval (tau). This outcome measure was to be analyzed in participants who received at least 1 dose of the PF-04950615.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] of PF-04950615</measure>
    <time_frame>Multiple dose (Day 99: pre-dose, 24, 72, 120, 168, 336, 504, 672, 1008 hr post-dose)</time_frame>
    <description>Area under the plasma concentration-time profile from time zero extrapolated to infinite time. This outcome measure was to be analyzed in participants who received at least 1 dose of the PF-04950615.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of PF-04950615</measure>
    <time_frame>Multiple dose (Day 99: pre-dose, 24, 72, 120, 168, 336, 504, 672, 1008 hr post-dose)</time_frame>
    <description>Area under the plasma concentration-time profile from time zero to the time of the last quantifiable concentration. This outcome measure was to be analyzed in participants who received at least 1 dose of the PF-04950615.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of PF-04950615</measure>
    <time_frame>Single dose (Day 1: pre-dose, 24, 48, 72, 96, 120, 144, 168 hr post-dose), Multiple dose (Day 99: pre-dose, 24, 72, 120, 168, 336, 504, 672, 1008 hr post-dose)</time_frame>
    <description>This outcome measure was to be analyzed in participants who received at least 1 dose of the PF-04950615.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum Observed Plasma Trough Concentration (Cmin) of PF-04950615</measure>
    <time_frame>Multiple dose (Day 99: pre-dose, 24, 72, 120, 168, 336, 504, 672, 1008 hr post-dose)</time_frame>
    <description>This outcome measure was to be analyzed in participants who received at least 1 dose of the PF-04950615.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-04950615</measure>
    <time_frame>Single dose (Day 1: pre-dose, 24, 48, 72, 96, 120, 144, 168 hour (hr) post-dose), Multiple dose (Day 99: pre-dose, 24, 72, 120, 168, 336, 504, 672, 1008 hr post-dose)</time_frame>
    <description>This outcome measure was to be analyzed in participants who received at least 1 dose of the PF-04950615.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Elimination Half-Life (t1/2) of PF-04950615</measure>
    <time_frame>Multiple dose (Day 99: pre-dose, 24, 72, 120, 168, 336, 504, 672, 1008 hr post-dose)</time_frame>
    <description>Terminal elimination half-life is the time measured for the plasma concentration to decrease by one half. This outcome measure was to be analyzed in participants who received at least 1 dose of the PF-04950615.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)</measure>
    <time_frame>Day 1, 5, 8, 15, 22, 29, 36, 43, 50, 57, 71, 85, 99, 106, 113, 127, 141</time_frame>
    <description>Concentration versus time summary was calculated by setting concentration values below the lower limit of quantification (LLQ =6.99 nanogram per milliliter [ng/mL]) to zero. Summary statistics were not to be presented if number of observations above lower limit of quantification (NALQ) =0. Here, 'Number analyzed' = Participants evaluable for this outcome measure at specified time points.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">218</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Population A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A total of 9 groups in two population. Population A comprises hypercholesterolemic Japanese subjects whose LDL-C is not controlled by a stable dose of atorvastatin. A subject who is receiving a stable dose of atorvastatin will be randomized into one out of 5 dose groups.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Population B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A total of 9 groups in two population. Population B comprises hypercholesterolemic Japanese subjects who are naïve for a treatment by lipid lowering drug and whose fasting LDL-cholesterol is not controlled. A subject who is treatment naïve will be randomized into one out of 4 dose groups.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bococizumab (PF-04950615;RN316)</intervention_name>
    <description>Atorvastatin plus PF-04950615 50 mg subcutaneous administration at every two weeks (Q14D SC) for 16 week</description>
    <arm_group_label>Population A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bococizumab (PF-04950615;RN316)</intervention_name>
    <description>Atorvastatin plus PF-04950615 100 mg Q14D SC for 16 week</description>
    <arm_group_label>Population A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bococizumab (PF-04950615;RN316)</intervention_name>
    <description>Atorvastatin plus PF-04950615 150 mg Q14D SC for 16 week</description>
    <arm_group_label>Population A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Atorvastatin plus PF-04950615 Placebo Q14D SC for 16 week</description>
    <arm_group_label>Population A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ezetimibe</intervention_name>
    <description>Atorvastatin plus Ezetimibe 10 mg oral administration once daily for 16 week (open)</description>
    <arm_group_label>Population A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bococizumab (PF-04950615;RN316)</intervention_name>
    <description>50 mg Q14D SC for 16 week</description>
    <arm_group_label>Population B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bococizumab (PF-04950615;RN316)</intervention_name>
    <description>100 mg Q14D SC for 16 week</description>
    <arm_group_label>Population B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bococizumab (PF-04950615;RN316)</intervention_name>
    <description>150 mg Q14D SC for 16 week</description>
    <arm_group_label>Population B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo Q14D SC for 16 week</description>
    <arm_group_label>Population B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects whose LDL-C is not controlled by a stable dose of atorvastatin (Population
             A).

          -  Subjects who are naïve to a treatment by lipid lowering drug and whose LDL-C is not
             controlled (Population B).

        Exclusion Criteria:

          -  Severe acute or chronic medical or psychiatric condition or laboratory abnormality.

          -  Pregnant females; breastfeeding females; males and females of childbearing potential;
             males and females of childbearing potential who are unwilling or unable to use a
             highly effective method of contraception.

          -  Subjects who were administered or prior exposed to PF-04950615 and/or anti-body
             targeting PCSK9.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maebashi Hirosegawa Clinic</name>
      <address>
        <city>Maebashi</city>
        <state>Gunma</state>
        <zip>371-0022</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yokohama Minoru Clinic</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>232-0064</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heishinkai Medical Group Incorporated OCROM Clinic</name>
      <address>
        <city>Suita</city>
        <state>Osaka</state>
        <zip>565-0853</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meiwa Hospital</name>
      <address>
        <city>Chiyoda-ku</city>
        <state>Tokyo</state>
        <zip>101-0041</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo-Eki Center-building Clinic</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <zip>103-0027</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heishinkai Medical Group Incorporated ToCROM Clinic</name>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <zip>160-0022</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Hospital Tokyo</name>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <zip>162-0053</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oda Clinic</name>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <zip>169-0072</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sekino Hospital</name>
      <address>
        <city>Toshima-ku</city>
        <state>Tokyo</state>
        <zip>171-0014</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1481036&amp;StudyName=Dose%20Ranging%20Study%20Of%20PF-04950615%20In%20Hypercholesterolemic%20Japanese%20Subjects</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>January 22, 2014</study_first_submitted>
  <study_first_submitted_qc>February 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 5, 2014</study_first_posted>
  <results_first_submitted>September 22, 2017</results_first_submitted>
  <results_first_submitted_qc>September 4, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">February 8, 2019</results_first_posted>
  <last_update_submitted>September 4, 2018</last_update_submitted>
  <last_update_submitted_qc>September 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PF-04950615</keyword>
  <keyword>Japan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ezetimibe</mesh_term>
    <mesh_term>Bococizumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Atorvastatin + PF-04950615 50 mg</title>
          <description>Participants with fasting lipoprotein cholesterol (LDL-C) level (greater than or equal to [&gt;=]100 milligram per deciliter [mg/dL]) received atorvastatin along with PF-04950615 50 milligram (mg) subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
        </group>
        <group group_id="P2">
          <title>Atorvastatin + PF-04950615 100 mg</title>
          <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 100 mg subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
        </group>
        <group group_id="P3">
          <title>Atorvastatin + PF-04950615 150 mg</title>
          <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 150 mg subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
        </group>
        <group group_id="P4">
          <title>Atorvastatin + PF-04950615 Placebo</title>
          <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 placebo subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
        </group>
        <group group_id="P5">
          <title>Atorvastatin + Ezetimibe 10 mg</title>
          <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with ezetimibe 10 mg tablet orally, once daily from Day 1 up to Day 112. Participants were on self-administered stable background atorvastatin therapy.</description>
        </group>
        <group group_id="P6">
          <title>PF-04950615 50 mg</title>
          <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 50 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naive to a treatment by lipid lowering drug.</description>
        </group>
        <group group_id="P7">
          <title>PF-04950615 100 mg</title>
          <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 100 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naive to a treatment by lipid lowering drug.</description>
        </group>
        <group group_id="P8">
          <title>PF-04950615 150 mg</title>
          <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 150 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naive to a treatment by lipid lowering drug.</description>
        </group>
        <group group_id="P9">
          <title>PF-04950615 Placebo</title>
          <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 placebo, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naive to a treatment by lipid lowering drug.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="24"/>
                <participants group_id="P4" count="26"/>
                <participants group_id="P5" count="22"/>
                <participants group_id="P6" count="25"/>
                <participants group_id="P7" count="25"/>
                <participants group_id="P8" count="24"/>
                <participants group_id="P9" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="23"/>
                <participants group_id="P4" count="25"/>
                <participants group_id="P5" count="22"/>
                <participants group_id="P6" count="24"/>
                <participants group_id="P7" count="23"/>
                <participants group_id="P8" count="24"/>
                <participants group_id="P9" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Does not meet entrance criteria</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety analysis set included all randomized and non-randomized participants who were administered at least 1 dose of study treatment.</population>
      <group_list>
        <group group_id="B1">
          <title>Atorvastatin + PF-04950615 50 mg</title>
          <description>Participants with fasting lipoprotein cholesterol (LDL-C) level (greater than or equal to [&gt;=]100 milligram per deciliter [mg/dL]) received atorvastatin along with PF-04950615 50 milligram (mg) subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
        </group>
        <group group_id="B2">
          <title>Atorvastatin + PF-04950615 100 mg</title>
          <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 100 mg subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
        </group>
        <group group_id="B3">
          <title>Atorvastatin + PF-04950615 150 mg</title>
          <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 150 mg subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
        </group>
        <group group_id="B4">
          <title>Atorvastatin + PF-04950615 Placebo</title>
          <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 placebo subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
        </group>
        <group group_id="B5">
          <title>Atorvastatin + Ezetimibe 10 mg</title>
          <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with ezetimibe 10 mg tablet orally, once daily from Day 1 up to Day 112. Participants were on self-administered stable background atorvastatin therapy.</description>
        </group>
        <group group_id="B6">
          <title>PF-04950615 50 mg</title>
          <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 50 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naive to a treatment by lipid lowering drug.</description>
        </group>
        <group group_id="B7">
          <title>PF-04950615 100 mg</title>
          <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 100 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naive to a treatment by lipid lowering drug.</description>
        </group>
        <group group_id="B8">
          <title>PF-04950615 150 mg</title>
          <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 150 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naive to a treatment by lipid lowering drug.</description>
        </group>
        <group group_id="B9">
          <title>PF-04950615 Placebo</title>
          <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 placebo, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naive to a treatment by lipid lowering drug.</description>
        </group>
        <group group_id="B10">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
            <count group_id="B2" value="24"/>
            <count group_id="B3" value="24"/>
            <count group_id="B4" value="26"/>
            <count group_id="B5" value="22"/>
            <count group_id="B6" value="25"/>
            <count group_id="B7" value="25"/>
            <count group_id="B8" value="24"/>
            <count group_id="B9" value="23"/>
            <count group_id="B10" value="218"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Less than (&lt;) 18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0" spread="8.9"/>
                    <measurement group_id="B2" value="0" spread="12.2"/>
                    <measurement group_id="B3" value="0" spread="8.6"/>
                    <measurement group_id="B4" value="0" spread="11.2"/>
                    <measurement group_id="B5" value="0" spread="10.7"/>
                    <measurement group_id="B6" value="0" spread="8.4"/>
                    <measurement group_id="B7" value="0" spread="10.6"/>
                    <measurement group_id="B8" value="0" spread="8.1"/>
                    <measurement group_id="B9" value="0" spread="11.7"/>
                    <measurement group_id="B10" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>18-44 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="2"/>
                    <measurement group_id="B10" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>45-64 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="14"/>
                    <measurement group_id="B6" value="16"/>
                    <measurement group_id="B7" value="14"/>
                    <measurement group_id="B8" value="20"/>
                    <measurement group_id="B9" value="12"/>
                    <measurement group_id="B10" value="134"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Greater than or equal to (&gt;=) 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="8"/>
                    <measurement group_id="B7" value="8"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="9"/>
                    <measurement group_id="B10" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="10"/>
                    <measurement group_id="B6" value="13"/>
                    <measurement group_id="B7" value="15"/>
                    <measurement group_id="B8" value="9"/>
                    <measurement group_id="B9" value="10"/>
                    <measurement group_id="B10" value="100"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="12"/>
                    <measurement group_id="B6" value="12"/>
                    <measurement group_id="B7" value="10"/>
                    <measurement group_id="B8" value="15"/>
                    <measurement group_id="B9" value="13"/>
                    <measurement group_id="B10" value="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change From Baseline in Fasting Low Density Lipoprotein-Cholesterol (LDL-C) at Day 85</title>
        <description>LDL-C is cholesterol in the bloodstream that is carried by low density lipoprotein. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value. Percent change from baseline = ([observed value divided by baseline value] minus 1) multiplied by 100.</description>
        <time_frame>Baseline, Day 85</time_frame>
        <population>Full analysis set (FAS) included all the participants who were randomized and administered at least 1 dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin + PF-04950615 50 mg</title>
            <description>Participants with fasting lipoprotein cholesterol (LDL-C) level (greater than or equal to [&gt;=]100 milligram per deciliter [mg/dL]) received atorvastatin along with PF-04950615 50 milligram (mg) subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin + PF-04950615 100 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 100 mg subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin + PF-04950615 150 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 150 mg subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O4">
            <title>Atorvastatin + PF-04950615 Placebo</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 placebo subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O5">
            <title>Atorvastatin + Ezetimibe 10 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with ezetimibe 10 mg tablet orally, once daily from Day 1 up to Day 112. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O6">
            <title>PF-04950615 50 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 50 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O7">
            <title>PF-04950615 100 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 100 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O8">
            <title>PF-04950615 150 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 150 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O9">
            <title>PF-04950615 Placebo</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 placebo, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naive to a treatment by lipid lowering drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Fasting Low Density Lipoprotein-Cholesterol (LDL-C) at Day 85</title>
          <description>LDL-C is cholesterol in the bloodstream that is carried by low density lipoprotein. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value. Percent change from baseline = ([observed value divided by baseline value] minus 1) multiplied by 100.</description>
          <population>Full analysis set (FAS) included all the participants who were randomized and administered at least 1 dose of study treatment.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="26"/>
                <count group_id="O5" value="22"/>
                <count group_id="O6" value="25"/>
                <count group_id="O7" value="23"/>
                <count group_id="O8" value="24"/>
                <count group_id="O9" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-55.65" spread="15.748" lower_limit="-60.388" upper_limit="-49.639"/>
                    <measurement group_id="O2" value="-68.25" spread="18.769" lower_limit="-77.547" upper_limit="-66.313"/>
                    <measurement group_id="O3" value="-74.00" spread="13.848" lower_limit="-82.354" upper_limit="-71.066"/>
                    <measurement group_id="O4" value="-5.91" spread="14.323" lower_limit="-10.453" upper_limit="0.102"/>
                    <measurement group_id="O5" value="-18.56" spread="15.968"/>
                    <measurement group_id="O6" value="-47.25" spread="17.699"/>
                    <measurement group_id="O7" value="-62.24" spread="16.097"/>
                    <measurement group_id="O8" value="-65.89" spread="10.779"/>
                    <measurement group_id="O9" value="-1.21" spread="14.815"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Adjusted mean difference and 2-sided 95% confidence interval were derived from the mixed-effect model for repeated measures (MMRM) model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-value (adjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-49.838</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.775</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-57.335</ci_lower_limit>
            <ci_upper_limit>-42.340</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-value (adjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-66.754</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.912</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-74.523</ci_lower_limit>
            <ci_upper_limit>-58.986</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (adjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-71.534</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.903</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-79.284</ci_lower_limit>
            <ci_upper_limit>-63.784</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (adjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-47.531</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.016</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-55.511</ci_lower_limit>
            <ci_upper_limit>-39.551</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (adjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-62.624</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.993</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-70.557</ci_lower_limit>
            <ci_upper_limit>-54.691</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (adjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-64.268</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.955</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-72.128</ci_lower_limit>
            <ci_upper_limit>-56.409</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent Change From Baseline in Fasting Low Density Lipoprotein-Cholesterol (LDL-C) at Day 113</title>
        <description>LDL-C is cholesterol in the bloodstream that is carried by low density lipoprotein. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value. Percent change from baseline = ([observed value divided by baseline value] minus 1) multiplied by 100.</description>
        <time_frame>Baseline, Day 113</time_frame>
        <population>FAS included all the participants who were randomized and administered at least 1 dose of study treatment. Here, number of participants analyzed (N) signifies number of participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin + PF-04950615 50 mg</title>
            <description>Participants with fasting lipoprotein cholesterol (LDL-C) level (greater than or equal to [&gt;=]100 milligram per deciliter [mg/dL]) received atorvastatin along with PF-04950615 50 milligram (mg) subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin + PF-04950615 100 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 100 mg subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin + PF-04950615 150 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 150 mg subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O4">
            <title>Atorvastatin + PF-04950615 Placebo</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 placebo subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O5">
            <title>Atorvastatin + Ezetimibe 10 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with ezetimibe 10 mg tablet orally, once daily from Day 1 up to Day 112. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O6">
            <title>PF-04950615 50 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 50 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O7">
            <title>PF-04950615 100 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 100 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O8">
            <title>PF-04950615 150 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 150 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O9">
            <title>PF-04950615 Placebo</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 placebo, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naive to a treatment by lipid lowering drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Fasting Low Density Lipoprotein-Cholesterol (LDL-C) at Day 113</title>
          <description>LDL-C is cholesterol in the bloodstream that is carried by low density lipoprotein. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value. Percent change from baseline = ([observed value divided by baseline value] minus 1) multiplied by 100.</description>
          <population>FAS included all the participants who were randomized and administered at least 1 dose of study treatment. Here, number of participants analyzed (N) signifies number of participants evaluable for this outcome measure.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="22"/>
                <count group_id="O6" value="25"/>
                <count group_id="O7" value="23"/>
                <count group_id="O8" value="23"/>
                <count group_id="O9" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-54.41" spread="12.062" lower_limit="-60.388" upper_limit="-49.639"/>
                    <measurement group_id="O2" value="-64.46" spread="19.149" lower_limit="-77.547" upper_limit="-66.313"/>
                    <measurement group_id="O3" value="-69.98" spread="19.074" lower_limit="-82.354" upper_limit="-71.066"/>
                    <measurement group_id="O4" value="-12.10" spread="12.727" lower_limit="-10.453" upper_limit="0.102"/>
                    <measurement group_id="O5" value="-20.55" spread="18.682"/>
                    <measurement group_id="O6" value="-44.94" spread="19.641"/>
                    <measurement group_id="O7" value="-61.79" spread="15.476"/>
                    <measurement group_id="O8" value="-66.98" spread="12.396"/>
                    <measurement group_id="O9" value="0.39" spread="16.246"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Adjusted mean difference and 2-sided 95% confidence interval were derived from the mixed-effect model for repeated measures (MMRM) model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (adjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-42.293</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.587</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-49.417</ci_lower_limit>
            <ci_upper_limit>-35.168</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (adjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-56.262</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.696</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-63.603</ci_lower_limit>
            <ci_upper_limit>-48.921</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (adjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-61.384</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.700</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-68.733</ci_lower_limit>
            <ci_upper_limit>-54.035</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (adjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-47.578</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.273</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-56.067</ci_lower_limit>
            <ci_upper_limit>-39.088</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (adjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-63.346</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.244</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-71.776</ci_lower_limit>
            <ci_upper_limit>-54.915</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (adjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-66.691</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.226</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-75.088</ci_lower_limit>
            <ci_upper_limit>-58.295</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Low Density Lipoprotein-Cholesterol (LDL-C)</title>
        <description>LDL-C is cholesterol in the bloodstream that is carried by low density lipoprotein. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value.</description>
        <time_frame>Baseline, Day 5, 8, 15, 22, 29, 36, 43, 50, 57, 71, 85, 99, 106, 113, 127, 141, 155, 169</time_frame>
        <population>FAS included all the participants who were randomized and administered at least 1 dose of study treatment. Here, ‘Number analyzed’ = Participants evaluable for this outcome measure at specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin + PF-04950615 50 mg</title>
            <description>Participants with fasting lipoprotein cholesterol (LDL-C) level (greater than or equal to [&gt;=]100 milligram per deciliter [mg/dL]) received atorvastatin along with PF-04950615 50 milligram (mg) subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin + PF-04950615 100 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 100 mg subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin + PF-04950615 150 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 150 mg subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O4">
            <title>Atorvastatin + PF-04950615 Placebo</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 placebo subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O5">
            <title>Atorvastatin + Ezetimibe 10 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with ezetimibe 10 mg tablet orally, once daily from Day 1 up to Day 112. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O6">
            <title>PF-04950615 50 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 50 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O7">
            <title>PF-04950615 100 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 100 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O8">
            <title>PF-04950615 150 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 150 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O9">
            <title>PF-04950615 Placebo</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 placebo, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naive to a treatment by lipid lowering drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Low Density Lipoprotein-Cholesterol (LDL-C)</title>
          <description>LDL-C is cholesterol in the bloodstream that is carried by low density lipoprotein. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value.</description>
          <population>FAS included all the participants who were randomized and administered at least 1 dose of study treatment. Here, ‘Number analyzed’ = Participants evaluable for this outcome measure at specified time points.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="26"/>
                <count group_id="O5" value="22"/>
                <count group_id="O6" value="25"/>
                <count group_id="O7" value="25"/>
                <count group_id="O8" value="24"/>
                <count group_id="O9" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="25"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="135.36" spread="23.652"/>
                    <measurement group_id="O2" value="123.85" spread="20.585"/>
                    <measurement group_id="O3" value="129.19" spread="17.769"/>
                    <measurement group_id="O4" value="135.90" spread="24.697"/>
                    <measurement group_id="O5" value="135.36" spread="24.745"/>
                    <measurement group_id="O6" value="164.22" spread="25.839"/>
                    <measurement group_id="O7" value="158.00" spread="20.004"/>
                    <measurement group_id="O8" value="159.90" spread="19.800"/>
                    <measurement group_id="O9" value="155.22" spread="23.096"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="23"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="25"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.72" spread="24.917"/>
                    <measurement group_id="O2" value="71.83" spread="26.020"/>
                    <measurement group_id="O3" value="76.04" spread="17.111"/>
                    <measurement group_id="O4" value="130.35" spread="22.280"/>
                    <measurement group_id="O5" value="111.50" spread="23.118"/>
                    <measurement group_id="O6" value="128.68" spread="30.905"/>
                    <measurement group_id="O7" value="120.20" spread="21.352"/>
                    <measurement group_id="O8" value="114.63" spread="30.177"/>
                    <measurement group_id="O9" value="165.09" spread="22.880"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="21"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="22"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.36" spread="18.932"/>
                    <measurement group_id="O2" value="55.38" spread="28.309"/>
                    <measurement group_id="O3" value="57.71" spread="16.433"/>
                    <measurement group_id="O4" value="132.08" spread="21.244"/>
                    <measurement group_id="O5" value="105.86" spread="21.070"/>
                    <measurement group_id="O6" value="118.20" spread="33.823"/>
                    <measurement group_id="O7" value="102.63" spread="26.577"/>
                    <measurement group_id="O8" value="96.50" spread="36.130"/>
                    <measurement group_id="O9" value="167.22" spread="23.537"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="25"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.76" spread="18.807"/>
                    <measurement group_id="O2" value="51.96" spread="23.921"/>
                    <measurement group_id="O3" value="39.00" spread="16.395"/>
                    <measurement group_id="O4" value="132.50" spread="19.449"/>
                    <measurement group_id="O5" value="102.64" spread="19.458"/>
                    <measurement group_id="O6" value="113.28" spread="36.371"/>
                    <measurement group_id="O7" value="80.44" spread="25.366"/>
                    <measurement group_id="O8" value="77.08" spread="25.943"/>
                    <measurement group_id="O9" value="165.39" spread="21.148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.08" spread="19.577"/>
                    <measurement group_id="O2" value="37.58" spread="20.011"/>
                    <measurement group_id="O3" value="31.00" spread="11.176"/>
                    <measurement group_id="O4" value="133.27" spread="19.359"/>
                    <measurement group_id="O5" value="101.68" spread="21.825"/>
                    <measurement group_id="O6" value="90.32" spread="34.956"/>
                    <measurement group_id="O7" value="67.29" spread="26.527"/>
                    <measurement group_id="O8" value="67.71" spread="32.399"/>
                    <measurement group_id="O9" value="166.04" spread="15.741"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="25"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.56" spread="24.316"/>
                    <measurement group_id="O2" value="48.29" spread="21.814"/>
                    <measurement group_id="O3" value="34.26" spread="13.965"/>
                    <measurement group_id="O4" value="129.60" spread="23.381"/>
                    <measurement group_id="O5" value="107.50" spread="23.299"/>
                    <measurement group_id="O6" value="93.36" spread="36.718"/>
                    <measurement group_id="O7" value="65.20" spread="17.970"/>
                    <measurement group_id="O8" value="63.58" spread="23.404"/>
                    <measurement group_id="O9" value="168.14" spread="24.032"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.40" spread="19.967"/>
                    <measurement group_id="O2" value="35.13" spread="17.306"/>
                    <measurement group_id="O3" value="29.52" spread="11.233"/>
                    <measurement group_id="O4" value="128.50" spread="23.930"/>
                    <measurement group_id="O5" value="103.05" spread="26.462"/>
                    <measurement group_id="O6" value="80.64" spread="34.744"/>
                    <measurement group_id="O7" value="60.67" spread="19.257"/>
                    <measurement group_id="O8" value="60.75" spread="27.619"/>
                    <measurement group_id="O9" value="154.00" spread="22.815"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="25"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.24" spread="21.357"/>
                    <measurement group_id="O2" value="39.63" spread="20.342"/>
                    <measurement group_id="O3" value="31.83" spread="11.750"/>
                    <measurement group_id="O4" value="126.23" spread="14.356"/>
                    <measurement group_id="O5" value="104.95" spread="23.941"/>
                    <measurement group_id="O6" value="87.76" spread="36.555"/>
                    <measurement group_id="O7" value="64.84" spread="19.882"/>
                    <measurement group_id="O8" value="61.83" spread="29.732"/>
                    <measurement group_id="O9" value="167.30" spread="21.850"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 50</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.76" spread="16.042"/>
                    <measurement group_id="O2" value="32.33" spread="16.578"/>
                    <measurement group_id="O3" value="29.96" spread="11.400"/>
                    <measurement group_id="O4" value="127.92" spread="20.392"/>
                    <measurement group_id="O5" value="106.23" spread="21.728"/>
                    <measurement group_id="O6" value="76.96" spread="32.194"/>
                    <measurement group_id="O7" value="57.91" spread="20.889"/>
                    <measurement group_id="O8" value="59.29" spread="28.406"/>
                    <measurement group_id="O9" value="158.83" spread="17.031"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 57</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.88" spread="18.306"/>
                    <measurement group_id="O2" value="37.21" spread="18.352"/>
                    <measurement group_id="O3" value="29.61" spread="11.053"/>
                    <measurement group_id="O4" value="125.27" spread="20.330"/>
                    <measurement group_id="O5" value="99.27" spread="26.705"/>
                    <measurement group_id="O6" value="81.32" spread="33.628"/>
                    <measurement group_id="O7" value="63.54" spread="25.072"/>
                    <measurement group_id="O8" value="55.75" spread="26.272"/>
                    <measurement group_id="O9" value="152.91" spread="15.395"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 71</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.50" spread="22.683"/>
                    <measurement group_id="O2" value="36.29" spread="18.196"/>
                    <measurement group_id="O3" value="33.13" spread="13.384"/>
                    <measurement group_id="O4" value="130.31" spread="21.031"/>
                    <measurement group_id="O5" value="109.18" spread="26.412"/>
                    <measurement group_id="O6" value="90.96" spread="34.188"/>
                    <measurement group_id="O7" value="60.63" spread="24.315"/>
                    <measurement group_id="O8" value="57.33" spread="25.237"/>
                    <measurement group_id="O9" value="156.70" spread="25.663"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.96" spread="19.650"/>
                    <measurement group_id="O2" value="38.00" spread="19.077"/>
                    <measurement group_id="O3" value="33.91" spread="19.400"/>
                    <measurement group_id="O4" value="126.38" spread="21.478"/>
                    <measurement group_id="O5" value="110.64" spread="33.530"/>
                    <measurement group_id="O6" value="86.64" spread="30.447"/>
                    <measurement group_id="O7" value="59.83" spread="27.495"/>
                    <measurement group_id="O8" value="54.71" spread="18.388"/>
                    <measurement group_id="O9" value="151.30" spread="21.137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 99</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="22"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.48" spread="23.208"/>
                    <measurement group_id="O2" value="41.96" spread="18.995"/>
                    <measurement group_id="O3" value="38.09" spread="25.183"/>
                    <measurement group_id="O4" value="125.80" spread="15.992"/>
                    <measurement group_id="O5" value="106.14" spread="31.001"/>
                    <measurement group_id="O6" value="93.80" spread="29.672"/>
                    <measurement group_id="O7" value="61.67" spread="31.175"/>
                    <measurement group_id="O8" value="54.25" spread="20.339"/>
                    <measurement group_id="O9" value="163.70" spread="17.778"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 106</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="22"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.16" spread="20.874"/>
                    <measurement group_id="O2" value="32.13" spread="18.059"/>
                    <measurement group_id="O3" value="37.36" spread="24.849"/>
                    <measurement group_id="O4" value="127.76" spread="17.973"/>
                    <measurement group_id="O5" value="104.14" spread="25.496"/>
                    <measurement group_id="O6" value="84.52" spread="29.679"/>
                    <measurement group_id="O7" value="57.00" spread="25.719"/>
                    <measurement group_id="O8" value="57.42" spread="22.654"/>
                    <measurement group_id="O9" value="155.57" spread="17.010"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 113</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="23"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.17" spread="20.417"/>
                    <measurement group_id="O2" value="42.88" spread="19.427"/>
                    <measurement group_id="O3" value="38.48" spread="24.346"/>
                    <measurement group_id="O4" value="118.88" spread="22.883"/>
                    <measurement group_id="O5" value="107.32" spread="30.459"/>
                    <measurement group_id="O6" value="89.44" spread="29.798"/>
                    <measurement group_id="O7" value="61.48" spread="28.511"/>
                    <measurement group_id="O8" value="53.39" spread="20.954"/>
                    <measurement group_id="O9" value="153.30" spread="16.255"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 127</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108.16" spread="21.893"/>
                    <measurement group_id="O2" value="86.71" spread="27.414"/>
                    <measurement group_id="O3" value="61.87" spread="33.267"/>
                    <measurement group_id="O4" value="131.92" spread="21.922"/>
                    <measurement group_id="O5" value="132.73" spread="29.660"/>
                    <measurement group_id="O6" value="137.00" spread="36.894"/>
                    <measurement group_id="O7" value="87.22" spread="42.031"/>
                    <measurement group_id="O8" value="78.96" spread="25.696"/>
                    <measurement group_id="O9" value="161.17" spread="24.383"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 141</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="126.13" spread="26.555"/>
                    <measurement group_id="O2" value="111.38" spread="24.588"/>
                    <measurement group_id="O3" value="95.30" spread="37.497"/>
                    <measurement group_id="O4" value="129.32" spread="20.860"/>
                    <measurement group_id="O5" value="139.14" spread="38.095"/>
                    <measurement group_id="O6" value="160.80" spread="37.487"/>
                    <measurement group_id="O7" value="130.22" spread="40.707"/>
                    <measurement group_id="O8" value="103.08" spread="34.759"/>
                    <measurement group_id="O9" value="163.52" spread="22.224"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 155</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="23"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="126.52" spread="23.631"/>
                    <measurement group_id="O2" value="113.75" spread="19.236"/>
                    <measurement group_id="O3" value="110.57" spread="26.678"/>
                    <measurement group_id="O4" value="133.92" spread="23.240"/>
                    <measurement group_id="O5" value="139.45" spread="35.880"/>
                    <measurement group_id="O6" value="165.17" spread="31.251"/>
                    <measurement group_id="O7" value="140.78" spread="29.645"/>
                    <measurement group_id="O8" value="119.54" spread="32.896"/>
                    <measurement group_id="O9" value="158.17" spread="15.135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 169</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="24"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="23"/>
                    <count group_id="O9" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="131.28" spread="25.988"/>
                    <measurement group_id="O2" value="123.42" spread="25.782"/>
                    <measurement group_id="O3" value="124.04" spread="24.453"/>
                    <measurement group_id="O4" value="129.28" spread="24.576"/>
                    <measurement group_id="O5" value="140.91" spread="39.309"/>
                    <measurement group_id="O6" value="168.50" spread="28.657"/>
                    <measurement group_id="O7" value="154.52" spread="21.715"/>
                    <measurement group_id="O8" value="137.13" spread="32.817"/>
                    <measurement group_id="O9" value="168.55" spread="19.767"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) at Day 85 and Day 113</title>
        <description>LDL-C is cholesterol in the bloodstream that is carried by low density lipoprotein. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value. Change from baseline = observed value minus baseline value.</description>
        <time_frame>Baseline, Day 85, 113</time_frame>
        <population>FAS included all the participants who were randomized and administered at least 1 dose of study treatment. Here, ‘Number analyzed’ = Participants evaluable for this outcome measure at specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin + PF-04950615 50 mg</title>
            <description>Participants with fasting lipoprotein cholesterol (LDL-C) level (greater than or equal to [&gt;=]100 milligram per deciliter [mg/dL]) received atorvastatin along with PF-04950615 50 milligram (mg) subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin + PF-04950615 100 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 100 mg subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin + PF-04950615 150 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 150 mg subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O4">
            <title>Atorvastatin + PF-04950615 Placebo</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 placebo subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O5">
            <title>Atorvastatin + Ezetimibe 10 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with ezetimibe 10 mg tablet orally, once daily from Day 1 up to Day 112. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O6">
            <title>PF-04950615 50 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 50 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O7">
            <title>PF-04950615 100 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 100 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O8">
            <title>PF-04950615 150 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 150 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O9">
            <title>PF-04950615 Placebo</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 placebo, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naive to a treatment by lipid lowering drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) at Day 85 and Day 113</title>
          <description>LDL-C is cholesterol in the bloodstream that is carried by low density lipoprotein. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value. Change from baseline = observed value minus baseline value.</description>
          <population>FAS included all the participants who were randomized and administered at least 1 dose of study treatment. Here, ‘Number analyzed’ = Participants evaluable for this outcome measure at specified time points.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="26"/>
                <count group_id="O5" value="22"/>
                <count group_id="O6" value="25"/>
                <count group_id="O7" value="25"/>
                <count group_id="O8" value="24"/>
                <count group_id="O9" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Day 85</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-76.40" spread="26.447"/>
                    <measurement group_id="O2" value="-85.85" spread="28.977"/>
                    <measurement group_id="O3" value="-95.11" spread="21.145"/>
                    <measurement group_id="O4" value="-9.52" spread="21.041"/>
                    <measurement group_id="O5" value="-24.73" spread="23.125"/>
                    <measurement group_id="O6" value="-77.58" spread="29.943"/>
                    <measurement group_id="O7" value="-99.28" spread="32.550"/>
                    <measurement group_id="O8" value="-105.19" spread="19.833"/>
                    <measurement group_id="O9" value="-3.91" spread="23.632"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 113</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="23"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-73.33" spread="18.047"/>
                    <measurement group_id="O2" value="-80.98" spread="28.902"/>
                    <measurement group_id="O3" value="-90.54" spread="28.496"/>
                    <measurement group_id="O4" value="-17.48" spread="20.767"/>
                    <measurement group_id="O5" value="-28.05" spread="23.663"/>
                    <measurement group_id="O6" value="-74.78" spread="34.970"/>
                    <measurement group_id="O7" value="-97.63" spread="25.545"/>
                    <measurement group_id="O8" value="-107.57" spread="21.765"/>
                    <measurement group_id="O9" value="-1.91" spread="20.147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 85 : Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-67.254</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.785</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-76.757</ci_lower_limit>
            <ci_upper_limit>-57.752</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 85 : Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-87.122</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.959</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-96.969</ci_lower_limit>
            <ci_upper_limit>-77.275</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 85 : Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-93.327</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.949</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-103.153</ci_lower_limit>
            <ci_upper_limit>-83.501</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 85 : Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-71.724</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.243</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-84.128</ci_lower_limit>
            <ci_upper_limit>-59.321</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 85 : Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-96.206</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.209</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-108.541</ci_lower_limit>
            <ci_upper_limit>-83.872</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-98.533</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.145</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-110.743</ci_lower_limit>
            <ci_upper_limit>-86.323</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-56.225</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.736</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-65.630</ci_lower_limit>
            <ci_upper_limit>-46.819</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-73.813</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.881</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-83.507</ci_lower_limit>
            <ci_upper_limit>-64.119</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-81.239</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.885</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-90.939</ci_lower_limit>
            <ci_upper_limit>-71.538</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-72.573</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.983</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-84.461</ci_lower_limit>
            <ci_upper_limit>-60.684</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-96.222</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.948</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-108.039</ci_lower_limit>
            <ci_upper_limit>-84.405</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 113:Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-102.184</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.919</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-113.945</ci_lower_limit>
            <ci_upper_limit>-90.424</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Cholesterol (TC)</title>
        <description>Total cholesterol is the sum of all the cholesterol within the blood. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value.</description>
        <time_frame>Baseline, Day 5, 8, 15, 22, 29, 36, 43, 50, 57, 71, 85, 99, 106, 113, 127, 141, 155, 169</time_frame>
        <population>FAS included all the participants who were randomized and administered at least 1 dose of study treatment. Here, ‘Number analyzed’ = Participants evaluable for this outcome measure at specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin + PF-04950615 50 mg</title>
            <description>Participants with fasting lipoprotein cholesterol (LDL-C) level (greater than or equal to [&gt;=]100 milligram per deciliter [mg/dL]) received atorvastatin along with PF-04950615 50 milligram (mg) subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin + PF-04950615 100 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 100 mg subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin + PF-04950615 150 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 150 mg subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O4">
            <title>Atorvastatin + PF-04950615 Placebo</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 placebo subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O5">
            <title>Atorvastatin + Ezetimibe 10 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with ezetimibe 10 mg tablet orally, once daily from Day 1 up to Day 112. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O6">
            <title>PF-04950615 50 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 50 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O7">
            <title>PF-04950615 100 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 100 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O8">
            <title>PF-04950615 150 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 150 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O9">
            <title>PF-04950615 Placebo</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 placebo, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naive to a treatment by lipid lowering drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Cholesterol (TC)</title>
          <description>Total cholesterol is the sum of all the cholesterol within the blood. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value.</description>
          <population>FAS included all the participants who were randomized and administered at least 1 dose of study treatment. Here, ‘Number analyzed’ = Participants evaluable for this outcome measure at specified time points.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="26"/>
                <count group_id="O5" value="22"/>
                <count group_id="O6" value="25"/>
                <count group_id="O7" value="25"/>
                <count group_id="O8" value="24"/>
                <count group_id="O9" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="25"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="214.16" spread="30.658"/>
                    <measurement group_id="O2" value="210.29" spread="21.594"/>
                    <measurement group_id="O3" value="211.71" spread="23.065"/>
                    <measurement group_id="O4" value="222.44" spread="31.317"/>
                    <measurement group_id="O5" value="222.84" spread="25.395"/>
                    <measurement group_id="O6" value="245.94" spread="30.425"/>
                    <measurement group_id="O7" value="243.26" spread="21.967"/>
                    <measurement group_id="O8" value="244.19" spread="29.987"/>
                    <measurement group_id="O9" value="242.04" spread="22.956"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="23"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="25"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="169.20" spread="28.586"/>
                    <measurement group_id="O2" value="154.83" spread="30.045"/>
                    <measurement group_id="O3" value="156.91" spread="22.240"/>
                    <measurement group_id="O4" value="219.42" spread="24.861"/>
                    <measurement group_id="O5" value="197.77" spread="25.487"/>
                    <measurement group_id="O6" value="211.56" spread="37.176"/>
                    <measurement group_id="O7" value="203.56" spread="28.777"/>
                    <measurement group_id="O8" value="199.58" spread="41.618"/>
                    <measurement group_id="O9" value="249.09" spread="24.156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="21"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="22"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="149.72" spread="24.979"/>
                    <measurement group_id="O2" value="137.71" spread="31.992"/>
                    <measurement group_id="O3" value="136.50" spread="21.364"/>
                    <measurement group_id="O4" value="222.68" spread="28.253"/>
                    <measurement group_id="O5" value="190.19" spread="20.856"/>
                    <measurement group_id="O6" value="202.44" spread="37.095"/>
                    <measurement group_id="O7" value="184.58" spread="30.935"/>
                    <measurement group_id="O8" value="186.73" spread="44.905"/>
                    <measurement group_id="O9" value="254.26" spread="22.481"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="25"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="154.20" spread="26.011"/>
                    <measurement group_id="O2" value="137.83" spread="27.241"/>
                    <measurement group_id="O3" value="120.75" spread="25.589"/>
                    <measurement group_id="O4" value="221.69" spread="23.988"/>
                    <measurement group_id="O5" value="190.50" spread="20.964"/>
                    <measurement group_id="O6" value="198.64" spread="39.145"/>
                    <measurement group_id="O7" value="165.48" spread="30.456"/>
                    <measurement group_id="O8" value="165.71" spread="37.735"/>
                    <measurement group_id="O9" value="251.91" spread="24.830"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="129.28" spread="22.856"/>
                    <measurement group_id="O2" value="119.00" spread="26.462"/>
                    <measurement group_id="O3" value="112.78" spread="19.247"/>
                    <measurement group_id="O4" value="218.12" spread="24.006"/>
                    <measurement group_id="O5" value="190.64" spread="23.768"/>
                    <measurement group_id="O6" value="176.28" spread="36.510"/>
                    <measurement group_id="O7" value="152.63" spread="29.854"/>
                    <measurement group_id="O8" value="153.67" spread="43.213"/>
                    <measurement group_id="O9" value="253.57" spread="15.716"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="25"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="141.04" spread="27.355"/>
                    <measurement group_id="O2" value="133.54" spread="25.507"/>
                    <measurement group_id="O3" value="114.91" spread="24.487"/>
                    <measurement group_id="O4" value="217.12" spread="24.280"/>
                    <measurement group_id="O5" value="192.41" spread="31.173"/>
                    <measurement group_id="O6" value="176.36" spread="41.260"/>
                    <measurement group_id="O7" value="153.20" spread="25.762"/>
                    <measurement group_id="O8" value="150.42" spread="34.557"/>
                    <measurement group_id="O9" value="256.73" spread="22.391"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124.12" spread="22.380"/>
                    <measurement group_id="O2" value="113.88" spread="25.000"/>
                    <measurement group_id="O3" value="107.35" spread="19.590"/>
                    <measurement group_id="O4" value="217.08" spread="26.204"/>
                    <measurement group_id="O5" value="187.55" spread="30.803"/>
                    <measurement group_id="O6" value="163.48" spread="39.528"/>
                    <measurement group_id="O7" value="147.08" spread="25.568"/>
                    <measurement group_id="O8" value="144.63" spread="40.577"/>
                    <measurement group_id="O9" value="244.65" spread="24.356"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="25"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139.40" spread="23.944"/>
                    <measurement group_id="O2" value="128.83" spread="30.724"/>
                    <measurement group_id="O3" value="113.75" spread="23.167"/>
                    <measurement group_id="O4" value="214.62" spread="19.179"/>
                    <measurement group_id="O5" value="190.86" spread="28.734"/>
                    <measurement group_id="O6" value="171.96" spread="40.287"/>
                    <measurement group_id="O7" value="151.80" spread="23.638"/>
                    <measurement group_id="O8" value="147.25" spread="41.429"/>
                    <measurement group_id="O9" value="254.04" spread="19.793"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 50</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120.04" spread="20.687"/>
                    <measurement group_id="O2" value="112.63" spread="23.585"/>
                    <measurement group_id="O3" value="107.74" spread="22.471"/>
                    <measurement group_id="O4" value="215.42" spread="23.262"/>
                    <measurement group_id="O5" value="189.18" spread="24.209"/>
                    <measurement group_id="O6" value="161.00" spread="37.653"/>
                    <measurement group_id="O7" value="145.22" spread="24.814"/>
                    <measurement group_id="O8" value="144.17" spread="40.223"/>
                    <measurement group_id="O9" value="246.09" spread="17.776"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 57</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="134.16" spread="25.826"/>
                    <measurement group_id="O2" value="116.96" spread="24.489"/>
                    <measurement group_id="O3" value="104.61" spread="20.045"/>
                    <measurement group_id="O4" value="208.04" spread="23.282"/>
                    <measurement group_id="O5" value="184.14" spread="31.148"/>
                    <measurement group_id="O6" value="158.96" spread="39.046"/>
                    <measurement group_id="O7" value="148.00" spread="30.107"/>
                    <measurement group_id="O8" value="135.83" spread="39.794"/>
                    <measurement group_id="O9" value="236.78" spread="16.105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 71</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="142.13" spread="29.489"/>
                    <measurement group_id="O2" value="121.04" spread="28.608"/>
                    <measurement group_id="O3" value="113.48" spread="25.056"/>
                    <measurement group_id="O4" value="218.38" spread="23.474"/>
                    <measurement group_id="O5" value="192.91" spread="31.288"/>
                    <measurement group_id="O6" value="174.64" spread="37.758"/>
                    <measurement group_id="O7" value="146.17" spread="29.736"/>
                    <measurement group_id="O8" value="142.42" spread="37.326"/>
                    <measurement group_id="O9" value="243.74" spread="24.849"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="135.52" spread="25.161"/>
                    <measurement group_id="O2" value="119.58" spread="24.959"/>
                    <measurement group_id="O3" value="109.57" spread="27.611"/>
                    <measurement group_id="O4" value="208.88" spread="24.747"/>
                    <measurement group_id="O5" value="198.82" spread="36.000"/>
                    <measurement group_id="O6" value="165.44" spread="32.651"/>
                    <measurement group_id="O7" value="141.09" spread="31.318"/>
                    <measurement group_id="O8" value="134.17" spread="30.972"/>
                    <measurement group_id="O9" value="231.52" spread="22.701"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 99</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="22"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="151.24" spread="31.139"/>
                    <measurement group_id="O2" value="128.58" spread="28.864"/>
                    <measurement group_id="O3" value="122.36" spread="36.702"/>
                    <measurement group_id="O4" value="216.28" spread="19.250"/>
                    <measurement group_id="O5" value="194.05" spread="33.230"/>
                    <measurement group_id="O6" value="178.36" spread="33.103"/>
                    <measurement group_id="O7" value="149.83" spread="33.780"/>
                    <measurement group_id="O8" value="139.13" spread="32.510"/>
                    <measurement group_id="O9" value="249.83" spread="19.277"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 106</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="22"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="126.40" spread="29.017"/>
                    <measurement group_id="O2" value="114.75" spread="26.967"/>
                    <measurement group_id="O3" value="118.55" spread="29.987"/>
                    <measurement group_id="O4" value="212.36" spread="22.002"/>
                    <measurement group_id="O5" value="190.27" spread="28.352"/>
                    <measurement group_id="O6" value="167.84" spread="32.859"/>
                    <measurement group_id="O7" value="142.26" spread="32.265"/>
                    <measurement group_id="O8" value="139.92" spread="35.003"/>
                    <measurement group_id="O9" value="241.65" spread="18.982"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 113</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="23"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="140.63" spread="26.650"/>
                    <measurement group_id="O2" value="124.58" spread="27.910"/>
                    <measurement group_id="O3" value="115.17" spread="30.293"/>
                    <measurement group_id="O4" value="201.64" spread="26.967"/>
                    <measurement group_id="O5" value="191.73" spread="34.189"/>
                    <measurement group_id="O6" value="169.72" spread="31.052"/>
                    <measurement group_id="O7" value="146.00" spread="33.889"/>
                    <measurement group_id="O8" value="134.17" spread="31.400"/>
                    <measurement group_id="O9" value="236.83" spread="16.808"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 127</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="193.96" spread="26.253"/>
                    <measurement group_id="O2" value="176.88" spread="32.328"/>
                    <measurement group_id="O3" value="147.87" spread="37.486"/>
                    <measurement group_id="O4" value="219.32" spread="26.684"/>
                    <measurement group_id="O5" value="221.18" spread="32.444"/>
                    <measurement group_id="O6" value="223.16" spread="39.032"/>
                    <measurement group_id="O7" value="176.74" spread="46.917"/>
                    <measurement group_id="O8" value="166.63" spread="34.144"/>
                    <measurement group_id="O9" value="249.78" spread="25.598"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 141</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="209.75" spread="32.446"/>
                    <measurement group_id="O2" value="202.71" spread="26.989"/>
                    <measurement group_id="O3" value="184.09" spread="38.141"/>
                    <measurement group_id="O4" value="216.48" spread="22.450"/>
                    <measurement group_id="O5" value="229.50" spread="38.480"/>
                    <measurement group_id="O6" value="247.36" spread="40.025"/>
                    <measurement group_id="O7" value="217.43" spread="43.351"/>
                    <measurement group_id="O8" value="192.96" spread="37.406"/>
                    <measurement group_id="O9" value="253.48" spread="21.494"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 155</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="23"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="208.32" spread="28.912"/>
                    <measurement group_id="O2" value="203.83" spread="24.533"/>
                    <measurement group_id="O3" value="195.26" spread="31.865"/>
                    <measurement group_id="O4" value="221.28" spread="24.455"/>
                    <measurement group_id="O5" value="228.86" spread="37.640"/>
                    <measurement group_id="O6" value="250.00" spread="34.453"/>
                    <measurement group_id="O7" value="227.83" spread="31.438"/>
                    <measurement group_id="O8" value="208.25" spread="33.069"/>
                    <measurement group_id="O9" value="246.35" spread="15.171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 169</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="24"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="23"/>
                    <count group_id="O9" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="212.96" spread="29.508"/>
                    <measurement group_id="O2" value="212.79" spread="25.267"/>
                    <measurement group_id="O3" value="211.00" spread="31.348"/>
                    <measurement group_id="O4" value="221.00" spread="26.091"/>
                    <measurement group_id="O5" value="234.95" spread="43.216"/>
                    <measurement group_id="O6" value="254.17" spread="32.859"/>
                    <measurement group_id="O7" value="245.57" spread="34.103"/>
                    <measurement group_id="O8" value="227.65" spread="39.088"/>
                    <measurement group_id="O9" value="258.64" spread="20.537"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Total Cholesterol (TC) at Day 85 and Day 113</title>
        <description>Total cholesterol is the sum of all the cholesterol within the blood. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value.</description>
        <time_frame>Baseline, Day 85, 113</time_frame>
        <population>FAS included all the participants who were randomized and administered at least 1 dose of study treatment. Here, ‘Number analyzed’ = Participants evaluable for this outcome measure at specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin + PF-04950615 50 mg</title>
            <description>Participants with fasting lipoprotein cholesterol (LDL-C) level (greater than or equal to [&gt;=]100 milligram per deciliter [mg/dL]) received atorvastatin along with PF-04950615 50 milligram (mg) subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin + PF-04950615 100 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 100 mg subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin + PF-04950615 150 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 150 mg subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O4">
            <title>Atorvastatin + PF-04950615 Placebo</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 placebo subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O5">
            <title>Atorvastatin + Ezetimibe 10 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with ezetimibe 10 mg tablet orally, once daily from Day 1 up to Day 112. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O6">
            <title>PF-04950615 50 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 50 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O7">
            <title>PF-04950615 100 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 100 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O8">
            <title>PF-04950615 150 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 150 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O9">
            <title>PF-04950615 Placebo</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 placebo, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naive to a treatment by lipid lowering drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Total Cholesterol (TC) at Day 85 and Day 113</title>
          <description>Total cholesterol is the sum of all the cholesterol within the blood. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value.</description>
          <population>FAS included all the participants who were randomized and administered at least 1 dose of study treatment. Here, ‘Number analyzed’ = Participants evaluable for this outcome measure at specified time points.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="26"/>
                <count group_id="O5" value="22"/>
                <count group_id="O6" value="25"/>
                <count group_id="O7" value="25"/>
                <count group_id="O8" value="24"/>
                <count group_id="O9" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Day 85</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-78.64" spread="28.525"/>
                    <measurement group_id="O2" value="-90.71" spread="31.705"/>
                    <measurement group_id="O3" value="-101.43" spread="25.436"/>
                    <measurement group_id="O4" value="-13.56" spread="22.346"/>
                    <measurement group_id="O5" value="-24.02" spread="26.166"/>
                    <measurement group_id="O6" value="-80.50" spread="31.851"/>
                    <measurement group_id="O7" value="-102.80" spread="34.603"/>
                    <measurement group_id="O8" value="-110.02" spread="24.119"/>
                    <measurement group_id="O9" value="-10.52" spread="26.111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 113</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="23"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-73.44" spread="21.242"/>
                    <measurement group_id="O2" value="-85.71" spread="30.263"/>
                    <measurement group_id="O3" value="-95.83" spread="27.765"/>
                    <measurement group_id="O4" value="-21.68" spread="23.686"/>
                    <measurement group_id="O5" value="-31.11" spread="24.992"/>
                    <measurement group_id="O6" value="-76.22" spread="36.301"/>
                    <measurement group_id="O7" value="-97.89" spread="29.274"/>
                    <measurement group_id="O8" value="-111.96" spread="24.871"/>
                    <measurement group_id="O9" value="-5.22" spread="20.333"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 85 : Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-value (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-69.537</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.721</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-80.900</ci_lower_limit>
            <ci_upper_limit>-58.175</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 85 : Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-86.446</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.855</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-98.074</ci_lower_limit>
            <ci_upper_limit>-74.818</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 85 : Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-98.273</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.898</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-109.983</ci_lower_limit>
            <ci_upper_limit>-86.563</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 85 : Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-71.435</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>7.209</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-85.757</ci_lower_limit>
            <ci_upper_limit>-57.112</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 85 : Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-94.959</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>7.236</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-109.333</ci_lower_limit>
            <ci_upper_limit>-80.585</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 85 : Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-98.519</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>7.150</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-112.727</ci_lower_limit>
            <ci_upper_limit>-84.311</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-55.191</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.741</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-66.592</ci_lower_limit>
            <ci_upper_limit>-43.791</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-72.211</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.848</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-83.825</ci_lower_limit>
            <ci_upper_limit>-60.597</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-83.065</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.913</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-94.807</ci_lower_limit>
            <ci_upper_limit>-71.323</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-73.879</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.678</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-87.147</ci_lower_limit>
            <ci_upper_limit>-60.612</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-95.428</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.697</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-108.732</ci_lower_limit>
            <ci_upper_limit>-82.124</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-104.859</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.654</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-118.079</ci_lower_limit>
            <ci_upper_limit>-91.639</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Total Cholesterol (TC) at Day 85 and Day 113</title>
        <description>Total cholesterol is the sum of all the cholesterol within the blood. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value. Percent change from baseline = ([observed value divided by baseline value] minus 1) multiplied by 100.</description>
        <time_frame>Baseline, Day 85, 113</time_frame>
        <population>FAS included all the participants who were randomized and administered at least 1 dose of study treatment. Here, ‘Number analyzed’ = Participants evaluable for this outcome measure at specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin + PF-04950615 50 mg</title>
            <description>Participants with fasting lipoprotein cholesterol (LDL-C) level (greater than or equal to [&gt;=]100 milligram per deciliter [mg/dL]) received atorvastatin along with PF-04950615 50 milligram (mg) subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin + PF-04950615 100 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 100 mg subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin + PF-04950615 150 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 150 mg subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O4">
            <title>Atorvastatin + PF-04950615 Placebo</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 placebo subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O5">
            <title>Atorvastatin + Ezetimibe 10 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with ezetimibe 10 mg tablet orally, once daily from Day 1 up to Day 112. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O6">
            <title>PF-04950615 50 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 50 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O7">
            <title>PF-04950615 100 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 100 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O8">
            <title>PF-04950615 150 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 150 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O9">
            <title>PF-04950615 Placebo</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 placebo, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naive to a treatment by lipid lowering drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Total Cholesterol (TC) at Day 85 and Day 113</title>
          <description>Total cholesterol is the sum of all the cholesterol within the blood. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value. Percent change from baseline = ([observed value divided by baseline value] minus 1) multiplied by 100.</description>
          <population>FAS included all the participants who were randomized and administered at least 1 dose of study treatment. Here, ‘Number analyzed’ = Participants evaluable for this outcome measure at specified time points.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="26"/>
                <count group_id="O5" value="22"/>
                <count group_id="O6" value="25"/>
                <count group_id="O7" value="25"/>
                <count group_id="O8" value="24"/>
                <count group_id="O9" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Day 85</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-36.26" spread="11.313"/>
                    <measurement group_id="O2" value="-42.64" spread="13.310"/>
                    <measurement group_id="O3" value="-48.22" spread="11.066"/>
                    <measurement group_id="O4" value="-5.47" spread="9.038"/>
                    <measurement group_id="O5" value="-10.85" spread="11.295"/>
                    <measurement group_id="O6" value="-32.56" spread="12.011"/>
                    <measurement group_id="O7" value="-41.98" spread="12.224"/>
                    <measurement group_id="O8" value="-45.28" spread="9.539"/>
                    <measurement group_id="O9" value="-3.82" spread="10.484"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 113</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="23"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-34.28" spread="8.799"/>
                    <measurement group_id="O2" value="-40.55" spread="13.471"/>
                    <measurement group_id="O3" value="-45.58" spread="12.422"/>
                    <measurement group_id="O4" value="-9.18" spread="9.204"/>
                    <measurement group_id="O5" value="-14.02" spread="10.900"/>
                    <measurement group_id="O6" value="-30.50" spread="13.212"/>
                    <measurement group_id="O7" value="-40.27" spread="11.798"/>
                    <measurement group_id="O8" value="-45.71" spread="9.786"/>
                    <measurement group_id="O9" value="-1.62" spread="8.941"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 85 : Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-31.642</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.717</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-37.039</ci_lower_limit>
            <ci_upper_limit>-26.246</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 85 : Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-39.880</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.781</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-45.403</ci_lower_limit>
            <ci_upper_limit>-34.358</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 85 : Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-45.889</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.800</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-51.450</ci_lower_limit>
            <ci_upper_limit>-40.329</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 85 : Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-30.137</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.006</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-36.110</ci_lower_limit>
            <ci_upper_limit>-24.164</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 85 : Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-39.525</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.018</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-45.520</ci_lower_limit>
            <ci_upper_limit>-33.531</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-41.372</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.983</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-47.299</ci_lower_limit>
            <ci_upper_limit>-35.445</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-25.374</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.690</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-30.717</ci_lower_limit>
            <ci_upper_limit>-20.032</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-33.490</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.741</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-38.934</ci_lower_limit>
            <ci_upper_limit>-28.047</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-38.760</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.770</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-44.262</ci_lower_limit>
            <ci_upper_limit>-33.258</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-30.847</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.879</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-36.568</ci_lower_limit>
            <ci_upper_limit>-25.127</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-40.019</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.887</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-45.754</ci_lower_limit>
            <ci_upper_limit>-34.285</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 113:Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-43.947</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.869</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-49.647</ci_lower_limit>
            <ci_upper_limit>-38.247</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apolipoprotein B (ApoB)</title>
        <description>ApoB is a major protein that makes up LDL cholesterol and is involved in transporting cholesterol and triglycerides to cells and tissues in the body. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value.</description>
        <time_frame>Baseline, Day 5, 8, 15, 22, 29, 36, 43, 50, 57, 71, 85, 99, 106, 113, 127, 141, 155, 169</time_frame>
        <population>FAS included all the participants who were randomized and administered at least 1 dose of study treatment. Here, ‘Number analyzed’ = Participants evaluable for this outcome measure at specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin + PF-04950615 50 mg</title>
            <description>Participants with fasting lipoprotein cholesterol (LDL-C) level (greater than or equal to [&gt;=]100 milligram per deciliter [mg/dL]) received atorvastatin along with PF-04950615 50 milligram (mg) subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin + PF-04950615 100 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 100 mg subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin + PF-04950615 150 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 150 mg subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O4">
            <title>Atorvastatin + PF-04950615 Placebo</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 placebo subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O5">
            <title>Atorvastatin + Ezetimibe 10 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with ezetimibe 10 mg tablet orally, once daily from Day 1 up to Day 112. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O6">
            <title>PF-04950615 50 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 50 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O7">
            <title>PF-04950615 100 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 100 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O8">
            <title>PF-04950615 150 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 150 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O9">
            <title>PF-04950615 Placebo</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 placebo, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naive to a treatment by lipid lowering drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Apolipoprotein B (ApoB)</title>
          <description>ApoB is a major protein that makes up LDL cholesterol and is involved in transporting cholesterol and triglycerides to cells and tissues in the body. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value.</description>
          <population>FAS included all the participants who were randomized and administered at least 1 dose of study treatment. Here, ‘Number analyzed’ = Participants evaluable for this outcome measure at specified time points.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="26"/>
                <count group_id="O5" value="22"/>
                <count group_id="O6" value="25"/>
                <count group_id="O7" value="25"/>
                <count group_id="O8" value="24"/>
                <count group_id="O9" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="25"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.76" spread="14.383"/>
                    <measurement group_id="O2" value="92.54" spread="12.362"/>
                    <measurement group_id="O3" value="90.40" spread="12.732"/>
                    <measurement group_id="O4" value="95.65" spread="13.229"/>
                    <measurement group_id="O5" value="96.70" spread="13.382"/>
                    <measurement group_id="O6" value="106.54" spread="15.800"/>
                    <measurement group_id="O7" value="104.02" spread="14.652"/>
                    <measurement group_id="O8" value="101.88" spread="11.494"/>
                    <measurement group_id="O9" value="103.13" spread="13.608"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="23"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="25"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.72" spread="15.175"/>
                    <measurement group_id="O2" value="59.83" spread="14.269"/>
                    <measurement group_id="O3" value="60.26" spread="8.853"/>
                    <measurement group_id="O4" value="94.62" spread="12.847"/>
                    <measurement group_id="O5" value="84.68" spread="13.570"/>
                    <measurement group_id="O6" value="88.40" spread="18.777"/>
                    <measurement group_id="O7" value="82.88" spread="13.179"/>
                    <measurement group_id="O8" value="78.00" spread="14.025"/>
                    <measurement group_id="O9" value="104.86" spread="11.902"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="21"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="22"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.12" spread="12.245"/>
                    <measurement group_id="O2" value="49.04" spread="15.982"/>
                    <measurement group_id="O3" value="47.42" spread="9.050"/>
                    <measurement group_id="O4" value="95.72" spread="16.395"/>
                    <measurement group_id="O5" value="80.38" spread="13.113"/>
                    <measurement group_id="O6" value="82.52" spread="19.402"/>
                    <measurement group_id="O7" value="71.71" spread="13.614"/>
                    <measurement group_id="O8" value="70.27" spread="16.237"/>
                    <measurement group_id="O9" value="107.61" spread="11.357"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="25"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.20" spread="15.658"/>
                    <measurement group_id="O2" value="49.38" spread="15.528"/>
                    <measurement group_id="O3" value="36.50" spread="8.703"/>
                    <measurement group_id="O4" value="96.65" spread="13.069"/>
                    <measurement group_id="O5" value="79.36" spread="9.639"/>
                    <measurement group_id="O6" value="82.24" spread="21.127"/>
                    <measurement group_id="O7" value="62.28" spread="16.403"/>
                    <measurement group_id="O8" value="58.08" spread="12.265"/>
                    <measurement group_id="O9" value="107.39" spread="12.052"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.28" spread="13.227"/>
                    <measurement group_id="O2" value="36.83" spread="12.923"/>
                    <measurement group_id="O3" value="31.09" spread="5.938"/>
                    <measurement group_id="O4" value="96.35" spread="10.954"/>
                    <measurement group_id="O5" value="79.77" spread="12.976"/>
                    <measurement group_id="O6" value="68.76" spread="20.949"/>
                    <measurement group_id="O7" value="53.46" spread="14.700"/>
                    <measurement group_id="O8" value="50.54" spread="15.300"/>
                    <measurement group_id="O9" value="108.35" spread="10.530"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="25"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.08" spread="16.595"/>
                    <measurement group_id="O2" value="46.42" spread="16.264"/>
                    <measurement group_id="O3" value="32.83" spread="8.611"/>
                    <measurement group_id="O4" value="96.00" spread="11.800"/>
                    <measurement group_id="O5" value="80.73" spread="12.691"/>
                    <measurement group_id="O6" value="69.32" spread="20.613"/>
                    <measurement group_id="O7" value="54.20" spread="12.285"/>
                    <measurement group_id="O8" value="50.25" spread="11.752"/>
                    <measurement group_id="O9" value="107.23" spread="12.134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.04" spread="11.998"/>
                    <measurement group_id="O2" value="35.50" spread="13.603"/>
                    <measurement group_id="O3" value="29.43" spread="6.036"/>
                    <measurement group_id="O4" value="96.27" spread="14.717"/>
                    <measurement group_id="O5" value="80.18" spread="13.828"/>
                    <measurement group_id="O6" value="62.40" spread="19.885"/>
                    <measurement group_id="O7" value="49.25" spread="8.115"/>
                    <measurement group_id="O8" value="46.92" spread="14.191"/>
                    <measurement group_id="O9" value="103.74" spread="13.363"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="25"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.36" spread="14.494"/>
                    <measurement group_id="O2" value="42.50" spread="17.942"/>
                    <measurement group_id="O3" value="31.96" spread="7.538"/>
                    <measurement group_id="O4" value="94.31" spread="9.216"/>
                    <measurement group_id="O5" value="82.68" spread="12.797"/>
                    <measurement group_id="O6" value="67.24" spread="19.959"/>
                    <measurement group_id="O7" value="53.60" spread="14.283"/>
                    <measurement group_id="O8" value="48.50" spread="14.301"/>
                    <measurement group_id="O9" value="110.39" spread="11.645"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 50</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.48" spread="10.759"/>
                    <measurement group_id="O2" value="34.08" spread="12.728"/>
                    <measurement group_id="O3" value="30.52" spread="6.660"/>
                    <measurement group_id="O4" value="95.69" spread="12.802"/>
                    <measurement group_id="O5" value="82.86" spread="12.822"/>
                    <measurement group_id="O6" value="62.28" spread="19.932"/>
                    <measurement group_id="O7" value="49.43" spread="11.469"/>
                    <measurement group_id="O8" value="47.58" spread="14.443"/>
                    <measurement group_id="O9" value="107.22" spread="11.062"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 57</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.44" spread="14.077"/>
                    <measurement group_id="O2" value="38.29" spread="16.236"/>
                    <measurement group_id="O3" value="29.48" spread="6.052"/>
                    <measurement group_id="O4" value="93.81" spread="12.316"/>
                    <measurement group_id="O5" value="79.68" spread="15.490"/>
                    <measurement group_id="O6" value="62.00" spread="19.660"/>
                    <measurement group_id="O7" value="53.25" spread="17.745"/>
                    <measurement group_id="O8" value="45.79" spread="12.322"/>
                    <measurement group_id="O9" value="104.13" spread="9.057"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 71</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.83" spread="16.903"/>
                    <measurement group_id="O2" value="38.71" spread="16.648"/>
                    <measurement group_id="O3" value="32.00" spread="7.634"/>
                    <measurement group_id="O4" value="97.23" spread="11.884"/>
                    <measurement group_id="O5" value="85.18" spread="14.378"/>
                    <measurement group_id="O6" value="69.96" spread="19.673"/>
                    <measurement group_id="O7" value="50.63" spread="11.568"/>
                    <measurement group_id="O8" value="47.79" spread="12.112"/>
                    <measurement group_id="O9" value="107.78" spread="16.082"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.32" spread="15.258"/>
                    <measurement group_id="O2" value="39.21" spread="15.291"/>
                    <measurement group_id="O3" value="33.65" spread="14.717"/>
                    <measurement group_id="O4" value="93.46" spread="12.666"/>
                    <measurement group_id="O5" value="86.77" spread="16.934"/>
                    <measurement group_id="O6" value="68.68" spread="17.409"/>
                    <measurement group_id="O7" value="49.35" spread="15.183"/>
                    <measurement group_id="O8" value="45.13" spread="10.678"/>
                    <measurement group_id="O9" value="102.09" spread="12.387"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 99</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="22"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.36" spread="17.291"/>
                    <measurement group_id="O2" value="44.29" spread="17.853"/>
                    <measurement group_id="O3" value="37.55" spread="18.913"/>
                    <measurement group_id="O4" value="95.08" spread="12.165"/>
                    <measurement group_id="O5" value="84.05" spread="16.247"/>
                    <measurement group_id="O6" value="72.56" spread="18.063"/>
                    <measurement group_id="O7" value="53.63" spread="17.272"/>
                    <measurement group_id="O8" value="45.88" spread="11.211"/>
                    <measurement group_id="O9" value="110.91" spread="11.049"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 106</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="22"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.12" spread="13.233"/>
                    <measurement group_id="O2" value="34.71" spread="15.029"/>
                    <measurement group_id="O3" value="35.55" spread="15.987"/>
                    <measurement group_id="O4" value="94.36" spread="12.192"/>
                    <measurement group_id="O5" value="83.32" spread="14.965"/>
                    <measurement group_id="O6" value="66.72" spread="17.111"/>
                    <measurement group_id="O7" value="48.87" spread="13.168"/>
                    <measurement group_id="O8" value="47.00" spread="12.332"/>
                    <measurement group_id="O9" value="107.48" spread="10.117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 113</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="23"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.50" spread="13.593"/>
                    <measurement group_id="O2" value="42.83" spread="16.612"/>
                    <measurement group_id="O3" value="36.48" spread="15.111"/>
                    <measurement group_id="O4" value="88.40" spread="13.438"/>
                    <measurement group_id="O5" value="82.77" spread="15.593"/>
                    <measurement group_id="O6" value="69.08" spread="17.007"/>
                    <measurement group_id="O7" value="52.52" spread="15.774"/>
                    <measurement group_id="O8" value="45.87" spread="11.530"/>
                    <measurement group_id="O9" value="105.61" spread="9.940"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 127</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.00" spread="13.871"/>
                    <measurement group_id="O2" value="73.04" spread="21.566"/>
                    <measurement group_id="O3" value="54.61" spread="24.203"/>
                    <measurement group_id="O4" value="95.16" spread="12.216"/>
                    <measurement group_id="O5" value="98.50" spread="16.280"/>
                    <measurement group_id="O6" value="97.20" spread="20.827"/>
                    <measurement group_id="O7" value="69.91" spread="28.257"/>
                    <measurement group_id="O8" value="62.75" spread="19.525"/>
                    <measurement group_id="O9" value="111.35" spread="14.288"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 141</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.50" spread="14.611"/>
                    <measurement group_id="O2" value="87.71" spread="18.112"/>
                    <measurement group_id="O3" value="74.87" spread="25.118"/>
                    <measurement group_id="O4" value="95.08" spread="12.024"/>
                    <measurement group_id="O5" value="100.45" spread="19.043"/>
                    <measurement group_id="O6" value="108.96" spread="21.279"/>
                    <measurement group_id="O7" value="92.70" spread="27.420"/>
                    <measurement group_id="O8" value="77.67" spread="25.466"/>
                    <measurement group_id="O9" value="110.09" spread="12.109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 155</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="23"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.16" spread="14.291"/>
                    <measurement group_id="O2" value="89.00" spread="15.836"/>
                    <measurement group_id="O3" value="81.87" spread="16.652"/>
                    <measurement group_id="O4" value="96.00" spread="11.832"/>
                    <measurement group_id="O5" value="101.23" spread="18.619"/>
                    <measurement group_id="O6" value="111.39" spread="17.758"/>
                    <measurement group_id="O7" value="98.26" spread="19.262"/>
                    <measurement group_id="O8" value="86.04" spread="23.451"/>
                    <measurement group_id="O9" value="108.43" spread="10.422"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 169</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="24"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="23"/>
                    <count group_id="O9" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.36" spread="16.176"/>
                    <measurement group_id="O2" value="93.63" spread="14.455"/>
                    <measurement group_id="O3" value="91.57" spread="15.147"/>
                    <measurement group_id="O4" value="96.88" spread="13.532"/>
                    <measurement group_id="O5" value="103.09" spread="20.718"/>
                    <measurement group_id="O6" value="112.46" spread="16.005"/>
                    <measurement group_id="O7" value="105.91" spread="17.661"/>
                    <measurement group_id="O8" value="95.74" spread="21.764"/>
                    <measurement group_id="O9" value="111.41" spread="9.879"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Apolipoprotein B (ApoB) at Day 85 and Day 113</title>
        <description>ApoB is a major protein that makes up LDL cholesterol and is involved in transporting cholesterol and triglycerides to cells and tissues in the body. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value. Change from baseline = observed value minus baseline value.</description>
        <time_frame>Baseline, Day 85, 113</time_frame>
        <population>FAS included all the participants who were randomized and administered at least 1 dose of study treatment. Here, ‘Number analyzed’ = Participants evaluable for this outcome measure at specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin + PF-04950615 50 mg</title>
            <description>Participants with fasting lipoprotein cholesterol (LDL-C) level (greater than or equal to [&gt;=]100 milligram per deciliter [mg/dL]) received atorvastatin along with PF-04950615 50 milligram (mg) subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin + PF-04950615 100 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 100 mg subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin + PF-04950615 150 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 150 mg subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O4">
            <title>Atorvastatin + PF-04950615 Placebo</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 placebo subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O5">
            <title>Atorvastatin + Ezetimibe 10 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with ezetimibe 10 mg tablet orally, once daily from Day 1 up to Day 112. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O6">
            <title>PF-04950615 50 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 50 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O7">
            <title>PF-04950615 100 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 100 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O8">
            <title>PF-04950615 150 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 150 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O9">
            <title>PF-04950615 Placebo</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 placebo, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naive to a treatment by lipid lowering drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Apolipoprotein B (ApoB) at Day 85 and Day 113</title>
          <description>ApoB is a major protein that makes up LDL cholesterol and is involved in transporting cholesterol and triglycerides to cells and tissues in the body. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value. Change from baseline = observed value minus baseline value.</description>
          <population>FAS included all the participants who were randomized and administered at least 1 dose of study treatment. Here, ‘Number analyzed’ = Participants evaluable for this outcome measure at specified time points.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="26"/>
                <count group_id="O5" value="22"/>
                <count group_id="O6" value="25"/>
                <count group_id="O7" value="25"/>
                <count group_id="O8" value="24"/>
                <count group_id="O9" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Day 85</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-41.44" spread="16.385"/>
                    <measurement group_id="O2" value="-53.33" spread="19.097"/>
                    <measurement group_id="O3" value="-56.43" spread="17.650"/>
                    <measurement group_id="O4" value="-2.19" spread="10.703"/>
                    <measurement group_id="O5" value="-9.93" spread="14.350"/>
                    <measurement group_id="O6" value="-37.86" spread="18.125"/>
                    <measurement group_id="O7" value="-54.33" spread="21.080"/>
                    <measurement group_id="O8" value="-56.75" spread="14.506"/>
                    <measurement group_id="O9" value="-1.04" spread="13.020"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 113</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="23"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-39.56" spread="12.011"/>
                    <measurement group_id="O2" value="-49.71" spread="18.699"/>
                    <measurement group_id="O3" value="-53.61" spread="16.526"/>
                    <measurement group_id="O4" value="-7.70" spread="12.436"/>
                    <measurement group_id="O5" value="-13.93" spread="12.650"/>
                    <measurement group_id="O6" value="-37.46" spread="18.504"/>
                    <measurement group_id="O7" value="-51.15" spread="16.855"/>
                    <measurement group_id="O8" value="-56.83" spread="15.501"/>
                    <measurement group_id="O9" value="2.48" spread="11.107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 85 : Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-41.118</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.344</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-47.760</ci_lower_limit>
            <ci_upper_limit>-34.476</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-54.787</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.402</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-61.543</ci_lower_limit>
            <ci_upper_limit>-48.032</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-60.549</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.453</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-67.403</ci_lower_limit>
            <ci_upper_limit>-53.694</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-36.589</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.730</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-43.999</ci_lower_limit>
            <ci_upper_limit>-29.178</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-54.683</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.734</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-62.102</ci_lower_limit>
            <ci_upper_limit>-47.265</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-56.517</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.688</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-63.845</ci_lower_limit>
            <ci_upper_limit>-49.189</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-33.262</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.196</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-39.608</ci_lower_limit>
            <ci_upper_limit>-26.915</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-45.956</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.239</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-52.388</ci_lower_limit>
            <ci_upper_limit>-39.523</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-51.500</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.305</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-58.063</ci_lower_limit>
            <ci_upper_limit>-44.937</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-40.474</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.547</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-47.523</ci_lower_limit>
            <ci_upper_limit>-33.426</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-54.634</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.549</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-61.685</ci_lower_limit>
            <ci_upper_limit>-47.583</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 113:Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-59.608</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.520</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-66.602</ci_lower_limit>
            <ci_upper_limit>-52.614</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Apolipoprotein B (ApoB) at Day 85 and Day 113</title>
        <description>ApoB is a major protein that makes up LDL cholesterol and is involved in transporting cholesterol and triglycerides to cells and tissues in the body. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value. Percent change from baseline = ([observed value divided by baseline value] minus 1) multiplied by 100.</description>
        <time_frame>Baseline, Day 85, 113</time_frame>
        <population>FAS included all the participants who were randomized and administered at least 1 dose of study treatment. Here, ‘Number analyzed’ = Participants evaluable for this outcome measure at specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin + PF-04950615 50 mg</title>
            <description>Participants with fasting lipoprotein cholesterol (LDL-C) level (greater than or equal to [&gt;=]100 milligram per deciliter [mg/dL]) received atorvastatin along with PF-04950615 50 milligram (mg) subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin + PF-04950615 100 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 100 mg subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin + PF-04950615 150 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 150 mg subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O4">
            <title>Atorvastatin + PF-04950615 Placebo</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 placebo subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O5">
            <title>Atorvastatin + Ezetimibe 10 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with ezetimibe 10 mg tablet orally, once daily from Day 1 up to Day 112. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O6">
            <title>PF-04950615 50 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 50 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O7">
            <title>PF-04950615 100 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 100 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O8">
            <title>PF-04950615 150 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 150 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O9">
            <title>PF-04950615 Placebo</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 placebo, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naive to a treatment by lipid lowering drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Apolipoprotein B (ApoB) at Day 85 and Day 113</title>
          <description>ApoB is a major protein that makes up LDL cholesterol and is involved in transporting cholesterol and triglycerides to cells and tissues in the body. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value. Percent change from baseline = ([observed value divided by baseline value] minus 1) multiplied by 100.</description>
          <population>FAS included all the participants who were randomized and administered at least 1 dose of study treatment. Here, ‘Number analyzed’ = Participants evaluable for this outcome measure at specified time points.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="26"/>
                <count group_id="O5" value="22"/>
                <count group_id="O6" value="25"/>
                <count group_id="O7" value="25"/>
                <count group_id="O8" value="24"/>
                <count group_id="O9" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Day 85</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-44.30" spread="15.675"/>
                    <measurement group_id="O2" value="-57.02" spread="17.985"/>
                    <measurement group_id="O3" value="-62.31" spread="15.684"/>
                    <measurement group_id="O4" value="-1.77" spread="10.567"/>
                    <measurement group_id="O5" value="-9.97" spread="14.426"/>
                    <measurement group_id="O6" value="-35.16" spread="15.906"/>
                    <measurement group_id="O7" value="-51.62" spread="16.289"/>
                    <measurement group_id="O8" value="-55.31" spread="11.060"/>
                    <measurement group_id="O9" value="-0.13" spread="12.144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 113</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="23"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-42.64" spread="11.864"/>
                    <measurement group_id="O2" value="-53.45" spread="18.449"/>
                    <measurement group_id="O3" value="-59.48" spread="15.320"/>
                    <measurement group_id="O4" value="-7.54" spread="11.662"/>
                    <measurement group_id="O5" value="-14.17" spread="12.713"/>
                    <measurement group_id="O6" value="-34.66" spread="16.214"/>
                    <measurement group_id="O7" value="-49.10" spread="14.474"/>
                    <measurement group_id="O8" value="-54.88" spread="12.109"/>
                    <measurement group_id="O9" value="3.43" spread="12.038"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-43.265</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.566</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-50.347</ci_lower_limit>
            <ci_upper_limit>-36.183</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-57.962</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.628</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-65.167</ci_lower_limit>
            <ci_upper_limit>-50.758</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-64.729</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.682</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-72.039</ci_lower_limit>
            <ci_upper_limit>-57.419</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-36.428</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.535</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-43.451</ci_lower_limit>
            <ci_upper_limit>-29.405</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-53.296</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.538</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-60.325</ci_lower_limit>
            <ci_upper_limit>-46.267</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-55.489</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.496</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-62.436</ci_lower_limit>
            <ci_upper_limit>-48.542</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-35.288</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.410</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-42.059</ci_lower_limit>
            <ci_upper_limit>-28.516</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-48.845</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.456</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-55.709</ci_lower_limit>
            <ci_upper_limit>-41.982</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-55.114</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.526</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-62.116</ci_lower_limit>
            <ci_upper_limit>-48.112</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-40.045</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.560</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-47.118</ci_lower_limit>
            <ci_upper_limit>-32.971</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-53.810</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.560</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-60.883</ci_lower_limit>
            <ci_upper_limit>-46.737</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 113:Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-58.620</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.533</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-65.640</ci_lower_limit>
            <ci_upper_limit>-51.600</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apolipoprotein A-I (ApoA-I)</title>
        <description>ApoA1 is a major protein that is a component of HDL cholesterol and helps in clearing cholesterol from the blood by removing cholesterol from organs and tissues to be destroyed by the liver. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value.</description>
        <time_frame>Baseline, Day 5, 8, 15, 22, 29, 36, 43, 50, 57, 71, 85, 99, 106, 113, 127, 141, 155, 169</time_frame>
        <population>FAS included all the participants who were randomized and administered at least 1 dose of study treatment. Here, ‘Number analyzed’ = Participants evaluable for this outcome measure at specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin + PF-04950615 50 mg</title>
            <description>Participants with fasting lipoprotein cholesterol (LDL-C) level (greater than or equal to [&gt;=]100 milligram per deciliter [mg/dL]) received atorvastatin along with PF-04950615 50 milligram (mg) subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin + PF-04950615 100 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 100 mg subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin + PF-04950615 150 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 150 mg subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O4">
            <title>Atorvastatin + PF-04950615 Placebo</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 placebo subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O5">
            <title>Atorvastatin + Ezetimibe 10 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with ezetimibe 10 mg tablet orally, once daily from Day 1 up to Day 112. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O6">
            <title>PF-04950615 50 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 50 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O7">
            <title>PF-04950615 100 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 100 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O8">
            <title>PF-04950615 150 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 150 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O9">
            <title>PF-04950615 Placebo</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 placebo, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naive to a treatment by lipid lowering drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Apolipoprotein A-I (ApoA-I)</title>
          <description>ApoA1 is a major protein that is a component of HDL cholesterol and helps in clearing cholesterol from the blood by removing cholesterol from organs and tissues to be destroyed by the liver. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value.</description>
          <population>FAS included all the participants who were randomized and administered at least 1 dose of study treatment. Here, ‘Number analyzed’ = Participants evaluable for this outcome measure at specified time points.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="26"/>
                <count group_id="O5" value="22"/>
                <count group_id="O6" value="25"/>
                <count group_id="O7" value="25"/>
                <count group_id="O8" value="24"/>
                <count group_id="O9" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="25"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="137.02" spread="13.235"/>
                    <measurement group_id="O2" value="142.60" spread="16.507"/>
                    <measurement group_id="O3" value="140.31" spread="18.813"/>
                    <measurement group_id="O4" value="145.65" spread="21.908"/>
                    <measurement group_id="O5" value="145.34" spread="16.171"/>
                    <measurement group_id="O6" value="138.90" spread="21.808"/>
                    <measurement group_id="O7" value="145.38" spread="19.260"/>
                    <measurement group_id="O8" value="146.75" spread="25.587"/>
                    <measurement group_id="O9" value="150.13" spread="16.834"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="23"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="25"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="140.72" spread="14.644"/>
                    <measurement group_id="O2" value="146.65" spread="16.773"/>
                    <measurement group_id="O3" value="144.48" spread="19.943"/>
                    <measurement group_id="O4" value="146.08" spread="21.505"/>
                    <measurement group_id="O5" value="144.68" spread="16.193"/>
                    <measurement group_id="O6" value="142.12" spread="22.260"/>
                    <measurement group_id="O7" value="145.12" spread="18.485"/>
                    <measurement group_id="O8" value="149.79" spread="24.285"/>
                    <measurement group_id="O9" value="150.09" spread="17.989"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="21"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="22"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="140.44" spread="14.972"/>
                    <measurement group_id="O2" value="147.46" spread="16.707"/>
                    <measurement group_id="O3" value="146.88" spread="19.200"/>
                    <measurement group_id="O4" value="147.00" spread="21.527"/>
                    <measurement group_id="O5" value="145.57" spread="16.351"/>
                    <measurement group_id="O6" value="146.76" spread="25.406"/>
                    <measurement group_id="O7" value="145.79" spread="19.260"/>
                    <measurement group_id="O8" value="152.45" spread="28.118"/>
                    <measurement group_id="O9" value="150.48" spread="16.782"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="25"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="141.56" spread="13.811"/>
                    <measurement group_id="O2" value="153.00" spread="16.325"/>
                    <measurement group_id="O3" value="150.46" spread="20.479"/>
                    <measurement group_id="O4" value="147.04" spread="22.704"/>
                    <measurement group_id="O5" value="148.50" spread="18.918"/>
                    <measurement group_id="O6" value="145.76" spread="23.197"/>
                    <measurement group_id="O7" value="150.08" spread="20.762"/>
                    <measurement group_id="O8" value="157.04" spread="25.154"/>
                    <measurement group_id="O9" value="151.00" spread="19.214"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143.20" spread="15.554"/>
                    <measurement group_id="O2" value="152.88" spread="18.473"/>
                    <measurement group_id="O3" value="151.78" spread="20.576"/>
                    <measurement group_id="O4" value="145.31" spread="21.481"/>
                    <measurement group_id="O5" value="146.41" spread="17.012"/>
                    <measurement group_id="O6" value="145.96" spread="22.354"/>
                    <measurement group_id="O7" value="150.08" spread="19.019"/>
                    <measurement group_id="O8" value="155.17" spread="23.265"/>
                    <measurement group_id="O9" value="151.65" spread="17.185"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="25"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="144.32" spread="15.118"/>
                    <measurement group_id="O2" value="155.79" spread="19.598"/>
                    <measurement group_id="O3" value="151.78" spread="22.913"/>
                    <measurement group_id="O4" value="144.28" spread="20.633"/>
                    <measurement group_id="O5" value="146.23" spread="17.221"/>
                    <measurement group_id="O6" value="146.36" spread="22.503"/>
                    <measurement group_id="O7" value="150.04" spread="21.763"/>
                    <measurement group_id="O8" value="155.96" spread="23.143"/>
                    <measurement group_id="O9" value="154.32" spread="15.304"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143.48" spread="15.273"/>
                    <measurement group_id="O2" value="149.88" spread="17.957"/>
                    <measurement group_id="O3" value="150.13" spread="21.102"/>
                    <measurement group_id="O4" value="143.46" spread="20.609"/>
                    <measurement group_id="O5" value="145.91" spread="18.652"/>
                    <measurement group_id="O6" value="145.08" spread="22.953"/>
                    <measurement group_id="O7" value="153.33" spread="19.417"/>
                    <measurement group_id="O8" value="155.08" spread="24.063"/>
                    <measurement group_id="O9" value="149.30" spread="18.639"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="25"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="144.52" spread="12.842"/>
                    <measurement group_id="O2" value="153.88" spread="18.262"/>
                    <measurement group_id="O3" value="150.33" spread="22.584"/>
                    <measurement group_id="O4" value="142.42" spread="21.495"/>
                    <measurement group_id="O5" value="144.64" spread="16.105"/>
                    <measurement group_id="O6" value="146.00" spread="21.050"/>
                    <measurement group_id="O7" value="152.32" spread="21.059"/>
                    <measurement group_id="O8" value="155.75" spread="32.193"/>
                    <measurement group_id="O9" value="149.04" spread="16.932"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 50</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="145.80" spread="15.042"/>
                    <measurement group_id="O2" value="151.25" spread="19.157"/>
                    <measurement group_id="O3" value="149.13" spread="19.008"/>
                    <measurement group_id="O4" value="143.46" spread="20.397"/>
                    <measurement group_id="O5" value="141.95" spread="15.807"/>
                    <measurement group_id="O6" value="142.84" spread="21.885"/>
                    <measurement group_id="O7" value="152.52" spread="19.739"/>
                    <measurement group_id="O8" value="153.92" spread="25.100"/>
                    <measurement group_id="O9" value="145.70" spread="14.348"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 57</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="138.40" spread="14.919"/>
                    <measurement group_id="O2" value="149.46" spread="19.509"/>
                    <measurement group_id="O3" value="145.83" spread="18.930"/>
                    <measurement group_id="O4" value="137.62" spread="18.206"/>
                    <measurement group_id="O5" value="142.18" spread="15.445"/>
                    <measurement group_id="O6" value="136.32" spread="20.010"/>
                    <measurement group_id="O7" value="145.96" spread="22.029"/>
                    <measurement group_id="O8" value="144.96" spread="25.049"/>
                    <measurement group_id="O9" value="138.87" spread="16.491"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 71</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="145.50" spread="16.192"/>
                    <measurement group_id="O2" value="152.92" spread="21.086"/>
                    <measurement group_id="O3" value="150.43" spread="21.002"/>
                    <measurement group_id="O4" value="142.62" spread="19.150"/>
                    <measurement group_id="O5" value="144.18" spread="15.383"/>
                    <measurement group_id="O6" value="143.88" spread="21.896"/>
                    <measurement group_id="O7" value="151.88" spread="17.523"/>
                    <measurement group_id="O8" value="154.25" spread="23.130"/>
                    <measurement group_id="O9" value="146.17" spread="14.981"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="138.04" spread="14.968"/>
                    <measurement group_id="O2" value="148.17" spread="16.818"/>
                    <measurement group_id="O3" value="144.04" spread="15.933"/>
                    <measurement group_id="O4" value="136.00" spread="20.229"/>
                    <measurement group_id="O5" value="144.23" spread="14.498"/>
                    <measurement group_id="O6" value="132.88" spread="19.303"/>
                    <measurement group_id="O7" value="145.13" spread="17.168"/>
                    <measurement group_id="O8" value="146.58" spread="23.006"/>
                    <measurement group_id="O9" value="136.30" spread="16.753"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 99</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="22"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="147.40" spread="18.771"/>
                    <measurement group_id="O2" value="154.54" spread="17.840"/>
                    <measurement group_id="O3" value="150.86" spread="21.108"/>
                    <measurement group_id="O4" value="147.48" spread="20.799"/>
                    <measurement group_id="O5" value="145.91" spread="16.798"/>
                    <measurement group_id="O6" value="143.88" spread="19.577"/>
                    <measurement group_id="O7" value="151.29" spread="21.612"/>
                    <measurement group_id="O8" value="149.83" spread="20.750"/>
                    <measurement group_id="O9" value="144.65" spread="19.812"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 106</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="22"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="145.92" spread="18.773"/>
                    <measurement group_id="O2" value="154.96" spread="19.282"/>
                    <measurement group_id="O3" value="150.23" spread="18.341"/>
                    <measurement group_id="O4" value="143.12" spread="17.822"/>
                    <measurement group_id="O5" value="144.64" spread="15.413"/>
                    <measurement group_id="O6" value="142.56" spread="21.143"/>
                    <measurement group_id="O7" value="149.26" spread="19.909"/>
                    <measurement group_id="O8" value="150.46" spread="21.444"/>
                    <measurement group_id="O9" value="141.17" spread="15.497"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 113</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="23"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139.21" spread="15.731"/>
                    <measurement group_id="O2" value="149.17" spread="18.719"/>
                    <measurement group_id="O3" value="144.13" spread="18.587"/>
                    <measurement group_id="O4" value="137.72" spread="21.454"/>
                    <measurement group_id="O5" value="145.00" spread="14.690"/>
                    <measurement group_id="O6" value="138.40" spread="19.581"/>
                    <measurement group_id="O7" value="149.09" spread="18.033"/>
                    <measurement group_id="O8" value="143.96" spread="21.353"/>
                    <measurement group_id="O9" value="140.04" spread="16.767"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 127</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="144.08" spread="18.630"/>
                    <measurement group_id="O2" value="148.75" spread="17.738"/>
                    <measurement group_id="O3" value="150.04" spread="23.145"/>
                    <measurement group_id="O4" value="145.60" spread="22.763"/>
                    <measurement group_id="O5" value="144.27" spread="14.701"/>
                    <measurement group_id="O6" value="141.68" spread="20.412"/>
                    <measurement group_id="O7" value="148.48" spread="18.012"/>
                    <measurement group_id="O8" value="149.17" spread="23.566"/>
                    <measurement group_id="O9" value="144.48" spread="15.237"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 141</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="145.46" spread="19.006"/>
                    <measurement group_id="O2" value="151.21" spread="18.990"/>
                    <measurement group_id="O3" value="154.17" spread="22.321"/>
                    <measurement group_id="O4" value="148.52" spread="23.261"/>
                    <measurement group_id="O5" value="144.45" spread="16.721"/>
                    <measurement group_id="O6" value="141.36" spread="20.968"/>
                    <measurement group_id="O7" value="148.74" spread="17.324"/>
                    <measurement group_id="O8" value="151.29" spread="22.831"/>
                    <measurement group_id="O9" value="149.13" spread="19.328"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 155</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="23"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143.52" spread="17.564"/>
                    <measurement group_id="O2" value="148.83" spread="20.267"/>
                    <measurement group_id="O3" value="149.52" spread="21.848"/>
                    <measurement group_id="O4" value="147.60" spread="23.076"/>
                    <measurement group_id="O5" value="147.09" spread="16.446"/>
                    <measurement group_id="O6" value="140.96" spread="23.437"/>
                    <measurement group_id="O7" value="148.09" spread="21.037"/>
                    <measurement group_id="O8" value="149.13" spread="23.899"/>
                    <measurement group_id="O9" value="148.83" spread="18.077"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 169</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="24"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="23"/>
                    <count group_id="O9" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="142.96" spread="20.387"/>
                    <measurement group_id="O2" value="151.54" spread="19.010"/>
                    <measurement group_id="O3" value="150.96" spread="19.025"/>
                    <measurement group_id="O4" value="154.88" spread="23.938"/>
                    <measurement group_id="O5" value="153.64" spread="21.367"/>
                    <measurement group_id="O6" value="144.13" spread="24.746"/>
                    <measurement group_id="O7" value="151.70" spread="21.699"/>
                    <measurement group_id="O8" value="151.13" spread="29.425"/>
                    <measurement group_id="O9" value="154.36" spread="19.742"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Apolipoprotein A-I (ApoA-I) at Day 85 and Day 113</title>
        <description>ApoA1 is a major protein that is a component of HDL cholesterol and helps in clearing cholesterol from the blood by removing cholesterol from organs and tissues to be destroyed by the liver. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value. Change from baseline = observed value minus baseline value.</description>
        <time_frame>Baseline, Day 85, 113</time_frame>
        <population>FAS included all the participants who were randomized and administered at least 1 dose of study treatment. Here, ‘Number analyzed’ = Participants evaluable for this outcome measure at specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin + PF-04950615 50 mg</title>
            <description>Participants with fasting lipoprotein cholesterol (LDL-C) level (greater than or equal to [&gt;=]100 milligram per deciliter [mg/dL]) received atorvastatin along with PF-04950615 50 milligram (mg) subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin + PF-04950615 100 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 100 mg subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin + PF-04950615 150 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 150 mg subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O4">
            <title>Atorvastatin + PF-04950615 Placebo</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 placebo subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O5">
            <title>Atorvastatin + Ezetimibe 10 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with ezetimibe 10 mg tablet orally, once daily from Day 1 up to Day 112. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O6">
            <title>PF-04950615 50 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 50 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O7">
            <title>PF-04950615 100 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 100 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O8">
            <title>PF-04950615 150 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 150 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O9">
            <title>PF-04950615 Placebo</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 placebo, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naive to a treatment by lipid lowering drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Apolipoprotein A-I (ApoA-I) at Day 85 and Day 113</title>
          <description>ApoA1 is a major protein that is a component of HDL cholesterol and helps in clearing cholesterol from the blood by removing cholesterol from organs and tissues to be destroyed by the liver. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value. Change from baseline = observed value minus baseline value.</description>
          <population>FAS included all the participants who were randomized and administered at least 1 dose of study treatment. Here, ‘Number analyzed’ = Participants evaluable for this outcome measure at specified time points.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="26"/>
                <count group_id="O5" value="22"/>
                <count group_id="O6" value="25"/>
                <count group_id="O7" value="25"/>
                <count group_id="O8" value="24"/>
                <count group_id="O9" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Day 85</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.02" spread="9.479"/>
                    <measurement group_id="O2" value="5.56" spread="10.575"/>
                    <measurement group_id="O3" value="3.63" spread="11.155"/>
                    <measurement group_id="O4" value="-9.65" spread="9.495"/>
                    <measurement group_id="O5" value="-1.11" spread="11.118"/>
                    <measurement group_id="O6" value="-6.02" spread="11.069"/>
                    <measurement group_id="O7" value="-2.09" spread="12.040"/>
                    <measurement group_id="O8" value="-0.17" spread="11.897"/>
                    <measurement group_id="O9" value="-13.83" spread="10.602"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 113</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="23"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.52" spread="9.226"/>
                    <measurement group_id="O2" value="6.56" spread="12.310"/>
                    <measurement group_id="O3" value="3.72" spread="11.977"/>
                    <measurement group_id="O4" value="-7.86" spread="13.052"/>
                    <measurement group_id="O5" value="-0.34" spread="10.783"/>
                    <measurement group_id="O6" value="-0.50" spread="9.512"/>
                    <measurement group_id="O7" value="1.87" spread="9.328"/>
                    <measurement group_id="O8" value="-3.54" spread="8.982"/>
                    <measurement group_id="O9" value="-10.09" spread="11.236"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 85 : Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>8.896</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.643</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.646</ci_lower_limit>
            <ci_upper_limit>14.145</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 85 : Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>15.429</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.662</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>10.141</ci_lower_limit>
            <ci_upper_limit>20.717</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 85 : Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>12.321</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.700</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>6.959</ci_lower_limit>
            <ci_upper_limit>17.683</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 85 : Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.014</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>6.804</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.041</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.761</ci_lower_limit>
            <ci_upper_limit>12.847</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>10.565</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.023</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.556</ci_lower_limit>
            <ci_upper_limit>16.573</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>12.895</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.969</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>6.993</ci_lower_limit>
            <ci_upper_limit>18.796</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.005</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>8.644</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.266</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.157</ci_lower_limit>
            <ci_upper_limit>15.130</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>14.708</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.272</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>8.208</ci_lower_limit>
            <ci_upper_limit>21.208</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>11.168</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.317</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.580</ci_lower_limit>
            <ci_upper_limit>17.757</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>8.132</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.609</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.947</ci_lower_limit>
            <ci_upper_limit>13.316</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>10.230</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.592</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.079</ci_lower_limit>
            <ci_upper_limit>15.381</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 113:Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.014</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>5.767</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.565</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.670</ci_lower_limit>
            <ci_upper_limit>10.864</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Apolipoprotein A-I (ApoA-I) at Day 85 and Day 113</title>
        <description>ApoA1 is a major protein that is a component of HDL cholesterol and helps in clearing cholesterol from the blood by removing cholesterol from organs and tissues to be destroyed by the liver. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value. Percent change from baseline = ([observed value divided by baseline value] minus 1) multiplied by 100.</description>
        <time_frame>Baseline, Day 85, 113</time_frame>
        <population>FAS included all the participants who were randomized and administered at least 1 dose of study treatment. Here, ‘Number analyzed’ = Participants evaluable for this outcome measure at specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin + PF-04950615 50 mg</title>
            <description>Participants with fasting lipoprotein cholesterol (LDL-C) level (greater than or equal to [&gt;=]100 milligram per deciliter [mg/dL]) received atorvastatin along with PF-04950615 50 milligram (mg) subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin + PF-04950615 100 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 100 mg subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin + PF-04950615 150 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 150 mg subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O4">
            <title>Atorvastatin + PF-04950615 Placebo</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 placebo subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O5">
            <title>Atorvastatin + Ezetimibe 10 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with ezetimibe 10 mg tablet orally, once daily from Day 1 up to Day 112. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O6">
            <title>PF-04950615 50 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 50 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O7">
            <title>PF-04950615 100 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 100 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O8">
            <title>PF-04950615 150 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 150 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O9">
            <title>PF-04950615 Placebo</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 placebo, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naive to a treatment by lipid lowering drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Apolipoprotein A-I (ApoA-I) at Day 85 and Day 113</title>
          <description>ApoA1 is a major protein that is a component of HDL cholesterol and helps in clearing cholesterol from the blood by removing cholesterol from organs and tissues to be destroyed by the liver. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value. Percent change from baseline = ([observed value divided by baseline value] minus 1) multiplied by 100.</description>
          <population>FAS included all the participants who were randomized and administered at least 1 dose of study treatment. Here, ‘Number analyzed’ = Participants evaluable for this outcome measure at specified time points.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="26"/>
                <count group_id="O5" value="22"/>
                <count group_id="O6" value="25"/>
                <count group_id="O7" value="25"/>
                <count group_id="O8" value="24"/>
                <count group_id="O9" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Day 85</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.87" spread="7.002"/>
                    <measurement group_id="O2" value="4.20" spread="7.438"/>
                    <measurement group_id="O3" value="3.26" spread="8.418"/>
                    <measurement group_id="O4" value="-6.44" spread="6.252"/>
                    <measurement group_id="O5" value="-0.34" spread="7.749"/>
                    <measurement group_id="O6" value="-3.82" spread="8.033"/>
                    <measurement group_id="O7" value="-1.00" spread="8.245"/>
                    <measurement group_id="O8" value="0.44" spread="8.673"/>
                    <measurement group_id="O9" value="-9.10" spread="6.738"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 113</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="23"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.93" spread="6.789"/>
                    <measurement group_id="O2" value="4.82" spread="8.766"/>
                    <measurement group_id="O3" value="3.13" spread="8.663"/>
                    <measurement group_id="O4" value="-5.16" spread="8.106"/>
                    <measurement group_id="O5" value="0.15" spread="7.819"/>
                    <measurement group_id="O6" value="0.13" spread="7.013"/>
                    <measurement group_id="O7" value="1.53" spread="6.572"/>
                    <measurement group_id="O8" value="-1.84" spread="5.923"/>
                    <measurement group_id="O9" value="-6.55" spread="6.903"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 85 : Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>6.079</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.905</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.296</ci_lower_limit>
            <ci_upper_limit>9.863</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>10.786</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.918</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>6.976</ci_lower_limit>
            <ci_upper_limit>14.597</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>9.069</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.945</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.206</ci_lower_limit>
            <ci_upper_limit>12.932</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.014</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>4.859</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.173</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.541</ci_lower_limit>
            <ci_upper_limit>9.178</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>7.331</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.161</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.037</ci_lower_limit>
            <ci_upper_limit>11.624</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>9.075</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.122</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.856</ci_lower_limit>
            <ci_upper_limit>13.293</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.005</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>5.936</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.266</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.435</ci_lower_limit>
            <ci_upper_limit>10.437</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>10.213</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.271</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.702</ci_lower_limit>
            <ci_upper_limit>14.724</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>8.056</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.302</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.484</ci_lower_limit>
            <ci_upper_limit>12.629</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>5.846</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.778</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.312</ci_lower_limit>
            <ci_upper_limit>9.380</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>6.910</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.766</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.400</ci_lower_limit>
            <ci_upper_limit>10.421</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 113:Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.010</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>4.168</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.748</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.693</ci_lower_limit>
            <ci_upper_limit>7.642</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apolipoprotein A-II (ApoA-II)</title>
        <description>ApoA-II is the second most abundant component of the HDL cholesterol. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value.</description>
        <time_frame>Baseline, Day 5, 8, 15, 22, 29, 36, 43, 50, 57, 71, 85, 99, 106, 113, 127, 141, 155, 169</time_frame>
        <population>FAS included all the participants who were randomized and administered at least 1 dose of study treatment. Here, ‘Number analyzed’ = Participants evaluable for this outcome measure at specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin + PF-04950615 50 mg</title>
            <description>Participants with fasting lipoprotein cholesterol (LDL-C) level (greater than or equal to [&gt;=]100 milligram per deciliter [mg/dL]) received atorvastatin along with PF-04950615 50 milligram (mg) subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin + PF-04950615 100 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 100 mg subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin + PF-04950615 150 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 150 mg subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O4">
            <title>Atorvastatin + PF-04950615 Placebo</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 placebo subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O5">
            <title>Atorvastatin + Ezetimibe 10 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with ezetimibe 10 mg tablet orally, once daily from Day 1 up to Day 112. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O6">
            <title>PF-04950615 50 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 50 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O7">
            <title>PF-04950615 100 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 100 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O8">
            <title>PF-04950615 150 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 150 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O9">
            <title>PF-04950615 Placebo</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 placebo, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naive to a treatment by lipid lowering drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Apolipoprotein A-II (ApoA-II)</title>
          <description>ApoA-II is the second most abundant component of the HDL cholesterol. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value.</description>
          <population>FAS included all the participants who were randomized and administered at least 1 dose of study treatment. Here, ‘Number analyzed’ = Participants evaluable for this outcome measure at specified time points.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="26"/>
                <count group_id="O5" value="22"/>
                <count group_id="O6" value="25"/>
                <count group_id="O7" value="25"/>
                <count group_id="O8" value="24"/>
                <count group_id="O9" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="25"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.700" spread="3.6817"/>
                    <measurement group_id="O2" value="30.223" spread="2.8992"/>
                    <measurement group_id="O3" value="30.471" spread="2.8918"/>
                    <measurement group_id="O4" value="31.515" spread="3.8373"/>
                    <measurement group_id="O5" value="32.189" spread="3.2855"/>
                    <measurement group_id="O6" value="29.940" spread="3.3630"/>
                    <measurement group_id="O7" value="31.232" spread="3.9681"/>
                    <measurement group_id="O8" value="30.294" spread="3.0541"/>
                    <measurement group_id="O9" value="31.354" spread="3.9552"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="23"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="25"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.884" spread="3.6551"/>
                    <measurement group_id="O2" value="30.161" spread="2.9004"/>
                    <measurement group_id="O3" value="30.443" spread="3.4057"/>
                    <measurement group_id="O4" value="31.608" spread="3.6099"/>
                    <measurement group_id="O5" value="32.709" spread="3.4130"/>
                    <measurement group_id="O6" value="30.088" spread="3.4784"/>
                    <measurement group_id="O7" value="30.972" spread="4.2462"/>
                    <measurement group_id="O8" value="30.558" spread="3.0567"/>
                    <measurement group_id="O9" value="31.473" spread="4.1750"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="21"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="22"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.224" spread="2.8736"/>
                    <measurement group_id="O2" value="30.675" spread="3.1077"/>
                    <measurement group_id="O3" value="30.738" spread="2.9137"/>
                    <measurement group_id="O4" value="32.036" spread="3.2261"/>
                    <measurement group_id="O5" value="32.495" spread="3.0372"/>
                    <measurement group_id="O6" value="30.760" spread="3.3363"/>
                    <measurement group_id="O7" value="30.608" spread="3.8492"/>
                    <measurement group_id="O8" value="30.664" spread="3.2942"/>
                    <measurement group_id="O9" value="31.635" spread="3.6272"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="25"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.528" spread="3.7034"/>
                    <measurement group_id="O2" value="31.129" spread="2.9304"/>
                    <measurement group_id="O3" value="31.304" spread="3.0309"/>
                    <measurement group_id="O4" value="32.062" spread="3.2968"/>
                    <measurement group_id="O5" value="33.136" spread="3.6822"/>
                    <measurement group_id="O6" value="30.568" spread="3.3308"/>
                    <measurement group_id="O7" value="31.516" spread="3.9116"/>
                    <measurement group_id="O8" value="31.275" spread="3.4925"/>
                    <measurement group_id="O9" value="31.530" spread="4.6451"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.232" spread="3.1787"/>
                    <measurement group_id="O2" value="30.667" spread="3.4561"/>
                    <measurement group_id="O3" value="31.183" spread="3.8763"/>
                    <measurement group_id="O4" value="31.846" spread="3.0899"/>
                    <measurement group_id="O5" value="32.273" spread="3.2310"/>
                    <measurement group_id="O6" value="30.620" spread="3.3448"/>
                    <measurement group_id="O7" value="31.125" spread="4.0921"/>
                    <measurement group_id="O8" value="30.896" spread="3.0900"/>
                    <measurement group_id="O9" value="32.200" spread="3.6940"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="25"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.608" spread="3.2712"/>
                    <measurement group_id="O2" value="32.279" spread="4.1331"/>
                    <measurement group_id="O3" value="31.035" spread="3.7585"/>
                    <measurement group_id="O4" value="32.096" spread="3.6363"/>
                    <measurement group_id="O5" value="32.395" spread="3.1748"/>
                    <measurement group_id="O6" value="30.740" spread="3.0899"/>
                    <measurement group_id="O7" value="31.100" spread="3.6272"/>
                    <measurement group_id="O8" value="31.071" spread="2.8639"/>
                    <measurement group_id="O9" value="31.882" spread="3.6960"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.208" spread="3.5747"/>
                    <measurement group_id="O2" value="30.838" spread="3.3920"/>
                    <measurement group_id="O3" value="30.622" spread="3.3870"/>
                    <measurement group_id="O4" value="31.150" spread="3.3011"/>
                    <measurement group_id="O5" value="32.091" spread="4.0243"/>
                    <measurement group_id="O6" value="29.768" spread="3.2825"/>
                    <measurement group_id="O7" value="31.404" spread="4.0581"/>
                    <measurement group_id="O8" value="30.975" spread="3.3526"/>
                    <measurement group_id="O9" value="31.478" spread="3.7066"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="25"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.600" spread="3.8155"/>
                    <measurement group_id="O2" value="31.908" spread="4.2809"/>
                    <measurement group_id="O3" value="31.004" spread="3.6090"/>
                    <measurement group_id="O4" value="31.685" spread="3.6743"/>
                    <measurement group_id="O5" value="32.636" spread="3.1568"/>
                    <measurement group_id="O6" value="30.720" spread="3.6371"/>
                    <measurement group_id="O7" value="32.408" spread="4.0300"/>
                    <measurement group_id="O8" value="31.138" spread="3.4691"/>
                    <measurement group_id="O9" value="31.922" spread="3.8381"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 50</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.772" spread="3.9676"/>
                    <measurement group_id="O2" value="31.117" spread="3.5511"/>
                    <measurement group_id="O3" value="30.991" spread="2.9264"/>
                    <measurement group_id="O4" value="31.900" spread="3.5621"/>
                    <measurement group_id="O5" value="32.282" spread="3.5327"/>
                    <measurement group_id="O6" value="29.760" spread="3.8077"/>
                    <measurement group_id="O7" value="32.704" spread="3.8668"/>
                    <measurement group_id="O8" value="31.083" spread="3.8423"/>
                    <measurement group_id="O9" value="30.830" spread="3.7644"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 57</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.708" spread="5.1285"/>
                    <measurement group_id="O2" value="30.271" spread="4.0390"/>
                    <measurement group_id="O3" value="29.987" spread="3.2086"/>
                    <measurement group_id="O4" value="30.773" spread="3.4292"/>
                    <measurement group_id="O5" value="32.405" spread="3.0798"/>
                    <measurement group_id="O6" value="28.548" spread="3.8710"/>
                    <measurement group_id="O7" value="31.454" spread="4.3687"/>
                    <measurement group_id="O8" value="30.033" spread="3.9031"/>
                    <measurement group_id="O9" value="29.861" spread="3.3007"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 71</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.600" spread="4.3091"/>
                    <measurement group_id="O2" value="31.554" spread="4.3823"/>
                    <measurement group_id="O3" value="31.148" spread="2.8016"/>
                    <measurement group_id="O4" value="32.092" spread="3.5748"/>
                    <measurement group_id="O5" value="33.127" spread="3.3208"/>
                    <measurement group_id="O6" value="30.260" spread="3.9125"/>
                    <measurement group_id="O7" value="32.658" spread="3.9677"/>
                    <measurement group_id="O8" value="31.804" spread="3.5119"/>
                    <measurement group_id="O9" value="31.317" spread="4.0283"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.484" spread="4.5441"/>
                    <measurement group_id="O2" value="30.296" spread="4.2019"/>
                    <measurement group_id="O3" value="29.974" spread="3.3766"/>
                    <measurement group_id="O4" value="30.577" spread="4.1019"/>
                    <measurement group_id="O5" value="33.095" spread="3.4642"/>
                    <measurement group_id="O6" value="29.036" spread="3.6811"/>
                    <measurement group_id="O7" value="31.957" spread="4.8917"/>
                    <measurement group_id="O8" value="30.533" spread="4.0376"/>
                    <measurement group_id="O9" value="29.657" spread="3.6082"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 99</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="22"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.868" spread="4.2145"/>
                    <measurement group_id="O2" value="32.054" spread="4.3729"/>
                    <measurement group_id="O3" value="31.436" spread="3.7821"/>
                    <measurement group_id="O4" value="32.500" spread="4.3987"/>
                    <measurement group_id="O5" value="33.155" spread="3.9087"/>
                    <measurement group_id="O6" value="31.352" spread="3.8161"/>
                    <measurement group_id="O7" value="32.925" spread="5.9562"/>
                    <measurement group_id="O8" value="31.229" spread="2.9670"/>
                    <measurement group_id="O9" value="31.570" spread="4.3204"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 106</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="22"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.908" spread="4.1181"/>
                    <measurement group_id="O2" value="31.850" spread="3.8284"/>
                    <measurement group_id="O3" value="31.073" spread="3.3504"/>
                    <measurement group_id="O4" value="31.724" spread="3.5444"/>
                    <measurement group_id="O5" value="32.432" spread="3.6429"/>
                    <measurement group_id="O6" value="30.520" spread="3.9332"/>
                    <measurement group_id="O7" value="32.552" spread="4.3131"/>
                    <measurement group_id="O8" value="31.438" spread="3.7623"/>
                    <measurement group_id="O9" value="30.865" spread="3.7092"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 113</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="23"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.442" spread="4.1097"/>
                    <measurement group_id="O2" value="30.313" spread="4.1545"/>
                    <measurement group_id="O3" value="29.787" spread="3.3975"/>
                    <measurement group_id="O4" value="30.388" spread="3.3572"/>
                    <measurement group_id="O5" value="32.559" spread="3.0055"/>
                    <measurement group_id="O6" value="29.300" spread="3.3821"/>
                    <measurement group_id="O7" value="32.361" spread="4.1480"/>
                    <measurement group_id="O8" value="30.239" spread="3.2747"/>
                    <measurement group_id="O9" value="30.126" spread="3.5101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 127</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.068" spread="3.9869"/>
                    <measurement group_id="O2" value="31.358" spread="3.9263"/>
                    <measurement group_id="O3" value="31.370" spread="3.4158"/>
                    <measurement group_id="O4" value="31.824" spread="3.4922"/>
                    <measurement group_id="O5" value="32.905" spread="3.2614"/>
                    <measurement group_id="O6" value="30.904" spread="3.1115"/>
                    <measurement group_id="O7" value="32.374" spread="3.7973"/>
                    <measurement group_id="O8" value="31.242" spread="3.5215"/>
                    <measurement group_id="O9" value="31.839" spread="3.7256"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 141</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.704" spread="4.5005"/>
                    <measurement group_id="O2" value="32.325" spread="4.2787"/>
                    <measurement group_id="O3" value="32.835" spread="3.3582"/>
                    <measurement group_id="O4" value="32.044" spread="4.2146"/>
                    <measurement group_id="O5" value="32.818" spread="3.4188"/>
                    <measurement group_id="O6" value="31.412" spread="3.6261"/>
                    <measurement group_id="O7" value="33.287" spread="3.0694"/>
                    <measurement group_id="O8" value="32.029" spread="3.4970"/>
                    <measurement group_id="O9" value="32.178" spread="3.1213"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 155</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="23"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.164" spread="3.9476"/>
                    <measurement group_id="O2" value="31.629" spread="4.4463"/>
                    <measurement group_id="O3" value="31.878" spread="3.3637"/>
                    <measurement group_id="O4" value="31.956" spread="4.1374"/>
                    <measurement group_id="O5" value="32.877" spread="3.7858"/>
                    <measurement group_id="O6" value="31.061" spread="3.8024"/>
                    <measurement group_id="O7" value="32.891" spread="4.0870"/>
                    <measurement group_id="O8" value="31.867" spread="3.6487"/>
                    <measurement group_id="O9" value="31.439" spread="3.4050"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 169</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="24"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="23"/>
                    <count group_id="O9" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.848" spread="4.1778"/>
                    <measurement group_id="O2" value="32.033" spread="3.8588"/>
                    <measurement group_id="O3" value="32.352" spread="3.8903"/>
                    <measurement group_id="O4" value="33.120" spread="4.2339"/>
                    <measurement group_id="O5" value="33.623" spread="4.2722"/>
                    <measurement group_id="O6" value="31.433" spread="3.8678"/>
                    <measurement group_id="O7" value="33.578" spread="4.4671"/>
                    <measurement group_id="O8" value="32.070" spread="3.9987"/>
                    <measurement group_id="O9" value="32.345" spread="3.6908"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Apolipoprotein A-II (ApoA-II) at Day 85 and Day 113</title>
        <description>ApoA-II is the second most abundant component of the HDL cholesterol. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value. Change from baseline = observed value minus baseline value.</description>
        <time_frame>Baseline, Day 85, 113</time_frame>
        <population>FAS included all the participants who were randomized and administered at least 1 dose of study treatment. Here, ‘Number analyzed’ = Participants evaluable for this outcome measure at specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin + PF-04950615 50 mg</title>
            <description>Participants with fasting lipoprotein cholesterol (LDL-C) level (greater than or equal to [&gt;=]100 milligram per deciliter [mg/dL]) received atorvastatin along with PF-04950615 50 milligram (mg) subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin + PF-04950615 100 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 100 mg subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin + PF-04950615 150 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 150 mg subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O4">
            <title>Atorvastatin + PF-04950615 Placebo</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 placebo subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O5">
            <title>Atorvastatin + Ezetimibe 10 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with ezetimibe 10 mg tablet orally, once daily from Day 1 up to Day 112. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O6">
            <title>PF-04950615 50 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 50 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O7">
            <title>PF-04950615 100 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 100 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O8">
            <title>PF-04950615 150 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 150 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O9">
            <title>PF-04950615 Placebo</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 placebo, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naive to a treatment by lipid lowering drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Apolipoprotein A-II (ApoA-II) at Day 85 and Day 113</title>
          <description>ApoA-II is the second most abundant component of the HDL cholesterol. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value. Change from baseline = observed value minus baseline value.</description>
          <population>FAS included all the participants who were randomized and administered at least 1 dose of study treatment. Here, ‘Number analyzed’ = Participants evaluable for this outcome measure at specified time points.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="26"/>
                <count group_id="O5" value="22"/>
                <count group_id="O6" value="25"/>
                <count group_id="O7" value="25"/>
                <count group_id="O8" value="24"/>
                <count group_id="O9" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Day 85</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.216" spread="2.2274"/>
                    <measurement group_id="O2" value="0.073" spread="2.6605"/>
                    <measurement group_id="O3" value="-0.450" spread="2.3906"/>
                    <measurement group_id="O4" value="-0.938" spread="1.8339"/>
                    <measurement group_id="O5" value="0.907" spread="2.6785"/>
                    <measurement group_id="O6" value="-0.904" spread="2.3894"/>
                    <measurement group_id="O7" value="0.354" spread="3.3769"/>
                    <measurement group_id="O8" value="0.240" spread="3.1812"/>
                    <measurement group_id="O9" value="-1.698" spread="2.9589"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 113</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="23"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.073" spread="2.0937"/>
                    <measurement group_id="O2" value="0.090" spread="2.3882"/>
                    <measurement group_id="O3" value="-0.637" spread="2.2412"/>
                    <measurement group_id="O4" value="-1.104" spread="4.0438"/>
                    <measurement group_id="O5" value="0.370" spread="2.2388"/>
                    <measurement group_id="O6" value="-0.640" spread="2.0394"/>
                    <measurement group_id="O7" value="0.759" spread="2.2739"/>
                    <measurement group_id="O8" value="0.002" spread="2.8256"/>
                    <measurement group_id="O9" value="-1.228" spread="3.4404"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 85 : Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.127</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>0.7208</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.6289</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.5283</ci_lower_limit>
            <ci_upper_limit>1.9700</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 85 : Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.053</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>1.0574</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.6461</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.2259</ci_lower_limit>
            <ci_upper_limit>2.3406</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 85 : Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.354</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>0.2445</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.6511</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.0486</ci_lower_limit>
            <ci_upper_limit>1.5375</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.176</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>0.8055</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.8615</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.9066</ci_lower_limit>
            <ci_upper_limit>2.5177</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.011</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>2.0071</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.8641</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.2899</ci_lower_limit>
            <ci_upper_limit>3.7242</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.024</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>1.7116</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.8520</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0184</ci_lower_limit>
            <ci_upper_limit>3.4049</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.138</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>0.8585</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.7844</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.6992</ci_lower_limit>
            <ci_upper_limit>2.4163</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.137</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>0.8807</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.7990</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.7064</ci_lower_limit>
            <ci_upper_limit>2.4678</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.373</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>0.2624</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.8053</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.3370</ci_lower_limit>
            <ci_upper_limit>1.8618</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.333</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>0.3239</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.7472</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.1611</ci_lower_limit>
            <ci_upper_limit>1.8089</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.006</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>1.9322</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.7488</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.4441</ci_lower_limit>
            <ci_upper_limit>3.4203</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 113:Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.133</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>0.8340</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.7442</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.6451</ci_lower_limit>
            <ci_upper_limit>2.3130</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Apolipoprotein A-II (ApoA-II) at Day 85 and Day 113</title>
        <description>ApoA-II is the second most abundant component of the HDL cholesterol. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value. Percent change from baseline = ([observed value divided by baseline value] minus 1) multiplied by 100.</description>
        <time_frame>Baseline, Day 85, 113</time_frame>
        <population>FAS included all the participants who were randomized and administered at least 1 dose of study treatment. Here, ‘Number analyzed’ = Participants evaluable for this outcome measure at specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin + PF-04950615 50 mg</title>
            <description>Participants with fasting lipoprotein cholesterol (LDL-C) level (greater than or equal to [&gt;=]100 milligram per deciliter [mg/dL]) received atorvastatin along with PF-04950615 50 milligram (mg) subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin + PF-04950615 100 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 100 mg subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin + PF-04950615 150 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 150 mg subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O4">
            <title>Atorvastatin + PF-04950615 Placebo</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 placebo subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O5">
            <title>Atorvastatin + Ezetimibe 10 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with ezetimibe 10 mg tablet orally, once daily from Day 1 up to Day 112. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O6">
            <title>PF-04950615 50 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 50 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O7">
            <title>PF-04950615 100 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 100 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O8">
            <title>PF-04950615 150 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 150 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O9">
            <title>PF-04950615 Placebo</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 placebo, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naive to a treatment by lipid lowering drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Apolipoprotein A-II (ApoA-II) at Day 85 and Day 113</title>
          <description>ApoA-II is the second most abundant component of the HDL cholesterol. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value. Percent change from baseline = ([observed value divided by baseline value] minus 1) multiplied by 100.</description>
          <population>FAS included all the participants who were randomized and administered at least 1 dose of study treatment. Here, ‘Number analyzed’ = Participants evaluable for this outcome measure at specified time points.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="26"/>
                <count group_id="O5" value="22"/>
                <count group_id="O6" value="25"/>
                <count group_id="O7" value="25"/>
                <count group_id="O8" value="24"/>
                <count group_id="O9" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Day 85</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.85" spread="7.387"/>
                    <measurement group_id="O2" value="0.17" spread="8.699"/>
                    <measurement group_id="O3" value="-1.34" spread="7.672"/>
                    <measurement group_id="O4" value="-2.93" spread="5.741"/>
                    <measurement group_id="O5" value="3.13" spread="8.288"/>
                    <measurement group_id="O6" value="-2.87" spread="7.788"/>
                    <measurement group_id="O7" value="1.34" spread="10.779"/>
                    <measurement group_id="O8" value="0.98" spread="10.565"/>
                    <measurement group_id="O9" value="-4.97" spread="9.262"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 113</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="23"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.21" spread="6.972"/>
                    <measurement group_id="O2" value="0.13" spread="7.974"/>
                    <measurement group_id="O3" value="-1.99" spread="7.403"/>
                    <measurement group_id="O4" value="-2.77" spread="11.234"/>
                    <measurement group_id="O5" value="1.48" spread="6.776"/>
                    <measurement group_id="O6" value="-1.94" spread="6.337"/>
                    <measurement group_id="O7" value="2.64" spread="7.315"/>
                    <measurement group_id="O8" value="0.39" spread="9.526"/>
                    <measurement group_id="O9" value="-3.29" spread="10.137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 85 : Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.155</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>2.0813</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.0411</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.9730</ci_lower_limit>
            <ci_upper_limit>6.1356</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 85 : Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.062</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>3.2608</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.0965</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.9035</ci_lower_limit>
            <ci_upper_limit>7.4250</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 85 : Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.349</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>0.8224</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.1126</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.3733</ci_lower_limit>
            <ci_upper_limit>5.0182</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 85 : Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.202</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>2.3254</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.7702</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.1801</ci_lower_limit>
            <ci_upper_limit>7.8310</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 85 : Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.015</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>6.1048</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.7784</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.5833</ci_lower_limit>
            <ci_upper_limit>11.6263</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 85 : Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.030</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>5.2393</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.7396</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.2058</ci_lower_limit>
            <ci_upper_limit>10.6845</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 113 : Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.185</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>2.1827</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.4251</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.6334</ci_lower_limit>
            <ci_upper_limit>6.9988</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.195</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>2.1376</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.4716</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.7718</ci_lower_limit>
            <ci_upper_limit>7.0469</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.450</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>0.3113</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.4909</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.6358</ci_lower_limit>
            <ci_upper_limit>5.2584</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.397</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>0.6078</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.3322</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.0274</ci_lower_limit>
            <ci_upper_limit>5.2431</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.008</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>5.7096</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.3367</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.0659</ci_lower_limit>
            <ci_upper_limit>10.3532</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 113:Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.147</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>2.4558</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.3230</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.1608</ci_lower_limit>
            <ci_upper_limit>7.0724</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lipoprotein (a) (Lp[a])</title>
        <description>Lp(a) is a lipoprotein subclass which consists of an LDL-like particle and the specific apolipoprotein(a). Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value.</description>
        <time_frame>Baseline, Day 5, 8, 15, 22, 29, 36, 43, 50, 57, 71, 85, 99, 106, 113, 127, 141, 155, 169</time_frame>
        <population>FAS included all the participants who were randomized and administered at least 1 dose of study treatment. Here, ‘Number analyzed’ = Participants evaluable for this outcome measure at specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin + PF-04950615 50 mg</title>
            <description>Participants with fasting lipoprotein cholesterol (LDL-C) level (greater than or equal to [&gt;=]100 milligram per deciliter [mg/dL]) received atorvastatin along with PF-04950615 50 milligram (mg) subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin + PF-04950615 100 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 100 mg subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin + PF-04950615 150 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 150 mg subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O4">
            <title>Atorvastatin + PF-04950615 Placebo</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 placebo subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O5">
            <title>Atorvastatin + Ezetimibe 10 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with ezetimibe 10 mg tablet orally, once daily from Day 1 up to Day 112. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O6">
            <title>PF-04950615 50 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 50 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O7">
            <title>PF-04950615 100 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 100 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O8">
            <title>PF-04950615 150 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 150 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O9">
            <title>PF-04950615 Placebo</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 placebo, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naive to a treatment by lipid lowering drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Lipoprotein (a) (Lp[a])</title>
          <description>Lp(a) is a lipoprotein subclass which consists of an LDL-like particle and the specific apolipoprotein(a). Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value.</description>
          <population>FAS included all the participants who were randomized and administered at least 1 dose of study treatment. Here, ‘Number analyzed’ = Participants evaluable for this outcome measure at specified time points.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="26"/>
                <count group_id="O5" value="22"/>
                <count group_id="O6" value="25"/>
                <count group_id="O7" value="25"/>
                <count group_id="O8" value="24"/>
                <count group_id="O9" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="25"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.452" spread="13.1792"/>
                    <measurement group_id="O2" value="20.998" spread="17.2111"/>
                    <measurement group_id="O3" value="18.840" spread="16.7289"/>
                    <measurement group_id="O4" value="19.265" spread="14.3646"/>
                    <measurement group_id="O5" value="19.468" spread="18.4181"/>
                    <measurement group_id="O6" value="14.080" spread="11.9369"/>
                    <measurement group_id="O7" value="15.458" spread="12.6296"/>
                    <measurement group_id="O8" value="13.400" spread="9.0719"/>
                    <measurement group_id="O9" value="16.239" spread="10.1883"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="23"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="25"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.224" spread="13.4935"/>
                    <measurement group_id="O2" value="18.348" spread="17.7316"/>
                    <measurement group_id="O3" value="16.204" spread="16.6072"/>
                    <measurement group_id="O4" value="18.523" spread="15.2512"/>
                    <measurement group_id="O5" value="20.450" spread="18.8904"/>
                    <measurement group_id="O6" value="12.464" spread="10.5751"/>
                    <measurement group_id="O7" value="14.580" spread="12.2541"/>
                    <measurement group_id="O8" value="11.783" spread="9.3506"/>
                    <measurement group_id="O9" value="15.859" spread="10.9932"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="21"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="22"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.892" spread="13.2944"/>
                    <measurement group_id="O2" value="15.333" spread="18.3499"/>
                    <measurement group_id="O3" value="14.167" spread="15.5022"/>
                    <measurement group_id="O4" value="19.184" spread="14.7461"/>
                    <measurement group_id="O5" value="17.243" spread="15.7353"/>
                    <measurement group_id="O6" value="12.000" spread="11.8358"/>
                    <measurement group_id="O7" value="12.617" spread="10.4189"/>
                    <measurement group_id="O8" value="12.768" spread="8.9168"/>
                    <measurement group_id="O9" value="16.443" spread="12.1793"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="25"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.208" spread="12.9280"/>
                    <measurement group_id="O2" value="14.129" spread="17.8567"/>
                    <measurement group_id="O3" value="11.392" spread="14.1251"/>
                    <measurement group_id="O4" value="19.258" spread="16.0484"/>
                    <measurement group_id="O5" value="18.982" spread="20.4348"/>
                    <measurement group_id="O6" value="10.140" spread="10.0017"/>
                    <measurement group_id="O7" value="12.548" spread="10.9860"/>
                    <measurement group_id="O8" value="9.996" spread="8.1113"/>
                    <measurement group_id="O9" value="16.443" spread="11.4594"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.628" spread="12.4393"/>
                    <measurement group_id="O2" value="12.446" spread="16.1397"/>
                    <measurement group_id="O3" value="10.765" spread="13.3504"/>
                    <measurement group_id="O4" value="18.785" spread="16.0604"/>
                    <measurement group_id="O5" value="17.800" spread="18.6499"/>
                    <measurement group_id="O6" value="10.936" spread="10.1920"/>
                    <measurement group_id="O7" value="11.583" spread="11.3914"/>
                    <measurement group_id="O8" value="8.800" spread="7.1835"/>
                    <measurement group_id="O9" value="16.026" spread="11.0080"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="25"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.832" spread="12.3874"/>
                    <measurement group_id="O2" value="13.379" spread="16.2405"/>
                    <measurement group_id="O3" value="10.552" spread="12.7986"/>
                    <measurement group_id="O4" value="18.304" spread="15.6050"/>
                    <measurement group_id="O5" value="17.873" spread="18.0678"/>
                    <measurement group_id="O6" value="10.424" spread="10.6085"/>
                    <measurement group_id="O7" value="10.888" spread="9.8450"/>
                    <measurement group_id="O8" value="9.312" spread="7.3675"/>
                    <measurement group_id="O9" value="17.423" spread="11.1746"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.152" spread="11.9088"/>
                    <measurement group_id="O2" value="12.833" spread="16.0418"/>
                    <measurement group_id="O3" value="10.409" spread="12.7145"/>
                    <measurement group_id="O4" value="17.046" spread="14.4893"/>
                    <measurement group_id="O5" value="18.050" spread="19.5448"/>
                    <measurement group_id="O6" value="9.484" spread="10.6692"/>
                    <measurement group_id="O7" value="10.329" spread="9.7943"/>
                    <measurement group_id="O8" value="8.067" spread="6.7186"/>
                    <measurement group_id="O9" value="15.843" spread="10.8050"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="25"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.648" spread="12.2798"/>
                    <measurement group_id="O2" value="12.525" spread="16.1360"/>
                    <measurement group_id="O3" value="9.633" spread="12.4360"/>
                    <measurement group_id="O4" value="16.912" spread="14.1356"/>
                    <measurement group_id="O5" value="17.214" spread="18.6825"/>
                    <measurement group_id="O6" value="9.380" spread="9.6416"/>
                    <measurement group_id="O7" value="9.944" spread="9.7431"/>
                    <measurement group_id="O8" value="8.821" spread="7.6426"/>
                    <measurement group_id="O9" value="15.961" spread="10.3890"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 50</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.344" spread="11.3684"/>
                    <measurement group_id="O2" value="11.675" spread="14.8818"/>
                    <measurement group_id="O3" value="9.039" spread="12.0250"/>
                    <measurement group_id="O4" value="16.835" spread="14.2068"/>
                    <measurement group_id="O5" value="17.314" spread="19.6439"/>
                    <measurement group_id="O6" value="10.040" spread="10.4835"/>
                    <measurement group_id="O7" value="10.191" spread="9.2630"/>
                    <measurement group_id="O8" value="7.621" spread="6.5659"/>
                    <measurement group_id="O9" value="15.078" spread="9.7608"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 57</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.708" spread="10.3883"/>
                    <measurement group_id="O2" value="10.871" spread="13.5224"/>
                    <measurement group_id="O3" value="8.578" spread="11.2275"/>
                    <measurement group_id="O4" value="15.892" spread="14.0990"/>
                    <measurement group_id="O5" value="17.573" spread="21.9401"/>
                    <measurement group_id="O6" value="9.392" spread="10.2457"/>
                    <measurement group_id="O7" value="9.487" spread="8.2801"/>
                    <measurement group_id="O8" value="6.858" spread="6.2894"/>
                    <measurement group_id="O9" value="14.313" spread="9.3930"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 71</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.358" spread="12.3793"/>
                    <measurement group_id="O2" value="11.354" spread="14.0492"/>
                    <measurement group_id="O3" value="9.009" spread="11.7733"/>
                    <measurement group_id="O4" value="16.542" spread="13.5029"/>
                    <measurement group_id="O5" value="16.991" spread="20.0151"/>
                    <measurement group_id="O6" value="9.248" spread="11.4972"/>
                    <measurement group_id="O7" value="9.529" spread="8.6412"/>
                    <measurement group_id="O8" value="6.979" spread="6.5414"/>
                    <measurement group_id="O9" value="13.500" spread="9.4333"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.960" spread="11.6806"/>
                    <measurement group_id="O2" value="10.879" spread="14.1289"/>
                    <measurement group_id="O3" value="9.239" spread="11.1448"/>
                    <measurement group_id="O4" value="16.519" spread="14.5691"/>
                    <measurement group_id="O5" value="17.609" spread="19.7001"/>
                    <measurement group_id="O6" value="8.808" spread="10.3417"/>
                    <measurement group_id="O7" value="9.261" spread="7.6804"/>
                    <measurement group_id="O8" value="6.637" spread="5.6695"/>
                    <measurement group_id="O9" value="12.726" spread="8.9598"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 99</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="22"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.232" spread="12.5326"/>
                    <measurement group_id="O2" value="11.837" spread="15.6082"/>
                    <measurement group_id="O3" value="8.855" spread="13.9399"/>
                    <measurement group_id="O4" value="15.764" spread="14.4527"/>
                    <measurement group_id="O5" value="16.868" spread="19.6709"/>
                    <measurement group_id="O6" value="7.940" spread="9.6343"/>
                    <measurement group_id="O7" value="8.537" spread="7.6094"/>
                    <measurement group_id="O8" value="6.792" spread="5.6212"/>
                    <measurement group_id="O9" value="13.691" spread="9.5937"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 106</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="22"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.756" spread="11.7377"/>
                    <measurement group_id="O2" value="11.079" spread="14.2590"/>
                    <measurement group_id="O3" value="9.123" spread="14.1064"/>
                    <measurement group_id="O4" value="15.396" spread="12.8944"/>
                    <measurement group_id="O5" value="16.682" spread="18.8434"/>
                    <measurement group_id="O6" value="8.608" spread="9.5662"/>
                    <measurement group_id="O7" value="8.296" spread="7.3410"/>
                    <measurement group_id="O8" value="6.858" spread="6.1058"/>
                    <measurement group_id="O9" value="12.800" spread="8.9601"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 113</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="23"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.108" spread="12.3479"/>
                    <measurement group_id="O2" value="11.183" spread="14.5312"/>
                    <measurement group_id="O3" value="9.565" spread="14.0691"/>
                    <measurement group_id="O4" value="14.492" spread="12.9060"/>
                    <measurement group_id="O5" value="16.814" spread="17.8976"/>
                    <measurement group_id="O6" value="8.020" spread="9.0412"/>
                    <measurement group_id="O7" value="8.287" spread="7.6439"/>
                    <measurement group_id="O8" value="6.787" spread="5.8743"/>
                    <measurement group_id="O9" value="12.913" spread="9.7212"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 127</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.476" spread="14.6308"/>
                    <measurement group_id="O2" value="15.112" spread="16.5781"/>
                    <measurement group_id="O3" value="11.961" spread="15.6073"/>
                    <measurement group_id="O4" value="15.500" spread="13.0255"/>
                    <measurement group_id="O5" value="16.618" spread="19.1791"/>
                    <measurement group_id="O6" value="9.864" spread="10.2016"/>
                    <measurement group_id="O7" value="10.543" spread="9.2205"/>
                    <measurement group_id="O8" value="7.642" spread="6.9977"/>
                    <measurement group_id="O9" value="13.596" spread="9.3340"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 141</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.842" spread="15.6809"/>
                    <measurement group_id="O2" value="17.329" spread="18.9837"/>
                    <measurement group_id="O3" value="14.422" spread="17.3620"/>
                    <measurement group_id="O4" value="15.828" spread="13.7114"/>
                    <measurement group_id="O5" value="17.236" spread="18.8525"/>
                    <measurement group_id="O6" value="10.100" spread="10.9325"/>
                    <measurement group_id="O7" value="11.996" spread="10.0494"/>
                    <measurement group_id="O8" value="8.442" spread="6.7945"/>
                    <measurement group_id="O9" value="13.139" spread="9.2951"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 155</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="23"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.264" spread="15.4506"/>
                    <measurement group_id="O2" value="17.483" spread="19.9385"/>
                    <measurement group_id="O3" value="16.052" spread="16.9174"/>
                    <measurement group_id="O4" value="16.004" spread="13.7418"/>
                    <measurement group_id="O5" value="17.382" spread="19.8297"/>
                    <measurement group_id="O6" value="10.204" spread="11.2720"/>
                    <measurement group_id="O7" value="13.465" spread="10.8114"/>
                    <measurement group_id="O8" value="9.600" spread="7.5028"/>
                    <measurement group_id="O9" value="13.183" spread="9.1710"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 169</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="24"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="23"/>
                    <count group_id="O9" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.824" spread="15.1879"/>
                    <measurement group_id="O2" value="17.404" spread="18.0405"/>
                    <measurement group_id="O3" value="16.635" spread="17.8211"/>
                    <measurement group_id="O4" value="15.384" spread="13.7150"/>
                    <measurement group_id="O5" value="17.059" spread="20.8409"/>
                    <measurement group_id="O6" value="11.271" spread="11.4561"/>
                    <measurement group_id="O7" value="13.613" spread="11.5074"/>
                    <measurement group_id="O8" value="10.626" spread="8.0902"/>
                    <measurement group_id="O9" value="14.741" spread="10.3647"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Lipoprotein (a) (Lp[a]) at Day 85 and Day 113</title>
        <description>Lp(a) is a lipoprotein subclass which consists of an LDL-like particle and the specific apolipoprotein(a). Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value. Change from baseline = observed value minus baseline value.</description>
        <time_frame>Baseline, Day 85, 113</time_frame>
        <population>FAS included all the participants who were randomized and administered at least 1 dose of study treatment. Here, ‘Number analyzed’ = Participants evaluable for this outcome measure at specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin + PF-04950615 50 mg</title>
            <description>Participants with fasting lipoprotein cholesterol (LDL-C) level (greater than or equal to [&gt;=]100 milligram per deciliter [mg/dL]) received atorvastatin along with PF-04950615 50 milligram (mg) subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin + PF-04950615 100 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 100 mg subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin + PF-04950615 150 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 150 mg subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O4">
            <title>Atorvastatin + PF-04950615 Placebo</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 placebo subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O5">
            <title>Atorvastatin + Ezetimibe 10 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with ezetimibe 10 mg tablet orally, once daily from Day 1 up to Day 112. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O6">
            <title>PF-04950615 50 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 50 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O7">
            <title>PF-04950615 100 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 100 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O8">
            <title>PF-04950615 150 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 150 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O9">
            <title>PF-04950615 Placebo</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 placebo, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naive to a treatment by lipid lowering drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Lipoprotein (a) (Lp[a]) at Day 85 and Day 113</title>
          <description>Lp(a) is a lipoprotein subclass which consists of an LDL-like particle and the specific apolipoprotein(a). Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value. Change from baseline = observed value minus baseline value.</description>
          <population>FAS included all the participants who were randomized and administered at least 1 dose of study treatment. Here, ‘Number analyzed’ = Participants evaluable for this outcome measure at specified time points.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="26"/>
                <count group_id="O5" value="22"/>
                <count group_id="O6" value="25"/>
                <count group_id="O7" value="25"/>
                <count group_id="O8" value="24"/>
                <count group_id="O9" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Day 85</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.492" spread="5.1400"/>
                    <measurement group_id="O2" value="-10.119" spread="5.4374"/>
                    <measurement group_id="O3" value="-10.239" spread="8.2471"/>
                    <measurement group_id="O4" value="-2.746" spread="3.1292"/>
                    <measurement group_id="O5" value="-1.859" spread="3.0759"/>
                    <measurement group_id="O6" value="-5.272" spread="5.1528"/>
                    <measurement group_id="O7" value="-7.100" spread="5.9402"/>
                    <measurement group_id="O8" value="-6.763" spread="5.3474"/>
                    <measurement group_id="O9" value="-3.513" spread="3.6550"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 113</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="23"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.815" spread="4.6182"/>
                    <measurement group_id="O2" value="-9.815" spread="5.0568"/>
                    <measurement group_id="O3" value="-9.913" spread="6.6763"/>
                    <measurement group_id="O4" value="-3.574" spread="4.0251"/>
                    <measurement group_id="O5" value="-2.655" spread="3.1725"/>
                    <measurement group_id="O6" value="-6.060" spread="4.5477"/>
                    <measurement group_id="O7" value="-8.074" spread="6.0886"/>
                    <measurement group_id="O8" value="-7.098" spread="4.5025"/>
                    <measurement group_id="O9" value="-3.326" spread="3.4975"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 85 : Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-4.9203</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.3242</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.5504</ci_lower_limit>
            <ci_upper_limit>-2.2901</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 85 : Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-7.1983</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.3462</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.8718</ci_lower_limit>
            <ci_upper_limit>-4.5249</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 85 : Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-7.3118</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.3505</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.9935</ci_lower_limit>
            <ci_upper_limit>-4.6301</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 85 : Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-3.0629</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.0320</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.1132</ci_lower_limit>
            <ci_upper_limit>-1.0125</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 85 : Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-3.6209</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.0367</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.6804</ci_lower_limit>
            <ci_upper_limit>-1.5614</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 85 : Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-4.1778</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.0269</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.2184</ci_lower_limit>
            <ci_upper_limit>-2.1372</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.006</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-3.2914</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.2954</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.8649</ci_lower_limit>
            <ci_upper_limit>-0.7178</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-6.3569</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.3157</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.9706</ci_lower_limit>
            <ci_upper_limit>-3.7432</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-6.3962</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.3233</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.0247</ci_lower_limit>
            <ci_upper_limit>-3.7677</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-3.9228</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.9199</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.7506</ci_lower_limit>
            <ci_upper_limit>-2.0950</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-4.7094</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.9244</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.5459</ci_lower_limit>
            <ci_upper_limit>-2.8729</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 113:Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-4.4374</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.9187</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.2630</ci_lower_limit>
            <ci_upper_limit>-2.6118</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Lipoprotein (a) (Lp[a]) at Day 85 and Day 113</title>
        <description>Lp(a) is a lipoprotein subclass which consists of an LDL-like particle and the specific apolipoprotein(a). Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value. Percent change from baseline = ([observed value divided by baseline value] minus 1) multiplied by 100.</description>
        <time_frame>Baseline, Day 85, 113</time_frame>
        <population>FAS included all the participants who were randomized and administered at least 1 dose of study treatment. Here, ‘Number analyzed’ = Participants evaluable for this outcome measure at specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin + PF-04950615 50 mg</title>
            <description>Participants with fasting lipoprotein cholesterol (LDL-C) level (greater than or equal to [&gt;=]100 milligram per deciliter [mg/dL]) received atorvastatin along with PF-04950615 50 milligram (mg) subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin + PF-04950615 100 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 100 mg subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin + PF-04950615 150 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 150 mg subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O4">
            <title>Atorvastatin + PF-04950615 Placebo</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 placebo subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O5">
            <title>Atorvastatin + Ezetimibe 10 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with ezetimibe 10 mg tablet orally, once daily from Day 1 up to Day 112. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O6">
            <title>PF-04950615 50 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 50 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O7">
            <title>PF-04950615 100 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 100 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O8">
            <title>PF-04950615 150 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 150 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O9">
            <title>PF-04950615 Placebo</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 placebo, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naive to a treatment by lipid lowering drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Lipoprotein (a) (Lp[a]) at Day 85 and Day 113</title>
          <description>Lp(a) is a lipoprotein subclass which consists of an LDL-like particle and the specific apolipoprotein(a). Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value. Percent change from baseline = ([observed value divided by baseline value] minus 1) multiplied by 100.</description>
          <population>FAS included all the participants who were randomized and administered at least 1 dose of study treatment. Here, ‘Number analyzed’ = Participants evaluable for this outcome measure at specified time points.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="26"/>
                <count group_id="O5" value="22"/>
                <count group_id="O6" value="25"/>
                <count group_id="O7" value="25"/>
                <count group_id="O8" value="24"/>
                <count group_id="O9" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Day 85</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-47.11" spread="20.802"/>
                    <measurement group_id="O2" value="-58.53" spread="22.181"/>
                    <measurement group_id="O3" value="-46.51" spread="63.192"/>
                    <measurement group_id="O4" value="-19.37" spread="25.160"/>
                    <measurement group_id="O5" value="-15.22" spread="23.532"/>
                    <measurement group_id="O6" value="-37.85" spread="27.223"/>
                    <measurement group_id="O7" value="-37.29" spread="24.552"/>
                    <measurement group_id="O8" value="-43.37" spread="39.755"/>
                    <measurement group_id="O9" value="-18.40" spread="30.139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 113</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="23"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-42.30" spread="19.223"/>
                    <measurement group_id="O2" value="-57.94" spread="22.317"/>
                    <measurement group_id="O3" value="-59.42" spread="21.689"/>
                    <measurement group_id="O4" value="-24.35" spread="21.348"/>
                    <measurement group_id="O5" value="-18.64" spread="18.300"/>
                    <measurement group_id="O6" value="-45.26" spread="22.490"/>
                    <measurement group_id="O7" value="-47.60" spread="19.448"/>
                    <measurement group_id="O8" value="-49.77" spread="25.417"/>
                    <measurement group_id="O9" value="-15.89" spread="36.642"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 85 : Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-27.4492</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>10.2401</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-47.7872</ci_lower_limit>
            <ci_upper_limit>-7.1112</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 85 : Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-40.5908</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>10.4568</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-61.3577</ci_lower_limit>
            <ci_upper_limit>-19.8240</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 85 : Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.006</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-27.1630</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>10.5402</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-48.0927</ci_lower_limit>
            <ci_upper_limit>-6.2332</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 85 : Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-24.1677</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>8.8755</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-41.8023</ci_lower_limit>
            <ci_upper_limit>-6.5332</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 85 : Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.017</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-19.2255</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>8.9203</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-36.9471</ci_lower_limit>
            <ci_upper_limit>-1.5038</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 85 : Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-26.5155</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>8.8387</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-44.0795</ci_lower_limit>
            <ci_upper_limit>-8.9515</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-18.3898</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.1768</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-28.6698</ci_lower_limit>
            <ci_upper_limit>-8.1097</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-36.7882</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.2640</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-47.2423</ci_lower_limit>
            <ci_upper_limit>-26.3341</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-36.8453</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.3084</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-47.3864</ci_lower_limit>
            <ci_upper_limit>-26.3041</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-32.9411</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>7.8656</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-48.5748</ci_lower_limit>
            <ci_upper_limit>-17.3075</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-31.3176</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>7.9032</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-47.0238</ci_lower_limit>
            <ci_upper_limit>-15.6114</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 113:Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-32.8470</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>7.8576</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-48.4650</ci_lower_limit>
            <ci_upper_limit>-17.2289</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>High Density Lipoprotein- Cholesterol (HDL-C)</title>
        <description>HDL-C is cholesterol in the bloodstream that is carried by high density lipoprotein. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value.</description>
        <time_frame>Baseline, Day 5, 8, 15, 22, 29, 36, 43, 50, 57, 71, 85, 99, 106, 113, 127, 141, 155, 169</time_frame>
        <population>FAS included all the participants who were randomized and administered at least 1 dose of study treatment. Here, ‘Number analyzed’ = Participants evaluable for this outcome measure at specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin + PF-04950615 50 mg</title>
            <description>Participants with fasting lipoprotein cholesterol (LDL-C) level (greater than or equal to [&gt;=]100 milligram per deciliter [mg/dL]) received atorvastatin along with PF-04950615 50 milligram (mg) subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin + PF-04950615 100 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 100 mg subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin + PF-04950615 150 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 150 mg subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O4">
            <title>Atorvastatin + PF-04950615 Placebo</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 placebo subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O5">
            <title>Atorvastatin + Ezetimibe 10 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with ezetimibe 10 mg tablet orally, once daily from Day 1 up to Day 112. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O6">
            <title>PF-04950615 50 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 50 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O7">
            <title>PF-04950615 100 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 100 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O8">
            <title>PF-04950615 150 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 150 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O9">
            <title>PF-04950615 Placebo</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 placebo, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naive to a treatment by lipid lowering drug.</description>
          </group>
        </group_list>
        <measure>
          <title>High Density Lipoprotein- Cholesterol (HDL-C)</title>
          <description>HDL-C is cholesterol in the bloodstream that is carried by high density lipoprotein. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value.</description>
          <population>FAS included all the participants who were randomized and administered at least 1 dose of study treatment. Here, ‘Number analyzed’ = Participants evaluable for this outcome measure at specified time points.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="26"/>
                <count group_id="O5" value="22"/>
                <count group_id="O6" value="25"/>
                <count group_id="O7" value="25"/>
                <count group_id="O8" value="24"/>
                <count group_id="O9" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="25"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.58" spread="9.048"/>
                    <measurement group_id="O2" value="54.75" spread="11.789"/>
                    <measurement group_id="O3" value="57.00" spread="12.858"/>
                    <measurement group_id="O4" value="58.54" spread="14.683"/>
                    <measurement group_id="O5" value="56.98" spread="9.607"/>
                    <measurement group_id="O6" value="57.22" spread="14.146"/>
                    <measurement group_id="O7" value="60.40" spread="13.228"/>
                    <measurement group_id="O8" value="62.02" spread="21.455"/>
                    <measurement group_id="O9" value="60.87" spread="10.606"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="23"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="25"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.68" spread="11.131"/>
                    <measurement group_id="O2" value="57.04" spread="12.532"/>
                    <measurement group_id="O3" value="58.43" spread="13.480"/>
                    <measurement group_id="O4" value="58.19" spread="14.403"/>
                    <measurement group_id="O5" value="57.00" spread="9.866"/>
                    <measurement group_id="O6" value="57.20" spread="15.785"/>
                    <measurement group_id="O7" value="60.32" spread="13.643"/>
                    <measurement group_id="O8" value="62.08" spread="21.354"/>
                    <measurement group_id="O9" value="59.73" spread="11.344"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="21"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="22"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.48" spread="11.266"/>
                    <measurement group_id="O2" value="58.38" spread="12.700"/>
                    <measurement group_id="O3" value="60.33" spread="13.017"/>
                    <measurement group_id="O4" value="60.52" spread="14.234"/>
                    <measurement group_id="O5" value="58.67" spread="10.136"/>
                    <measurement group_id="O6" value="59.60" spread="15.729"/>
                    <measurement group_id="O7" value="61.33" spread="14.230"/>
                    <measurement group_id="O8" value="64.00" spread="23.420"/>
                    <measurement group_id="O9" value="60.57" spread="11.289"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="25"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.52" spread="8.637"/>
                    <measurement group_id="O2" value="59.96" spread="11.925"/>
                    <measurement group_id="O3" value="62.79" spread="15.562"/>
                    <measurement group_id="O4" value="59.35" spread="15.179"/>
                    <measurement group_id="O5" value="60.23" spread="12.208"/>
                    <measurement group_id="O6" value="60.24" spread="16.048"/>
                    <measurement group_id="O7" value="62.32" spread="15.513"/>
                    <measurement group_id="O8" value="66.58" spread="22.085"/>
                    <measurement group_id="O9" value="60.30" spread="11.117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.36" spread="11.158"/>
                    <measurement group_id="O2" value="60.08" spread="12.176"/>
                    <measurement group_id="O3" value="64.52" spread="14.585"/>
                    <measurement group_id="O4" value="58.08" spread="12.743"/>
                    <measurement group_id="O5" value="60.05" spread="10.017"/>
                    <measurement group_id="O6" value="60.92" spread="16.253"/>
                    <measurement group_id="O7" value="63.92" spread="13.529"/>
                    <measurement group_id="O8" value="65.38" spread="17.358"/>
                    <measurement group_id="O9" value="61.48" spread="11.233"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="25"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.96" spread="10.486"/>
                    <measurement group_id="O2" value="61.75" spread="13.553"/>
                    <measurement group_id="O3" value="63.83" spread="15.948"/>
                    <measurement group_id="O4" value="57.96" spread="13.192"/>
                    <measurement group_id="O5" value="59.00" spread="9.587"/>
                    <measurement group_id="O6" value="60.84" spread="16.222"/>
                    <measurement group_id="O7" value="62.52" spread="15.196"/>
                    <measurement group_id="O8" value="67.96" spread="20.412"/>
                    <measurement group_id="O9" value="64.14" spread="9.896"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.92" spread="10.622"/>
                    <measurement group_id="O2" value="60.50" spread="13.112"/>
                    <measurement group_id="O3" value="62.39" spread="14.151"/>
                    <measurement group_id="O4" value="57.62" spread="13.518"/>
                    <measurement group_id="O5" value="58.23" spread="10.314"/>
                    <measurement group_id="O6" value="59.76" spread="14.521"/>
                    <measurement group_id="O7" value="65.25" spread="14.411"/>
                    <measurement group_id="O8" value="65.21" spread="19.489"/>
                    <measurement group_id="O9" value="59.91" spread="10.833"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="25"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.76" spread="8.724"/>
                    <measurement group_id="O2" value="62.21" spread="13.266"/>
                    <measurement group_id="O3" value="62.29" spread="15.415"/>
                    <measurement group_id="O4" value="57.31" spread="13.936"/>
                    <measurement group_id="O5" value="58.82" spread="10.450"/>
                    <measurement group_id="O6" value="59.36" spread="14.950"/>
                    <measurement group_id="O7" value="63.64" spread="15.435"/>
                    <measurement group_id="O8" value="65.17" spread="18.846"/>
                    <measurement group_id="O9" value="59.74" spread="10.558"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 50</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.12" spread="10.248"/>
                    <measurement group_id="O2" value="60.04" spread="12.185"/>
                    <measurement group_id="O3" value="62.09" spread="14.058"/>
                    <measurement group_id="O4" value="57.81" spread="14.525"/>
                    <measurement group_id="O5" value="58.55" spread="10.835"/>
                    <measurement group_id="O6" value="59.40" spread="14.955"/>
                    <measurement group_id="O7" value="64.91" spread="13.651"/>
                    <measurement group_id="O8" value="65.21" spread="19.669"/>
                    <measurement group_id="O9" value="59.39" spread="10.586"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 57</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.40" spread="8.221"/>
                    <measurement group_id="O2" value="58.83" spread="13.830"/>
                    <measurement group_id="O3" value="60.35" spread="13.231"/>
                    <measurement group_id="O4" value="54.88" spread="12.745"/>
                    <measurement group_id="O5" value="57.45" spread="10.804"/>
                    <measurement group_id="O6" value="57.16" spread="12.589"/>
                    <measurement group_id="O7" value="61.92" spread="14.374"/>
                    <measurement group_id="O8" value="62.63" spread="20.549"/>
                    <measurement group_id="O9" value="56.61" spread="10.782"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 71</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.29" spread="9.438"/>
                    <measurement group_id="O2" value="62.96" spread="14.0492"/>
                    <measurement group_id="O3" value="64.83" spread="16.854"/>
                    <measurement group_id="O4" value="56.85" spread="12.069"/>
                    <measurement group_id="O5" value="58.00" spread="9.798"/>
                    <measurement group_id="O6" value="59.16" spread="13.539"/>
                    <measurement group_id="O7" value="63.92" spread="14.185"/>
                    <measurement group_id="O8" value="66.29" spread="20.354"/>
                    <measurement group_id="O9" value="57.78" spread="9.662"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.24" spread="9.926"/>
                    <measurement group_id="O2" value="59.54" spread="12.827"/>
                    <measurement group_id="O3" value="59.70" spread="11.315"/>
                    <measurement group_id="O4" value="53.96" spread="12.981"/>
                    <measurement group_id="O5" value="59.77" spread="10.438"/>
                    <measurement group_id="O6" value="55.04" spread="13.421"/>
                    <measurement group_id="O7" value="63.09" spread="13.211"/>
                    <measurement group_id="O8" value="62.00" spread="17.619"/>
                    <measurement group_id="O9" value="56.35" spread="10.075"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 99</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="22"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.68" spread="11.926"/>
                    <measurement group_id="O2" value="62.54" spread="13.462"/>
                    <measurement group_id="O3" value="62.32" spread="14.496"/>
                    <measurement group_id="O4" value="59.92" spread="12.812"/>
                    <measurement group_id="O5" value="60.36" spread="10.472"/>
                    <measurement group_id="O6" value="60.00" spread="13.051"/>
                    <measurement group_id="O7" value="64.54" spread="15.453"/>
                    <measurement group_id="O8" value="64.63" spread="18.946"/>
                    <measurement group_id="O9" value="59.30" spread="12.430"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 106</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="22"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.36" spread="11.489"/>
                    <measurement group_id="O2" value="63.25" spread="15.118"/>
                    <measurement group_id="O3" value="64.41" spread="13.355"/>
                    <measurement group_id="O4" value="58.28" spread="12.651"/>
                    <measurement group_id="O5" value="59.45" spread="10.117"/>
                    <measurement group_id="O6" value="60.08" spread="15.231"/>
                    <measurement group_id="O7" value="64.39" spread="15.718"/>
                    <measurement group_id="O8" value="65.17" spread="18.897"/>
                    <measurement group_id="O9" value="58.30" spread="11.703"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 113</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="23"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.13" spread="11.395"/>
                    <measurement group_id="O2" value="61.04" spread="14.245"/>
                    <measurement group_id="O3" value="59.39" spread="12.565"/>
                    <measurement group_id="O4" value="55.28" spread="13.145"/>
                    <measurement group_id="O5" value="60.32" spread="10.049"/>
                    <measurement group_id="O6" value="57.92" spread="14.617"/>
                    <measurement group_id="O7" value="63.00" spread="14.331"/>
                    <measurement group_id="O8" value="61.83" spread="18.218"/>
                    <measurement group_id="O9" value="56.17" spread="10.421"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 127</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.16" spread="12.212"/>
                    <measurement group_id="O2" value="59.46" spread="13.552"/>
                    <measurement group_id="O3" value="62.78" spread="14.013"/>
                    <measurement group_id="O4" value="60.72" spread="15.118"/>
                    <measurement group_id="O5" value="57.82" spread="9.272"/>
                    <measurement group_id="O6" value="58.56" spread="13.818"/>
                    <measurement group_id="O7" value="63.61" spread="16.160"/>
                    <measurement group_id="O8" value="63.88" spread="19.161"/>
                    <measurement group_id="O9" value="58.00" spread="10.838"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 141</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.58" spread="11.960"/>
                    <measurement group_id="O2" value="60.63" spread="13.682"/>
                    <measurement group_id="O3" value="64.26" spread="14.530"/>
                    <measurement group_id="O4" value="60.96" spread="15.970"/>
                    <measurement group_id="O5" value="59.09" spread="10.766"/>
                    <measurement group_id="O6" value="59.40" spread="16.081"/>
                    <measurement group_id="O7" value="63.26" spread="14.229"/>
                    <measurement group_id="O8" value="64.00" spread="20.167"/>
                    <measurement group_id="O9" value="62.39" spread="14.138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 155</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="23"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.72" spread="10.620"/>
                    <measurement group_id="O2" value="59.00" spread="14.341"/>
                    <measurement group_id="O3" value="61.96" spread="14.455"/>
                    <measurement group_id="O4" value="59.48" spread="14.535"/>
                    <measurement group_id="O5" value="59.45" spread="9.179"/>
                    <measurement group_id="O6" value="59.04" spread="16.425"/>
                    <measurement group_id="O7" value="63.00" spread="15.021"/>
                    <measurement group_id="O8" value="63.67" spread="20.550"/>
                    <measurement group_id="O9" value="61.87" spread="13.602"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 169</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="24"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="23"/>
                    <count group_id="O9" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.48" spread="11.794"/>
                    <measurement group_id="O2" value="59.04" spread="12.726"/>
                    <measurement group_id="O3" value="62.48" spread="14.441"/>
                    <measurement group_id="O4" value="61.88" spread="15.078"/>
                    <measurement group_id="O5" value="60.50" spread="11.827"/>
                    <measurement group_id="O6" value="60.29" spread="16.206"/>
                    <measurement group_id="O7" value="62.04" spread="15.155"/>
                    <measurement group_id="O8" value="65.00" spread="24.355"/>
                    <measurement group_id="O9" value="65.05" spread="13.584"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in High Density Lipoprotein- Cholesterol (HDL-C) at Day 85 and Day 113</title>
        <description>HDL-C is cholesterol in the bloodstream that is carried by high density lipoprotein. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value. Change from baseline = observed value minus baseline value.</description>
        <time_frame>Baseline, Day 85, 113</time_frame>
        <population>FAS included all the participants who were randomized and administered at least 1 dose of study treatment. Here, ‘Number analyzed’ = Participants evaluable for this outcome measure at specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin + PF-04950615 50 mg</title>
            <description>Participants with fasting lipoprotein cholesterol (LDL-C) level (greater than or equal to [&gt;=]100 milligram per deciliter [mg/dL]) received atorvastatin along with PF-04950615 50 milligram (mg) subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin + PF-04950615 100 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 100 mg subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin + PF-04950615 150 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 150 mg subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O4">
            <title>Atorvastatin + PF-04950615 Placebo</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 placebo subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O5">
            <title>Atorvastatin + Ezetimibe 10 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with ezetimibe 10 mg tablet orally, once daily from Day 1 up to Day 112. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O6">
            <title>PF-04950615 50 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 50 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O7">
            <title>PF-04950615 100 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 100 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O8">
            <title>PF-04950615 150 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 150 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O9">
            <title>PF-04950615 Placebo</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 placebo, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naive to a treatment by lipid lowering drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in High Density Lipoprotein- Cholesterol (HDL-C) at Day 85 and Day 113</title>
          <description>HDL-C is cholesterol in the bloodstream that is carried by high density lipoprotein. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value. Change from baseline = observed value minus baseline value.</description>
          <population>FAS included all the participants who were randomized and administered at least 1 dose of study treatment. Here, ‘Number analyzed’ = Participants evaluable for this outcome measure at specified time points.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="26"/>
                <count group_id="O5" value="22"/>
                <count group_id="O6" value="25"/>
                <count group_id="O7" value="25"/>
                <count group_id="O8" value="24"/>
                <count group_id="O9" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Day 85</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.66" spread="6.216"/>
                    <measurement group_id="O2" value="4.79" spread="5.568"/>
                    <measurement group_id="O3" value="2.63" spread="5.394"/>
                    <measurement group_id="O4" value="-4.58" spread="4.573"/>
                    <measurement group_id="O5" value="2.80" spread="6.223"/>
                    <measurement group_id="O6" value="-2.18" spread="6.065"/>
                    <measurement group_id="O7" value="1.46" spread="7.408"/>
                    <measurement group_id="O8" value="-0.02" spread="7.575"/>
                    <measurement group_id="O9" value="-4.52" spread="5.191"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 113</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="23"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.90" spread="6.437"/>
                    <measurement group_id="O2" value="6.29" spread="7.003"/>
                    <measurement group_id="O3" value="2.33" spread="8.053"/>
                    <measurement group_id="O4" value="-3.28" spread="7.264"/>
                    <measurement group_id="O5" value="3.34" spread="5.702"/>
                    <measurement group_id="O6" value="0.70" spread="6.489"/>
                    <measurement group_id="O7" value="1.37" spread="7.799"/>
                    <measurement group_id="O8" value="-0.63" spread="6.995"/>
                    <measurement group_id="O9" value="-4.70" spread="5.045"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 85 : Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>7.663</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.431</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.820</ci_lower_limit>
            <ci_upper_limit>10.506</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 85 : Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>9.290</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.460</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>6.389</ci_lower_limit>
            <ci_upper_limit>12.190</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 85 : Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>7.255</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.470</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.336</ci_lower_limit>
            <ci_upper_limit>10.175</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 85 : Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.110</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>2.228</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.806</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.361</ci_lower_limit>
            <ci_upper_limit>5.818</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 85 : Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>5.578</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.815</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.972</ci_lower_limit>
            <ci_upper_limit>9.185</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 85 : Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.005</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>4.712</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.789</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.156</ci_lower_limit>
            <ci_upper_limit>8.268</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>5.888</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.035</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.844</ci_lower_limit>
            <ci_upper_limit>9.932</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>9.251</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.062</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.153</ci_lower_limit>
            <ci_upper_limit>13.349</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.006</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>5.264</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.072</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.147</ci_lower_limit>
            <ci_upper_limit>9.380</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>5.065</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.843</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.402</ci_lower_limit>
            <ci_upper_limit>8.728</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>5.096</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.853</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.413</ci_lower_limit>
            <ci_upper_limit>8.780</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 113:Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.011</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>4.301</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.832</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.658</ci_lower_limit>
            <ci_upper_limit>7.943</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in High Density Lipoprotein- Cholesterol (HDL-C) at Day 85 and Day 113</title>
        <description>HDL-C is cholesterol in the bloodstream that is carried by high density lipoprotein. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value. Percent change from baseline = ([observed value divided by baseline value] minus 1) multiplied by 100.</description>
        <time_frame>Baseline, Day 85, 113</time_frame>
        <population>FAS included all the participants who were randomized and administered at least 1 dose of study treatment. Here, ‘Number analyzed’ = Participants evaluable for this outcome measure at specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin + PF-04950615 50 mg</title>
            <description>Participants with fasting lipoprotein cholesterol (LDL-C) level (greater than or equal to [&gt;=]100 milligram per deciliter [mg/dL]) received atorvastatin along with PF-04950615 50 milligram (mg) subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin + PF-04950615 100 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 100 mg subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin + PF-04950615 150 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 150 mg subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O4">
            <title>Atorvastatin + PF-04950615 Placebo</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 placebo subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O5">
            <title>Atorvastatin + Ezetimibe 10 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with ezetimibe 10 mg tablet orally, once daily from Day 1 up to Day 112. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O6">
            <title>PF-04950615 50 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 50 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O7">
            <title>PF-04950615 100 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 100 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O8">
            <title>PF-04950615 150 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 150 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O9">
            <title>PF-04950615 Placebo</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 placebo, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naive to a treatment by lipid lowering drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in High Density Lipoprotein- Cholesterol (HDL-C) at Day 85 and Day 113</title>
          <description>HDL-C is cholesterol in the bloodstream that is carried by high density lipoprotein. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value. Percent change from baseline = ([observed value divided by baseline value] minus 1) multiplied by 100.</description>
          <population>FAS included all the participants who were randomized and administered at least 1 dose of study treatment. Here, ‘Number analyzed’ = Participants evaluable for this outcome measure at specified time points.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="26"/>
                <count group_id="O5" value="22"/>
                <count group_id="O6" value="25"/>
                <count group_id="O7" value="25"/>
                <count group_id="O8" value="24"/>
                <count group_id="O9" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Day 85</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.26" spread="10.914"/>
                    <measurement group_id="O2" value="9.46" spread="11.132"/>
                    <measurement group_id="O3" value="5.86" spread="9.988"/>
                    <measurement group_id="O4" value="-7.31" spread="7.254"/>
                    <measurement group_id="O5" value="5.42" spread="10.501"/>
                    <measurement group_id="O6" value="-3.10" spread="10.471"/>
                    <measurement group_id="O7" value="2.93" spread="11.259"/>
                    <measurement group_id="O8" value="2.35" spread="12.101"/>
                    <measurement group_id="O9" value="-7.16" spread="8.271"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 113</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="23"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.39" spread="11.623"/>
                    <measurement group_id="O2" value="11.97" spread="13.385"/>
                    <measurement group_id="O3" value="5.27" spread="12.612"/>
                    <measurement group_id="O4" value="-4.83" spread="9.919"/>
                    <measurement group_id="O5" value="6.31" spread="9.989"/>
                    <measurement group_id="O6" value="1.86" spread="11.617"/>
                    <measurement group_id="O7" value="2.35" spread="10.959"/>
                    <measurement group_id="O8" value="1.05" spread="10.017"/>
                    <measurement group_id="O9" value="-7.53" spread="7.966"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 85 : Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>13.389</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.525</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>8.373</ci_lower_limit>
            <ci_upper_limit>18.405</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 85 : Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>16.546</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.576</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>11.430</ci_lower_limit>
            <ci_upper_limit>21.663</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 85 : Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>13.288</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.593</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>8.137</ci_lower_limit>
            <ci_upper_limit>18.438</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 85 : Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.081</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>4.112</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.909</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.671</ci_lower_limit>
            <ci_upper_limit>9.895</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 85 : Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>9.560</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.927</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.743</ci_lower_limit>
            <ci_upper_limit>15.377</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 85 : Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>9.826</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.878</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.103</ci_lower_limit>
            <ci_upper_limit>15.548</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>10.004</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.326</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.395</ci_lower_limit>
            <ci_upper_limit>16.612</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>16.252</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.367</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>9.560</ci_lower_limit>
            <ci_upper_limit>22.943</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>9.571</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.384</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.847</ci_lower_limit>
            <ci_upper_limit>16.295</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>9.029</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.858</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.348</ci_lower_limit>
            <ci_upper_limit>14.710</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>8.543</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.876</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.827</ci_lower_limit>
            <ci_upper_limit>14.260</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 113:Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>8.898</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.840</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.252</ci_lower_limit>
            <ci_upper_limit>14.544</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Very Low Density Lipoprotein-Cholesterol (VLDL-C)</title>
        <description>VLDL is a type of lipoprotein made by the liver and one of the five major groups of lipoproteins, that enable fats and cholesterol to move within the water-based solution of the bloodstream. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value.</description>
        <time_frame>Baseline, Day 5, 8, 15, 22, 29, 36, 43, 50, 57, 71, 85, 99, 106, 113, 127, 141, 155, 169</time_frame>
        <population>FAS included all the participants who were randomized and administered at least 1 dose of study treatment. Here, ‘Number analyzed’ = Participants evaluable for this outcome measure at specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin + PF-04950615 50 mg</title>
            <description>Participants with fasting lipoprotein cholesterol (LDL-C) level (greater than or equal to [&gt;=]100 milligram per deciliter [mg/dL]) received atorvastatin along with PF-04950615 50 milligram (mg) subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin + PF-04950615 100 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 100 mg subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin + PF-04950615 150 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 150 mg subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O4">
            <title>Atorvastatin + PF-04950615 Placebo</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 placebo subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O5">
            <title>Atorvastatin + Ezetimibe 10 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with ezetimibe 10 mg tablet orally, once daily from Day 1 up to Day 112. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O6">
            <title>PF-04950615 50 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 50 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O7">
            <title>PF-04950615 100 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 100 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O8">
            <title>PF-04950615 150 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 150 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O9">
            <title>PF-04950615 Placebo</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 placebo, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naive to a treatment by lipid lowering drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Very Low Density Lipoprotein-Cholesterol (VLDL-C)</title>
          <description>VLDL is a type of lipoprotein made by the liver and one of the five major groups of lipoproteins, that enable fats and cholesterol to move within the water-based solution of the bloodstream. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value.</description>
          <population>FAS included all the participants who were randomized and administered at least 1 dose of study treatment. Here, ‘Number analyzed’ = Participants evaluable for this outcome measure at specified time points.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="26"/>
                <count group_id="O5" value="22"/>
                <count group_id="O6" value="25"/>
                <count group_id="O7" value="25"/>
                <count group_id="O8" value="24"/>
                <count group_id="O9" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="25"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.92" spread="9.312"/>
                    <measurement group_id="O2" value="23.79" spread="11.286"/>
                    <measurement group_id="O3" value="20.92" spread="7.651"/>
                    <measurement group_id="O4" value="21.42" spread="6.858"/>
                    <measurement group_id="O5" value="22.48" spread="7.869"/>
                    <measurement group_id="O6" value="17.44" spread="7.509"/>
                    <measurement group_id="O7" value="17.66" spread="9.090"/>
                    <measurement group_id="O8" value="16.63" spread="6.273"/>
                    <measurement group_id="O9" value="17.50" spread="8.549"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="23"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="25"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.36" spread="9.999"/>
                    <measurement group_id="O2" value="19.70" spread="8.249"/>
                    <measurement group_id="O3" value="17.22" spread="5.977"/>
                    <measurement group_id="O4" value="23.85" spread="10.657"/>
                    <measurement group_id="O5" value="21.95" spread="8.249"/>
                    <measurement group_id="O6" value="19.80" spread="11.927"/>
                    <measurement group_id="O7" value="16.08" spread="8.356"/>
                    <measurement group_id="O8" value="18.00" spread="10.065"/>
                    <measurement group_id="O9" value="20.68" spread="10.035"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="21"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="22"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.64" spread="13.073"/>
                    <measurement group_id="O2" value="18.00" spread="6.574"/>
                    <measurement group_id="O3" value="15.58" spread="6.192"/>
                    <measurement group_id="O4" value="21.72" spread="10.577"/>
                    <measurement group_id="O5" value="20.29" spread="7.100"/>
                    <measurement group_id="O6" value="18.64" spread="9.995"/>
                    <measurement group_id="O7" value="16.25" spread="6.661"/>
                    <measurement group_id="O8" value="18.95" spread="9.810"/>
                    <measurement group_id="O9" value="22.48" spread="13.737"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="25"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.20" spread="8.921"/>
                    <measurement group_id="O2" value="20.42" spread="9.930"/>
                    <measurement group_id="O3" value="16.50" spread="9.869"/>
                    <measurement group_id="O4" value="23.04" spread="9.035"/>
                    <measurement group_id="O5" value="22.68" spread="9.712"/>
                    <measurement group_id="O6" value="18.52" spread="9.265"/>
                    <measurement group_id="O7" value="16.28" spread="8.735"/>
                    <measurement group_id="O8" value="16.25" spread="10.605"/>
                    <measurement group_id="O9" value="20.43" spread="10.612"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.04" spread="6.761"/>
                    <measurement group_id="O2" value="19.04" spread="7.410"/>
                    <measurement group_id="O3" value="14.65" spread="6.786"/>
                    <measurement group_id="O4" value="21.65" spread="7.573"/>
                    <measurement group_id="O5" value="21.59" spread="7.866"/>
                    <measurement group_id="O6" value="17.20" spread="7.984"/>
                    <measurement group_id="O7" value="16.42" spread="6.580"/>
                    <measurement group_id="O8" value="17.17" spread="14.199"/>
                    <measurement group_id="O9" value="18.13" spread="9.416"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="25"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.76" spread="7.253"/>
                    <measurement group_id="O2" value="19.88" spread="9.967"/>
                    <measurement group_id="O3" value="15.39" spread="4.717"/>
                    <measurement group_id="O4" value="21.88" spread="9.523"/>
                    <measurement group_id="O5" value="22.73" spread="10.552"/>
                    <measurement group_id="O6" value="17.00" spread="7.746"/>
                    <measurement group_id="O7" value="19.68" spread="16.106"/>
                    <measurement group_id="O8" value="13.04" spread="6.753"/>
                    <measurement group_id="O9" value="19.00" spread="8.258"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.96" spread="9.361"/>
                    <measurement group_id="O2" value="15.33" spread="4.984"/>
                    <measurement group_id="O3" value="14.04" spread="5.842"/>
                    <measurement group_id="O4" value="21.92" spread="9.587"/>
                    <measurement group_id="O5" value="21.59" spread="9.169"/>
                    <measurement group_id="O6" value="17.28" spread="6.901"/>
                    <measurement group_id="O7" value="16.46" spread="6.129"/>
                    <measurement group_id="O8" value="15.50" spread="5.905"/>
                    <measurement group_id="O9" value="24.22" spread="17.231"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="25"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.56" spread="6.246"/>
                    <measurement group_id="O2" value="21.33" spread="13.770"/>
                    <measurement group_id="O3" value="18.04" spread="10.813"/>
                    <measurement group_id="O4" value="23.65" spread="12.547"/>
                    <measurement group_id="O5" value="20.95" spread="7.712"/>
                    <measurement group_id="O6" value="20.00" spread="7.708"/>
                    <measurement group_id="O7" value="18.12" spread="7.316"/>
                    <measurement group_id="O8" value="16.96" spread="6.734"/>
                    <measurement group_id="O9" value="22.78" spread="11.631"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 50</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.36" spread="9.269"/>
                    <measurement group_id="O2" value="17.67" spread="6.787"/>
                    <measurement group_id="O3" value="14.39" spread="6.966"/>
                    <measurement group_id="O4" value="21.69" spread="11.235"/>
                    <measurement group_id="O5" value="19.23" spread="6.718"/>
                    <measurement group_id="O6" value="17.48" spread="8.186"/>
                    <measurement group_id="O7" value="17.04" spread="7.151"/>
                    <measurement group_id="O8" value="15.54" spread="7.818"/>
                    <measurement group_id="O9" value="22.26" spread="13.685"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 57</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.36" spread="6.034"/>
                    <measurement group_id="O2" value="17.46" spread="8.939"/>
                    <measurement group_id="O3" value="13.87" spread="4.674"/>
                    <measurement group_id="O4" value="20.88" spread="7.957"/>
                    <measurement group_id="O5" value="21.55" spread="5.878"/>
                    <measurement group_id="O6" value="15.44" spread="5.108"/>
                    <measurement group_id="O7" value="16.83" spread="12.437"/>
                    <measurement group_id="O8" value="13.54" spread="4.222"/>
                    <measurement group_id="O9" value="20.13" spread="10.092"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 71</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.92" spread="7.064"/>
                    <measurement group_id="O2" value="17.50" spread="9.212"/>
                    <measurement group_id="O3" value="13.83" spread="3.950"/>
                    <measurement group_id="O4" value="21.77" spread="9.868"/>
                    <measurement group_id="O5" value="20.82" spread="8.151"/>
                    <measurement group_id="O6" value="19.04" spread="6.846"/>
                    <measurement group_id="O7" value="16.79" spread="6.840"/>
                    <measurement group_id="O8" value="14.63" spread="6.337"/>
                    <measurement group_id="O9" value="22.61" spread="9.014"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.24" spread="6.247"/>
                    <measurement group_id="O2" value="17.63" spread="8.816"/>
                    <measurement group_id="O3" value="14.04" spread="6.745"/>
                    <measurement group_id="O4" value="22.58" spread="7.991"/>
                    <measurement group_id="O5" value="19.77" spread="5.936"/>
                    <measurement group_id="O6" value="16.68" spread="7.040"/>
                    <measurement group_id="O7" value="14.09" spread="6.735"/>
                    <measurement group_id="O8" value="14.04" spread="4.639"/>
                    <measurement group_id="O9" value="16.43" spread="8.877"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 99</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="22"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.20" spread="6.371"/>
                    <measurement group_id="O2" value="18.04" spread="10.378"/>
                    <measurement group_id="O3" value="18.68" spread="17.700"/>
                    <measurement group_id="O4" value="21.72" spread="11.085"/>
                    <measurement group_id="O5" value="20.14" spread="7.298"/>
                    <measurement group_id="O6" value="17.84" spread="6.756"/>
                    <measurement group_id="O7" value="16.46" spread="9.514"/>
                    <measurement group_id="O8" value="16.21" spread="8.490"/>
                    <measurement group_id="O9" value="21.13" spread="8.981"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 106</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="22"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.44" spread="6.545"/>
                    <measurement group_id="O2" value="15.96" spread="6.328"/>
                    <measurement group_id="O3" value="14.59" spread="5.981"/>
                    <measurement group_id="O4" value="19.32" spread="7.330"/>
                    <measurement group_id="O5" value="18.64" spread="6.499"/>
                    <measurement group_id="O6" value="17.76" spread="7.573"/>
                    <measurement group_id="O7" value="16.09" spread="5.672"/>
                    <measurement group_id="O8" value="13.13" spread="5.788"/>
                    <measurement group_id="O9" value="20.00" spread="9.376"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 113</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="23"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.83" spread="8.726"/>
                    <measurement group_id="O2" value="16.54" spread="7.863"/>
                    <measurement group_id="O3" value="15.26" spread="5.056"/>
                    <measurement group_id="O4" value="21.88" spread="14.701"/>
                    <measurement group_id="O5" value="18.50" spread="7.951"/>
                    <measurement group_id="O6" value="15.92" spread="8.246"/>
                    <measurement group_id="O7" value="15.96" spread="8.466"/>
                    <measurement group_id="O8" value="13.87" spread="6.107"/>
                    <measurement group_id="O9" value="19.39" spread="8.322"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 127</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.48" spread="11.594"/>
                    <measurement group_id="O2" value="23.21" spread="14.231"/>
                    <measurement group_id="O3" value="16.61" spread="7.686"/>
                    <measurement group_id="O4" value="19.32" spread="9.534"/>
                    <measurement group_id="O5" value="21.59" spread="7.992"/>
                    <measurement group_id="O6" value="19.72" spread="8.091"/>
                    <measurement group_id="O7" value="17.91" spread="11.445"/>
                    <measurement group_id="O8" value="17.38" spread="12.631"/>
                    <measurement group_id="O9" value="21.61" spread="13.121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 141</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.13" spread="7.279"/>
                    <measurement group_id="O2" value="22.25" spread="15.109"/>
                    <measurement group_id="O3" value="17.39" spread="5.007"/>
                    <measurement group_id="O4" value="19.16" spread="9.573"/>
                    <measurement group_id="O5" value="23.68" spread="9.564"/>
                    <measurement group_id="O6" value="19.52" spread="10.627"/>
                    <measurement group_id="O7" value="17.61" spread="7.518"/>
                    <measurement group_id="O8" value="18.54" spread="9.913"/>
                    <measurement group_id="O9" value="20.09" spread="9.409"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 155</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="23"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.00" spread="3.905"/>
                    <measurement group_id="O2" value="22.21" spread="11.858"/>
                    <measurement group_id="O3" value="16.52" spread="7.141"/>
                    <measurement group_id="O4" value="20.56" spread="9.319"/>
                    <measurement group_id="O5" value="21.41" spread="7.028"/>
                    <measurement group_id="O6" value="19.30" spread="9.632"/>
                    <measurement group_id="O7" value="16.17" spread="8.144"/>
                    <measurement group_id="O8" value="18.92" spread="10.738"/>
                    <measurement group_id="O9" value="18.57" spread="9.110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 169</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="24"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="23"/>
                    <count group_id="O9" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.88" spread="7.732"/>
                    <measurement group_id="O2" value="21.42" spread="7.442"/>
                    <measurement group_id="O3" value="17.30" spread="6.292"/>
                    <measurement group_id="O4" value="19.60" spread="7.286"/>
                    <measurement group_id="O5" value="24.55" spread="11.931"/>
                    <measurement group_id="O6" value="19.13" spread="8.644"/>
                    <measurement group_id="O7" value="23.00" spread="23.279"/>
                    <measurement group_id="O8" value="18.00" spread="10.167"/>
                    <measurement group_id="O9" value="19.68" spread="8.306"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Very Low Density Lipoprotein-Cholesterol (VLDL-C) at Day 85 and Day 113</title>
        <description>VLDL is a type of lipoprotein made by the liver and one of the five major groups of lipoproteins, that enable fats and cholesterol to move within the water-based solution of the bloodstream. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value. Change from baseline = observed value minus baseline value.</description>
        <time_frame>Baseline, Day 85, 113</time_frame>
        <population>FAS included all the participants who were randomized and administered at least 1 dose of study treatment. Here, ‘Number analyzed’ = Participants evaluable for this outcome measure at specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin + PF-04950615 50 mg</title>
            <description>Participants with fasting lipoprotein cholesterol (LDL-C) level (greater than or equal to [&gt;=]100 milligram per deciliter [mg/dL]) received atorvastatin along with PF-04950615 50 milligram (mg) subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin + PF-04950615 100 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 100 mg subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin + PF-04950615 150 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 150 mg subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O4">
            <title>Atorvastatin + PF-04950615 Placebo</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 placebo subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O5">
            <title>Atorvastatin + Ezetimibe 10 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with ezetimibe 10 mg tablet orally, once daily from Day 1 up to Day 112. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O6">
            <title>PF-04950615 50 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 50 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O7">
            <title>PF-04950615 100 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 100 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O8">
            <title>PF-04950615 150 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 150 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O9">
            <title>PF-04950615 Placebo</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 placebo, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naive to a treatment by lipid lowering drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Very Low Density Lipoprotein-Cholesterol (VLDL-C) at Day 85 and Day 113</title>
          <description>VLDL is a type of lipoprotein made by the liver and one of the five major groups of lipoproteins, that enable fats and cholesterol to move within the water-based solution of the bloodstream. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value. Change from baseline = observed value minus baseline value.</description>
          <population>FAS included all the participants who were randomized and administered at least 1 dose of study treatment. Here, ‘Number analyzed’ = Participants evaluable for this outcome measure at specified time points.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="26"/>
                <count group_id="O5" value="22"/>
                <count group_id="O6" value="25"/>
                <count group_id="O7" value="25"/>
                <count group_id="O8" value="24"/>
                <count group_id="O9" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Day 85</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.68" spread="6.973"/>
                    <measurement group_id="O2" value="-6.17" spread="7.171"/>
                    <measurement group_id="O3" value="-6.57" spread="6.726"/>
                    <measurement group_id="O4" value="1.15" spread="4.841"/>
                    <measurement group_id="O5" value="-2.70" spread="7.069"/>
                    <measurement group_id="O6" value="-0.76" spread="5.114"/>
                    <measurement group_id="O7" value="-2.63" spread="9.497"/>
                    <measurement group_id="O8" value="-2.58" spread="7.290"/>
                    <measurement group_id="O9" value="-1.07" spread="4.989"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 113</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="23"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.29" spread="8.538"/>
                    <measurement group_id="O2" value="-7.25" spread="9.067"/>
                    <measurement group_id="O3" value="-5.35" spread="6.619"/>
                    <measurement group_id="O4" value="0.34" spread="10.957"/>
                    <measurement group_id="O5" value="-3.98" spread="8.873"/>
                    <measurement group_id="O6" value="-1.52" spread="5.771"/>
                    <measurement group_id="O7" value="-0.76" spread="9.276"/>
                    <measurement group_id="O8" value="-2.98" spread="6.998"/>
                    <measurement group_id="O9" value="1.89" spread="5.762"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-7.462</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.434</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.311</ci_lower_limit>
            <ci_upper_limit>-4.614</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-6.693</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.469</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.610</ci_lower_limit>
            <ci_upper_limit>-3.776</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-8.755</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.479</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.692</ci_lower_limit>
            <ci_upper_limit>-5.817</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.484</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-0.072</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.773</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.596</ci_lower_limit>
            <ci_upper_limit>3.451</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.173</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-1.701</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.793</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.264</ci_lower_limit>
            <ci_upper_limit>1.862</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.135</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-1.953</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.761</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.452</ci_lower_limit>
            <ci_upper_limit>1.546</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.034</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-4.447</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.406</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.230</ci_lower_limit>
            <ci_upper_limit>0.335</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-6.764</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.442</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.617</ci_lower_limit>
            <ci_upper_limit>-1.910</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.009</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-5.951</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.458</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.836</ci_lower_limit>
            <ci_upper_limit>-1.066</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.056</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-3.070</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.915</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.876</ci_lower_limit>
            <ci_upper_limit>0.736</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.095</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-2.557</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.937</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.408</ci_lower_limit>
            <ci_upper_limit>1.293</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 113:Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-5.271</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.913</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.074</ci_lower_limit>
            <ci_upper_limit>-1.469</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Very Low Density Lipoprotein-Cholesterol (VLDL-C) at Day 85 and Day 113</title>
        <description>VLDL is a type of lipoprotein made by the liver and one of the five major groups of lipoproteins, that enable fats and cholesterol to move within the water-based solution of the bloodstream. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value. Percent change from baseline = ([observed value divided by baseline value] minus 1) multiplied by 100.</description>
        <time_frame>Baseline, Day 85, 113</time_frame>
        <population>FAS included all the participants who were randomized and administered at least 1 dose of study treatment. Here, ‘Number analyzed’ = Participants evaluable for this outcome measure at specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin + PF-04950615 50 mg</title>
            <description>Participants with fasting lipoprotein cholesterol (LDL-C) level (greater than or equal to [&gt;=]100 milligram per deciliter [mg/dL]) received atorvastatin along with PF-04950615 50 milligram (mg) subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin + PF-04950615 100 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 100 mg subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin + PF-04950615 150 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 150 mg subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O4">
            <title>Atorvastatin + PF-04950615 Placebo</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 placebo subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O5">
            <title>Atorvastatin + Ezetimibe 10 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with ezetimibe 10 mg tablet orally, once daily from Day 1 up to Day 112. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O6">
            <title>PF-04950615 50 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 50 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O7">
            <title>PF-04950615 100 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 100 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O8">
            <title>PF-04950615 150 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 150 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O9">
            <title>PF-04950615 Placebo</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 placebo, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naive to a treatment by lipid lowering drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Very Low Density Lipoprotein-Cholesterol (VLDL-C) at Day 85 and Day 113</title>
          <description>VLDL is a type of lipoprotein made by the liver and one of the five major groups of lipoproteins, that enable fats and cholesterol to move within the water-based solution of the bloodstream. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value. Percent change from baseline = ([observed value divided by baseline value] minus 1) multiplied by 100.</description>
          <population>FAS included all the participants who were randomized and administered at least 1 dose of study treatment. Here, ‘Number analyzed’ = Participants evaluable for this outcome measure at specified time points.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="26"/>
                <count group_id="O5" value="22"/>
                <count group_id="O6" value="25"/>
                <count group_id="O7" value="25"/>
                <count group_id="O8" value="24"/>
                <count group_id="O9" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Day 85</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="24"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.42" spread="30.458"/>
                    <measurement group_id="O2" value="-22.99" spread="25.647"/>
                    <measurement group_id="O3" value="-28.96" spread="25.281"/>
                    <measurement group_id="O4" value="7.08" spread="26.054"/>
                    <measurement group_id="O5" value="-6.48" spread="27.276"/>
                    <measurement group_id="O6" value="-7.61" spread="23.163"/>
                    <measurement group_id="O7" value="5.66" spread="76.931"/>
                    <measurement group_id="O8" value="-3.54" spread="45.821"/>
                    <measurement group_id="O9" value="-3.63" spread="39.826"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 113</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="24"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="23"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.23" spread="35.083"/>
                    <measurement group_id="O2" value="-26.62" spread="28.464"/>
                    <measurement group_id="O3" value="-19.28" spread="33.794"/>
                    <measurement group_id="O4" value="-1.89" spread="43.239"/>
                    <measurement group_id="O5" value="-10.80" spread="38.288"/>
                    <measurement group_id="O6" value="-9.72" spread="29.006"/>
                    <measurement group_id="O7" value="10.72" spread="65.297"/>
                    <measurement group_id="O8" value="-10.36" spread="36.732"/>
                    <measurement group_id="O9" value="18.73" spread="48.065"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-31.880</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>7.071</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-45.925</ci_lower_limit>
            <ci_upper_limit>-17.836</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-29.187</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>7.242</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-43.571</ci_lower_limit>
            <ci_upper_limit>-14.803</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-39.657</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>7.290</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-54.136</ci_lower_limit>
            <ci_upper_limit>-25.178</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.366</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-4.681</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>13.601</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-31.713</ci_lower_limit>
            <ci_upper_limit>22.350</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.773</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>10.227</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>13.586</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16.774</ci_lower_limit>
            <ci_upper_limit>37.228</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.422</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-2.646</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>13.362</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-29.206</ci_lower_limit>
            <ci_upper_limit>23.915</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.107</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-12.911</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>10.309</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-33.411</ci_lower_limit>
            <ci_upper_limit>7.589</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.015</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-23.119</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>10.461</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-43.923</ci_lower_limit>
            <ci_upper_limit>-2.315</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.054</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-17.159</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>10.535</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-38.108</ci_lower_limit>
            <ci_upper_limit>3.789</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.029</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-24.416</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>12.718</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-49.696</ci_lower_limit>
            <ci_upper_limit>0.865</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.311</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-6.287</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>12.705</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-31.541</ci_lower_limit>
            <ci_upper_limit>18.968</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 113:Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.006</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-32.443</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>12.555</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-57.400</ci_lower_limit>
            <ci_upper_limit>-7.485</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Triglyceride (TG)</title>
        <description>Triglycerides are a type of fat circulating in the blood and account for the majority of the fats circulating in the blood. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value.</description>
        <time_frame>Baseline, Day 5, 8, 15, 22, 29, 36, 43, 50, 57, 71, 85, 99, 106, 113, 127, 141, 155, 169</time_frame>
        <population>FAS included all the participants who were randomized and administered at least 1 dose of study treatment. Here, ‘Number analyzed’ = Participants evaluable for this outcome measure at specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin + PF-04950615 50 mg</title>
            <description>Participants with fasting lipoprotein cholesterol (LDL-C) level (greater than or equal to [&gt;=]100 milligram per deciliter [mg/dL]) received atorvastatin along with PF-04950615 50 milligram (mg) subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin + PF-04950615 100 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 100 mg subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin + PF-04950615 150 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 150 mg subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O4">
            <title>Atorvastatin + PF-04950615 Placebo</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 placebo subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O5">
            <title>Atorvastatin + Ezetimibe 10 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with ezetimibe 10 mg tablet orally, once daily from Day 1 up to Day 112. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O6">
            <title>PF-04950615 50 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 50 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O7">
            <title>PF-04950615 100 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 100 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O8">
            <title>PF-04950615 150 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 150 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O9">
            <title>PF-04950615 Placebo</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 placebo, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naive to a treatment by lipid lowering drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Triglyceride (TG)</title>
          <description>Triglycerides are a type of fat circulating in the blood and account for the majority of the fats circulating in the blood. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value.</description>
          <population>FAS included all the participants who were randomized and administered at least 1 dose of study treatment. Here, ‘Number analyzed’ = Participants evaluable for this outcome measure at specified time points.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="26"/>
                <count group_id="O5" value="22"/>
                <count group_id="O6" value="25"/>
                <count group_id="O7" value="25"/>
                <count group_id="O8" value="24"/>
                <count group_id="O9" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="25"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121.04" spread="56.152"/>
                    <measurement group_id="O2" value="158.21" spread="71.477"/>
                    <measurement group_id="O3" value="127.65" spread="59.878"/>
                    <measurement group_id="O4" value="140.23" spread="51.283"/>
                    <measurement group_id="O5" value="152.59" spread="50.105"/>
                    <measurement group_id="O6" value="122.40" spread="50.578"/>
                    <measurement group_id="O7" value="124.40" spread="59.717"/>
                    <measurement group_id="O8" value="111.58" spread="42.354"/>
                    <measurement group_id="O9" value="130.39" spread="49.826"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="23"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="25"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="134.20" spread="78.692"/>
                    <measurement group_id="O2" value="130.30" spread="58.718"/>
                    <measurement group_id="O3" value="112.17" spread="47.884"/>
                    <measurement group_id="O4" value="154.27" spread="74.707"/>
                    <measurement group_id="O5" value="146.41" spread="76.274"/>
                    <measurement group_id="O6" value="128.20" spread="79.256"/>
                    <measurement group_id="O7" value="115.40" spread="52.401"/>
                    <measurement group_id="O8" value="114.25" spread="61.969"/>
                    <measurement group_id="O9" value="121.09" spread="48.602"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="21"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="22"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="126.44" spread="123.041"/>
                    <measurement group_id="O2" value="124.58" spread="49.786"/>
                    <measurement group_id="O3" value="95.71" spread="42.796"/>
                    <measurement group_id="O4" value="150.40" spread="76.908"/>
                    <measurement group_id="O5" value="128.43" spread="50.155"/>
                    <measurement group_id="O6" value="122.72" spread="66.459"/>
                    <measurement group_id="O7" value="103.50" spread="48.515"/>
                    <measurement group_id="O8" value="130.91" spread="75.156"/>
                    <measurement group_id="O9" value="136.91" spread="91.378"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="25"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109.52" spread="65.672"/>
                    <measurement group_id="O2" value="143.96" spread="70.871"/>
                    <measurement group_id="O3" value="123.96" spread="108.066"/>
                    <measurement group_id="O4" value="149.31" spread="64.392"/>
                    <measurement group_id="O5" value="145.91" spread="79.420"/>
                    <measurement group_id="O6" value="125.64" spread="55.667"/>
                    <measurement group_id="O7" value="113.52" spread="60.601"/>
                    <measurement group_id="O8" value="114.25" spread="54.003"/>
                    <measurement group_id="O9" value="130.65" spread="53.724"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105.56" spread="45.283"/>
                    <measurement group_id="O2" value="119.17" spread="55.800"/>
                    <measurement group_id="O3" value="101.96" spread="54.725"/>
                    <measurement group_id="O4" value="133.65" spread="48.535"/>
                    <measurement group_id="O5" value="144.64" spread="68.531"/>
                    <measurement group_id="O6" value="125.00" spread="54.636"/>
                    <measurement group_id="O7" value="109.04" spread="49.088"/>
                    <measurement group_id="O8" value="113.79" spread="106.198"/>
                    <measurement group_id="O9" value="130.26" spread="59.246"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="25"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.84" spread="49.164"/>
                    <measurement group_id="O2" value="133.38" spread="74.370"/>
                    <measurement group_id="O3" value="100.04" spread="39.343"/>
                    <measurement group_id="O4" value="147.92" spread="68.536"/>
                    <measurement group_id="O5" value="130.00" spread="52.743"/>
                    <measurement group_id="O6" value="111.24" spread="46.683"/>
                    <measurement group_id="O7" value="142.84" spread="141.763"/>
                    <measurement group_id="O8" value="94.29" spread="37.698"/>
                    <measurement group_id="O9" value="122.09" spread="49.749"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113.68" spread="71.769"/>
                    <measurement group_id="O2" value="111.25" spread="45.529"/>
                    <measurement group_id="O3" value="96.52" spread="56.535"/>
                    <measurement group_id="O4" value="154.65" spread="59.929"/>
                    <measurement group_id="O5" value="139.95" spread="79.796"/>
                    <measurement group_id="O6" value="115.12" spread="54.424"/>
                    <measurement group_id="O7" value="109.17" spread="54.052"/>
                    <measurement group_id="O8" value="105.67" spread="38.421"/>
                    <measurement group_id="O9" value="158.30" spread="102.642"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="25"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108.16" spread="56.609"/>
                    <measurement group_id="O2" value="161.75" spread="134.409"/>
                    <measurement group_id="O3" value="130.71" spread="124.380"/>
                    <measurement group_id="O4" value="159.19" spread="85.270"/>
                    <measurement group_id="O5" value="135.23" spread="70.762"/>
                    <measurement group_id="O6" value="123.80" spread="52.925"/>
                    <measurement group_id="O7" value="119.44" spread="53.110"/>
                    <measurement group_id="O8" value="109.29" spread="54.365"/>
                    <measurement group_id="O9" value="140.61" spread="73.706"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 50</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108.12" spread="65.442"/>
                    <measurement group_id="O2" value="126.58" spread="56.883"/>
                    <measurement group_id="O3" value="100.57" spread="52.553"/>
                    <measurement group_id="O4" value="148.50" spread="77.558"/>
                    <measurement group_id="O5" value="121.64" spread="51.406"/>
                    <measurement group_id="O6" value="123.48" spread="61.199"/>
                    <measurement group_id="O7" value="114.22" spread="53.090"/>
                    <measurement group_id="O8" value="113.29" spread="53.870"/>
                    <measurement group_id="O9" value="142.30" spread="83.014"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 57</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.40" spread="49.048"/>
                    <measurement group_id="O2" value="124.25" spread="69.357"/>
                    <measurement group_id="O3" value="92.52" spread="45.106"/>
                    <measurement group_id="O4" value="139.50" spread="56.099"/>
                    <measurement group_id="O5" value="137.55" spread="53.502"/>
                    <measurement group_id="O6" value="102.28" spread="33.512"/>
                    <measurement group_id="O7" value="117.21" spread="84.666"/>
                    <measurement group_id="O8" value="90.67" spread="28.925"/>
                    <measurement group_id="O9" value="136.78" spread="67.987"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 71</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103.13" spread="51.243"/>
                    <measurement group_id="O2" value="125.50" spread="74.428"/>
                    <measurement group_id="O3" value="93.91" spread="39.340"/>
                    <measurement group_id="O4" value="156.27" spread="65.687"/>
                    <measurement group_id="O5" value="139.27" spread="85.017"/>
                    <measurement group_id="O6" value="122.68" spread="52.192"/>
                    <measurement group_id="O7" value="112.13" spread="56.034"/>
                    <measurement group_id="O8" value="103.13" spread="47.534"/>
                    <measurement group_id="O9" value="146.43" spread="64.368"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.36" spread="47.872"/>
                    <measurement group_id="O2" value="130.25" spread="78.800"/>
                    <measurement group_id="O3" value="95.00" spread="54.102"/>
                    <measurement group_id="O4" value="142.81" spread="57.891"/>
                    <measurement group_id="O5" value="142.45" spread="60.126"/>
                    <measurement group_id="O6" value="118.64" spread="46.593"/>
                    <measurement group_id="O7" value="100.04" spread="53.185"/>
                    <measurement group_id="O8" value="99.92" spread="40.798"/>
                    <measurement group_id="O9" value="119.17" spread="57.046"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 99</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="22"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110.56" spread="57.944"/>
                    <measurement group_id="O2" value="128.25" spread="70.840"/>
                    <measurement group_id="O3" value="131.32" spread="118.340"/>
                    <measurement group_id="O4" value="156.84" spread="70.931"/>
                    <measurement group_id="O5" value="137.82" spread="60.866"/>
                    <measurement group_id="O6" value="122.96" spread="55.697"/>
                    <measurement group_id="O7" value="118.17" spread="63.727"/>
                    <measurement group_id="O8" value="115.08" spread="63.629"/>
                    <measurement group_id="O9" value="133.91" spread="49.879"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 106</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="22"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.80" spread="46.662"/>
                    <measurement group_id="O2" value="116.29" spread="50.480"/>
                    <measurement group_id="O3" value="102.59" spread="50.880"/>
                    <measurement group_id="O4" value="131.68" spread="55.816"/>
                    <measurement group_id="O5" value="133.41" spread="68.902"/>
                    <measurement group_id="O6" value="116.16" spread="55.618"/>
                    <measurement group_id="O7" value="109.91" spread="45.304"/>
                    <measurement group_id="O8" value="93.54" spread="38.520"/>
                    <measurement group_id="O9" value="139.00" spread="53.142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 113</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="23"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101.58" spread="51.130"/>
                    <measurement group_id="O2" value="112.88" spread="60.824"/>
                    <measurement group_id="O3" value="94.39" spread="34.093"/>
                    <measurement group_id="O4" value="141.64" spread="96.032"/>
                    <measurement group_id="O5" value="129.14" spread="73.031"/>
                    <measurement group_id="O6" value="111.72" spread="53.875"/>
                    <measurement group_id="O7" value="116.26" spread="69.771"/>
                    <measurement group_id="O8" value="101.43" spread="52.274"/>
                    <measurement group_id="O9" value="136.61" spread="64.291"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 127</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="133.40" spread="71.046"/>
                    <measurement group_id="O2" value="159.25" spread="101.582"/>
                    <measurement group_id="O3" value="115.96" spread="63.954"/>
                    <measurement group_id="O4" value="133.40" spread="66.304"/>
                    <measurement group_id="O5" value="153.14" spread="62.304"/>
                    <measurement group_id="O6" value="138.08" spread="60.533"/>
                    <measurement group_id="O7" value="139.83" spread="103.182"/>
                    <measurement group_id="O8" value="124.50" spread="86.402"/>
                    <measurement group_id="O9" value="159.43" spread="89.130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 141</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115.13" spread="51.964"/>
                    <measurement group_id="O2" value="164.79" spread="129.257"/>
                    <measurement group_id="O3" value="123.39" spread="35.150"/>
                    <measurement group_id="O4" value="131.08" spread="56.266"/>
                    <measurement group_id="O5" value="156.27" spread="76.965"/>
                    <measurement group_id="O6" value="135.80" spread="75.159"/>
                    <measurement group_id="O7" value="119.91" spread="59.343"/>
                    <measurement group_id="O8" value="129.13" spread="70.190"/>
                    <measurement group_id="O9" value="137.35" spread="56.775"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 155</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="23"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115.44" spread="39.459"/>
                    <measurement group_id="O2" value="164.13" spread="102.919"/>
                    <measurement group_id="O3" value="113.83" spread="43.209"/>
                    <measurement group_id="O4" value="139.44" spread="65.901"/>
                    <measurement group_id="O5" value="149.23" spread="68.510"/>
                    <measurement group_id="O6" value="129.00" spread="70.010"/>
                    <measurement group_id="O7" value="119.91" spread="61.088"/>
                    <measurement group_id="O8" value="133.33" spread="81.100"/>
                    <measurement group_id="O9" value="131.74" spread="62.736"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 169</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="24"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="23"/>
                    <count group_id="O9" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120.76" spread="56.962"/>
                    <measurement group_id="O2" value="151.63" spread="59.252"/>
                    <measurement group_id="O3" value="122.43" spread="65.091"/>
                    <measurement group_id="O4" value="149.40" spread="58.176"/>
                    <measurement group_id="O5" value="167.91" spread="79.436"/>
                    <measurement group_id="O6" value="126.67" spread="60.290"/>
                    <measurement group_id="O7" value="166.22" spread="176.973"/>
                    <measurement group_id="O8" value="128.26" spread="71.260"/>
                    <measurement group_id="O9" value="125.41" spread="36.439"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Triglyceride (TG) at Day 85 and Day 113</title>
        <description>Triglycerides are a type of fat circulating in the blood and account for the majority of the fats circulating in the blood. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value. Change from baseline = observed value minus baseline value.</description>
        <time_frame>Baseline, Day 85, 113</time_frame>
        <population>FAS included all the participants who were randomized and administered at least 1 dose of study treatment. Here, ‘Number analyzed’ = Participants evaluable for this outcome measure at specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin + PF-04950615 50 mg</title>
            <description>Participants with fasting lipoprotein cholesterol (LDL-C) level (greater than or equal to [&gt;=]100 milligram per deciliter [mg/dL]) received atorvastatin along with PF-04950615 50 milligram (mg) subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin + PF-04950615 100 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 100 mg subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin + PF-04950615 150 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 150 mg subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O4">
            <title>Atorvastatin + PF-04950615 Placebo</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 placebo subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O5">
            <title>Atorvastatin + Ezetimibe 10 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with ezetimibe 10 mg tablet orally, once daily from Day 1 up to Day 112. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O6">
            <title>PF-04950615 50 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 50 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O7">
            <title>PF-04950615 100 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 100 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O8">
            <title>PF-04950615 150 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 150 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O9">
            <title>PF-04950615 Placebo</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 placebo, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naive to a treatment by lipid lowering drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Triglyceride (TG) at Day 85 and Day 113</title>
          <description>Triglycerides are a type of fat circulating in the blood and account for the majority of the fats circulating in the blood. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value. Change from baseline = observed value minus baseline value.</description>
          <population>FAS included all the participants who were randomized and administered at least 1 dose of study treatment. Here, ‘Number analyzed’ = Participants evaluable for this outcome measure at specified time points.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="26"/>
                <count group_id="O5" value="22"/>
                <count group_id="O6" value="25"/>
                <count group_id="O7" value="25"/>
                <count group_id="O8" value="24"/>
                <count group_id="O9" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Day 85</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.68" spread="41.898"/>
                    <measurement group_id="O2" value="-27.96" spread="49.754"/>
                    <measurement group_id="O3" value="-29.52" spread="40.669"/>
                    <measurement group_id="O4" value="2.58" spread="35.796"/>
                    <measurement group_id="O5" value="-10.14" spread="43.129"/>
                    <measurement group_id="O6" value="-3.76" spread="37.502"/>
                    <measurement group_id="O7" value="-15.87" spread="48.341"/>
                    <measurement group_id="O8" value="-11.67" spread="42.519"/>
                    <measurement group_id="O9" value="-11.22" spread="23.797"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 113</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="23"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.02" spread="41.197"/>
                    <measurement group_id="O2" value="-45.33" spread="53.285"/>
                    <measurement group_id="O3" value="-30.13" spread="48.592"/>
                    <measurement group_id="O4" value="-0.58" spread="63.896"/>
                    <measurement group_id="O5" value="-23.45" spread="51.443"/>
                    <measurement group_id="O6" value="-10.68" spread="27.488"/>
                    <measurement group_id="O7" value="0.35" spread="48.858"/>
                    <measurement group_id="O8" value="-12.46" spread="44.128"/>
                    <measurement group_id="O9" value="6.22" spread="32.888"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-35.967</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>10.822</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-57.463</ci_lower_limit>
            <ci_upper_limit>-14.472</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.005</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-29.186</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>11.044</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-51.123</ci_lower_limit>
            <ci_upper_limit>-7.249</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-40.010</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>11.160</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-62.175</ci_lower_limit>
            <ci_upper_limit>-17.845</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.614</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>3.170</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>10.906</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-18.502</ci_lower_limit>
            <ci_upper_limit>24.842</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.221</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-8.563</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>11.067</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-30.554</ci_lower_limit>
            <ci_upper_limit>13.427</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.303</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-5.649</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>10.933</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-27.376</ci_lower_limit>
            <ci_upper_limit>16.079</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.067</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-22.003</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>14.530</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-50.882</ci_lower_limit>
            <ci_upper_limit>6.875</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-41.761</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>14.676</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-70.934</ci_lower_limit>
            <ci_upper_limit>-12.588</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.010</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-34.933</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>14.832</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-64.410</ci_lower_limit>
            <ci_upper_limit>-5.456</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.064</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-17.978</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>11.725</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-41.282</ci_lower_limit>
            <ci_upper_limit>5.326</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.318</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-5.654</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>11.903</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-29.311</ci_lower_limit>
            <ci_upper_limit>18.004</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 113:Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.052</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-19.435</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>11.807</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-42.902</ci_lower_limit>
            <ci_upper_limit>4.032</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Triglyceride (TG) at Day 85 and Day 113</title>
        <description>Triglycerides are a type of fat circulating in the blood and account for the majority of the fats circulating in the blood. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value. Percent change from baseline = ([observed value divided by baseline value] minus 1) multiplied by 100.</description>
        <time_frame>Baseline, Day 85, 113</time_frame>
        <population>FAS included all the participants who were randomized and administered at least 1 dose of study treatment. Here, ‘Number analyzed’ = Participants evaluable for this outcome measure at specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin + PF-04950615 50 mg</title>
            <description>Participants with fasting lipoprotein cholesterol (LDL-C) level (greater than or equal to [&gt;=]100 milligram per deciliter [mg/dL]) received atorvastatin along with PF-04950615 50 milligram (mg) subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin + PF-04950615 100 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 100 mg subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin + PF-04950615 150 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 150 mg subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O4">
            <title>Atorvastatin + PF-04950615 Placebo</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 placebo subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O5">
            <title>Atorvastatin + Ezetimibe 10 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with ezetimibe 10 mg tablet orally, once daily from Day 1 up to Day 112. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O6">
            <title>PF-04950615 50 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 50 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O7">
            <title>PF-04950615 100 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 100 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O8">
            <title>PF-04950615 150 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 150 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O9">
            <title>PF-04950615 Placebo</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 placebo, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naive to a treatment by lipid lowering drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Triglyceride (TG) at Day 85 and Day 113</title>
          <description>Triglycerides are a type of fat circulating in the blood and account for the majority of the fats circulating in the blood. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value. Percent change from baseline = ([observed value divided by baseline value] minus 1) multiplied by 100.</description>
          <population>FAS included all the participants who were randomized and administered at least 1 dose of study treatment. Here, ‘Number analyzed’ = Participants evaluable for this outcome measure at specified time points.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="26"/>
                <count group_id="O5" value="22"/>
                <count group_id="O6" value="25"/>
                <count group_id="O7" value="25"/>
                <count group_id="O8" value="24"/>
                <count group_id="O9" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Day 85</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.00" spread="31.109"/>
                    <measurement group_id="O2" value="-16.85" spread="28.672"/>
                    <measurement group_id="O3" value="-23.38" spread="24.421"/>
                    <measurement group_id="O4" value="3.74" spread="27.803"/>
                    <measurement group_id="O5" value="-5.20" spread="23.919"/>
                    <measurement group_id="O6" value="2.62" spread="33.715"/>
                    <measurement group_id="O7" value="-9.40" spread="42.868"/>
                    <measurement group_id="O8" value="-5.21" spread="35.698"/>
                    <measurement group_id="O9" value="-9.33" spread="19.235"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 113</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="23"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.44" spread="26.916"/>
                    <measurement group_id="O2" value="-27.65" spread="26.827"/>
                    <measurement group_id="O3" value="-17.70" spread="29.263"/>
                    <measurement group_id="O4" value="-3.82" spread="36.247"/>
                    <measurement group_id="O5" value="-15.23" spread="24.917"/>
                    <measurement group_id="O6" value="-8.31" spread="19.500"/>
                    <measurement group_id="O7" value="1.32" spread="37.694"/>
                    <measurement group_id="O8" value="-8.47" spread="35.865"/>
                    <measurement group_id="O9" value="4.57" spread="29.077"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-25.974</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>7.674</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-41.217</ci_lower_limit>
            <ci_upper_limit>-10.731</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-21.110</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>7.831</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-36.665</ci_lower_limit>
            <ci_upper_limit>-5.555</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-31.034</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>7.917</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-46.758</ci_lower_limit>
            <ci_upper_limit>-15.310</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.799</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>8.034</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>9.553</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.948</ci_lower_limit>
            <ci_upper_limit>27.015</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.398</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-2.511</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>9.682</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-21.748</ci_lower_limit>
            <ci_upper_limit>16.727</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.515</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>0.369</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>9.580</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-18.668</ci_lower_limit>
            <ci_upper_limit>19.407</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.128</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-10.056</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>8.801</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-27.549</ci_lower_limit>
            <ci_upper_limit>7.437</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-24.352</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>8.882</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-42.008</ci_lower_limit>
            <ci_upper_limit>-6.695</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.049</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-14.994</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>8.987</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-32.858</ci_lower_limit>
            <ci_upper_limit>2.870</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.071</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-13.830</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>9.326</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-32.368</ci_lower_limit>
            <ci_upper_limit>4.709</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.361</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-3.378</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>9.464</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-22.191</ci_lower_limit>
            <ci_upper_limit>15.435</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 113:Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.056</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-15.035</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>9.389</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-33.698</ci_lower_limit>
            <ci_upper_limit>3.629</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)</title>
        <description>Non-HDL-C calculated as total cholesterol minus HDL cholesterol. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value.</description>
        <time_frame>Baseline, Day 5, 8, 15, 22, 29, 36, 43, 50, 57, 71, 85, 99, 106, 113, 127, 141, 155, 169</time_frame>
        <population>FAS included all the participants who were randomized and administered at least 1 dose of study treatment. Here, ‘Number analyzed’ = Participants evaluable for this outcome measure at specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin + PF-04950615 50 mg</title>
            <description>Participants with fasting lipoprotein cholesterol (LDL-C) level (greater than or equal to [&gt;=]100 milligram per deciliter [mg/dL]) received atorvastatin along with PF-04950615 50 milligram (mg) subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin + PF-04950615 100 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 100 mg subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin + PF-04950615 150 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 150 mg subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O4">
            <title>Atorvastatin + PF-04950615 Placebo</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 placebo subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O5">
            <title>Atorvastatin + Ezetimibe 10 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with ezetimibe 10 mg tablet orally, once daily from Day 1 up to Day 112. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O6">
            <title>PF-04950615 50 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 50 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O7">
            <title>PF-04950615 100 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 100 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O8">
            <title>PF-04950615 150 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 150 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O9">
            <title>PF-04950615 Placebo</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 placebo, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naive to a treatment by lipid lowering drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)</title>
          <description>Non-HDL-C calculated as total cholesterol minus HDL cholesterol. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value.</description>
          <population>FAS included all the participants who were randomized and administered at least 1 dose of study treatment. Here, ‘Number analyzed’ = Participants evaluable for this outcome measure at specified time points.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="26"/>
                <count group_id="O5" value="22"/>
                <count group_id="O6" value="25"/>
                <count group_id="O7" value="25"/>
                <count group_id="O8" value="24"/>
                <count group_id="O9" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="25"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="159.58" spread="29.033"/>
                    <measurement group_id="O2" value="155.54" spread="20.706"/>
                    <measurement group_id="O3" value="154.71" spread="22.511"/>
                    <measurement group_id="O4" value="163.90" spread="25.271"/>
                    <measurement group_id="O5" value="165.86" spread="26.655"/>
                    <measurement group_id="O6" value="188.72" spread="30.222"/>
                    <measurement group_id="O7" value="182.86" spread="22.842"/>
                    <measurement group_id="O8" value="182.17" spread="21.217"/>
                    <measurement group_id="O9" value="181.17" spread="23.577"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="23"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="25"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113.52" spread="28.259"/>
                    <measurement group_id="O2" value="97.78" spread="25.034"/>
                    <measurement group_id="O3" value="98.48" spread="15.003"/>
                    <measurement group_id="O4" value="161.23" spread="22.059"/>
                    <measurement group_id="O5" value="140.77" spread="26.324"/>
                    <measurement group_id="O6" value="154.36" spread="35.666"/>
                    <measurement group_id="O7" value="143.24" spread="23.520"/>
                    <measurement group_id="O8" value="137.50" spread="28.770"/>
                    <measurement group_id="O9" value="189.36" spread="24.432"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="21"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="22"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.24" spread="22.966"/>
                    <measurement group_id="O2" value="79.33" spread="27.140"/>
                    <measurement group_id="O3" value="76.17" spread="15.222"/>
                    <measurement group_id="O4" value="162.16" spread="29.067"/>
                    <measurement group_id="O5" value="131.52" spread="23.712"/>
                    <measurement group_id="O6" value="142.84" spread="36.478"/>
                    <measurement group_id="O7" value="123.25" spread="25.378"/>
                    <measurement group_id="O8" value="122.73" spread="29.183"/>
                    <measurement group_id="O9" value="193.70" spread="20.424"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="25"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.68" spread="27.248"/>
                    <measurement group_id="O2" value="77.88" spread="27.299"/>
                    <measurement group_id="O3" value="57.96" spread="16.134"/>
                    <measurement group_id="O4" value="162.35" spread="20.558"/>
                    <measurement group_id="O5" value="130.27" spread="19.489"/>
                    <measurement group_id="O6" value="138.40" spread="38.794"/>
                    <measurement group_id="O7" value="103.16" spread="26.742"/>
                    <measurement group_id="O8" value="99.13" spread="22.099"/>
                    <measurement group_id="O9" value="191.61" spread="22.845"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.92" spread="23.315"/>
                    <measurement group_id="O2" value="58.92" spread="23.638"/>
                    <measurement group_id="O3" value="48.26" spread="10.037"/>
                    <measurement group_id="O4" value="160.04" spread="19.838"/>
                    <measurement group_id="O5" value="130.59" spread="24.595"/>
                    <measurement group_id="O6" value="115.36" spread="37.861"/>
                    <measurement group_id="O7" value="88.71" spread="24.172"/>
                    <measurement group_id="O8" value="88.29" spread="28.964"/>
                    <measurement group_id="O9" value="192.09" spread="18.757"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="25"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.08" spread="26.644"/>
                    <measurement group_id="O2" value="71.79" spread="26.662"/>
                    <measurement group_id="O3" value="51.09" spread="14.820"/>
                    <measurement group_id="O4" value="159.16" spread="20.163"/>
                    <measurement group_id="O5" value="133.41" spread="30.589"/>
                    <measurement group_id="O6" value="115.52" spread="38.434"/>
                    <measurement group_id="O7" value="90.68" spread="25.610"/>
                    <measurement group_id="O8" value="82.46" spread="20.659"/>
                    <measurement group_id="O9" value="192.59" spread="23.425"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.20" spread="21.848"/>
                    <measurement group_id="O2" value="53.38" spread="22.329"/>
                    <measurement group_id="O3" value="44.96" spread="10.598"/>
                    <measurement group_id="O4" value="159.46" spread="25.221"/>
                    <measurement group_id="O5" value="129.32" spread="29.451"/>
                    <measurement group_id="O6" value="103.72" spread="37.651"/>
                    <measurement group_id="O7" value="81.83" spread="15.898"/>
                    <measurement group_id="O8" value="79.42" spread="26.345"/>
                    <measurement group_id="O9" value="184.74" spread="25.913"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="25"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.64" spread="23.937"/>
                    <measurement group_id="O2" value="66.63" spread="30.685"/>
                    <measurement group_id="O3" value="51.46" spread="14.926"/>
                    <measurement group_id="O4" value="157.31" spread="16.790"/>
                    <measurement group_id="O5" value="132.05" spread="29.005"/>
                    <measurement group_id="O6" value="112.60" spread="37.446"/>
                    <measurement group_id="O7" value="88.16" spread="23.005"/>
                    <measurement group_id="O8" value="82.08" spread="27.547"/>
                    <measurement group_id="O9" value="194.30" spread="22.876"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 50</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.92" spread="17.814"/>
                    <measurement group_id="O2" value="52.58" spread="21.847"/>
                    <measurement group_id="O3" value="45.65" spread="11.276"/>
                    <measurement group_id="O4" value="157.62" spread="22.608"/>
                    <measurement group_id="O5" value="130.64" spread="25.964"/>
                    <measurement group_id="O6" value="101.60" spread="36.427"/>
                    <measurement group_id="O7" value="80.30" spread="20.448"/>
                    <measurement group_id="O8" value="78.96" spread="27.207"/>
                    <measurement group_id="O9" value="186.70" spread="20.220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 57</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.76" spread="23.552"/>
                    <measurement group_id="O2" value="58.13" spread="23.709"/>
                    <measurement group_id="O3" value="44.26" spread="9.186"/>
                    <measurement group_id="O4" value="153.15" spread="19.601"/>
                    <measurement group_id="O5" value="126.68" spread="28.919"/>
                    <measurement group_id="O6" value="101.80" spread="35.249"/>
                    <measurement group_id="O7" value="86.08" spread="30.679"/>
                    <measurement group_id="O8" value="73.21" spread="24.568"/>
                    <measurement group_id="O9" value="180.17" spread="17.167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 71</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.83" spread="28.164"/>
                    <measurement group_id="O2" value="58.08" spread="26.357"/>
                    <measurement group_id="O3" value="48.65" spread="13.110"/>
                    <measurement group_id="O4" value="161.54" spread="22.089"/>
                    <measurement group_id="O5" value="134.91" spread="30.239"/>
                    <measurement group_id="O6" value="115.48" spread="36.001"/>
                    <measurement group_id="O7" value="82.25" spread="22.283"/>
                    <measurement group_id="O8" value="76.13" spread="22.793"/>
                    <measurement group_id="O9" value="185.96" spread="28.798"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.28" spread="25.268"/>
                    <measurement group_id="O2" value="60.04" spread="23.665"/>
                    <measurement group_id="O3" value="49.87" spread="24.464"/>
                    <measurement group_id="O4" value="154.92" spread="22.289"/>
                    <measurement group_id="O5" value="139.05" spread="36.247"/>
                    <measurement group_id="O6" value="110.40" spread="30.783"/>
                    <measurement group_id="O7" value="78.00" spread="27.144"/>
                    <measurement group_id="O8" value="72.17" spread="18.874"/>
                    <measurement group_id="O9" value="175.17" spread="24.398"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 99</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="22"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.56" spread="28.234"/>
                    <measurement group_id="O2" value="66.04" spread="29.895"/>
                    <measurement group_id="O3" value="60.05" spread="35.754"/>
                    <measurement group_id="O4" value="156.36" spread="18.830"/>
                    <measurement group_id="O5" value="133.68" spread="34.790"/>
                    <measurement group_id="O6" value="118.36" spread="32.875"/>
                    <measurement group_id="O7" value="85.29" spread="30.599"/>
                    <measurement group_id="O8" value="74.50" spread="19.496"/>
                    <measurement group_id="O9" value="190.52" spread="20.551"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 106</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="22"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.04" spread="24.315"/>
                    <measurement group_id="O2" value="51.50" spread="23.178"/>
                    <measurement group_id="O3" value="54.14" spread="28.648"/>
                    <measurement group_id="O4" value="154.08" spread="19.378"/>
                    <measurement group_id="O5" value="130.82" spread="29.301"/>
                    <measurement group_id="O6" value="107.76" spread="31.232"/>
                    <measurement group_id="O7" value="77.87" spread="23.470"/>
                    <measurement group_id="O8" value="74.75" spread="22.115"/>
                    <measurement group_id="O9" value="183.35" spread="19.664"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 113</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="23"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.50" spread="24.128"/>
                    <measurement group_id="O2" value="63.54" spread="25.086"/>
                    <measurement group_id="O3" value="55.78" spread="27.153"/>
                    <measurement group_id="O4" value="146.36" spread="23.787"/>
                    <measurement group_id="O5" value="131.41" spread="32.515"/>
                    <measurement group_id="O6" value="111.80" spread="30.993"/>
                    <measurement group_id="O7" value="83.00" spread="27.632"/>
                    <measurement group_id="O8" value="72.35" spread="20.232"/>
                    <measurement group_id="O9" value="180.65" spread="16.489"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 127</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="134.80" spread="24.100"/>
                    <measurement group_id="O2" value="117.42" spread="37.408"/>
                    <measurement group_id="O3" value="85.09" spread="41.318"/>
                    <measurement group_id="O4" value="158.60" spread="22.504"/>
                    <measurement group_id="O5" value="163.36" spread="33.835"/>
                    <measurement group_id="O6" value="164.60" spread="38.791"/>
                    <measurement group_id="O7" value="113.13" spread="46.332"/>
                    <measurement group_id="O8" value="102.75" spread="33.666"/>
                    <measurement group_id="O9" value="191.78" spread="28.623"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 141</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="149.17" spread="29.556"/>
                    <measurement group_id="O2" value="142.08" spread="32.188"/>
                    <measurement group_id="O3" value="119.83" spread="42.083"/>
                    <measurement group_id="O4" value="155.52" spread="20.490"/>
                    <measurement group_id="O5" value="170.41" spread="37.185"/>
                    <measurement group_id="O6" value="187.96" spread="41.528"/>
                    <measurement group_id="O7" value="154.17" spread="45.140"/>
                    <measurement group_id="O8" value="128.96" spread="44.304"/>
                    <measurement group_id="O9" value="191.09" spread="24.978"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 155</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="23"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="149.60" spread="26.876"/>
                    <measurement group_id="O2" value="144.83" spread="26.836"/>
                    <measurement group_id="O3" value="133.30" spread="30.526"/>
                    <measurement group_id="O4" value="161.80" spread="21.960"/>
                    <measurement group_id="O5" value="169.41" spread="37.377"/>
                    <measurement group_id="O6" value="190.96" spread="34.453"/>
                    <measurement group_id="O7" value="164.83" spread="34.193"/>
                    <measurement group_id="O8" value="144.58" spread="40.902"/>
                    <measurement group_id="O9" value="184.48" spread="18.030"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 169</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="24"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="23"/>
                    <count group_id="O9" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="155.48" spread="28.791"/>
                    <measurement group_id="O2" value="153.75" spread="25.535"/>
                    <measurement group_id="O3" value="148.52" spread="27.770"/>
                    <measurement group_id="O4" value="159.12" spread="20.961"/>
                    <measurement group_id="O5" value="174.45" spread="41.877"/>
                    <measurement group_id="O6" value="193.88" spread="33.789"/>
                    <measurement group_id="O7" value="183.52" spread="37.346"/>
                    <measurement group_id="O8" value="162.65" spread="40.341"/>
                    <measurement group_id="O9" value="193.59" spread="17.816"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Non-High Density Lipoprotein- Cholesterol (Non-HDL-C) at Day 85 and Day 113</title>
        <description>Non-HDL-C calculated as total cholesterol minus HDL cholesterol. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value. Change from baseline = observed value minus baseline value.</description>
        <time_frame>Baseline, Day 85, 113</time_frame>
        <population>FAS included all the participants who were randomized and administered at least 1 dose of study treatment. Here, ‘Number analyzed’ = Participants evaluable for this outcome measure at specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin + PF-04950615 50 mg</title>
            <description>Participants with fasting lipoprotein cholesterol (LDL-C) level (greater than or equal to [&gt;=]100 milligram per deciliter [mg/dL]) received atorvastatin along with PF-04950615 50 milligram (mg) subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin + PF-04950615 100 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 100 mg subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin + PF-04950615 150 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 150 mg subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O4">
            <title>Atorvastatin + PF-04950615 Placebo</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 placebo subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O5">
            <title>Atorvastatin + Ezetimibe 10 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with ezetimibe 10 mg tablet orally, once daily from Day 1 up to Day 112. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O6">
            <title>PF-04950615 50 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 50 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O7">
            <title>PF-04950615 100 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 100 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O8">
            <title>PF-04950615 150 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 150 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O9">
            <title>PF-04950615 Placebo</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 placebo, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naive to a treatment by lipid lowering drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Non-High Density Lipoprotein- Cholesterol (Non-HDL-C) at Day 85 and Day 113</title>
          <description>Non-HDL-C calculated as total cholesterol minus HDL cholesterol. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value. Change from baseline = observed value minus baseline value.</description>
          <population>FAS included all the participants who were randomized and administered at least 1 dose of study treatment. Here, ‘Number analyzed’ = Participants evaluable for this outcome measure at specified time points.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="26"/>
                <count group_id="O5" value="22"/>
                <count group_id="O6" value="25"/>
                <count group_id="O7" value="25"/>
                <count group_id="O8" value="24"/>
                <count group_id="O9" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Day 85</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-82.30" spread="30.323"/>
                    <measurement group_id="O2" value="-95.50" spread="32.345"/>
                    <measurement group_id="O3" value="-104.07" spread="27.573"/>
                    <measurement group_id="O4" value="-8.98" spread="20.888"/>
                    <measurement group_id="O5" value="-26.82" spread="28.796"/>
                    <measurement group_id="O6" value="-78.32" spread="33.436"/>
                    <measurement group_id="O7" value="-104.26" spread="34.056"/>
                    <measurement group_id="O8" value="-110.00" spread="24.274"/>
                    <measurement group_id="O9" value="-6.00" spread="24.009"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 113</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="23"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-77.33" spread="22.371"/>
                    <measurement group_id="O2" value="-92.00" spread="32.099"/>
                    <measurement group_id="O3" value="-98.15" spread="28.798"/>
                    <measurement group_id="O4" value="-18.40" spread="22.784"/>
                    <measurement group_id="O5" value="-34.45" spread="26.242"/>
                    <measurement group_id="O6" value="-76.92" spread="35.588"/>
                    <measurement group_id="O7" value="-99.26" spread="27.347"/>
                    <measurement group_id="O8" value="-111.33" spread="24.646"/>
                    <measurement group_id="O9" value="-0.52" spread="20.267"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-76.189</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.431</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-86.975</ci_lower_limit>
            <ci_upper_limit>-65.403</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-95.205</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.556</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-106.238</ci_lower_limit>
            <ci_upper_limit>-84.172</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-106.077</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.622</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-117.239</ci_lower_limit>
            <ci_upper_limit>-94.915</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-71.234</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.622</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-84.390</ci_lower_limit>
            <ci_upper_limit>-58.077</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-100.638</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.609</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-113.768</ci_lower_limit>
            <ci_upper_limit>-87.508</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-103.386</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.525</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-116.353</ci_lower_limit>
            <ci_upper_limit>-90.420</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-61.124</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.382</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-71.813</ci_lower_limit>
            <ci_upper_limit>-50.435</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-81.837</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.480</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-92.721</ci_lower_limit>
            <ci_upper_limit>-70.954</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-89.683</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.567</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-100.740</ci_lower_limit>
            <ci_upper_limit>-78.627</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-76.747</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.118</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-88.902</ci_lower_limit>
            <ci_upper_limit>-64.593</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-100.666</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.098</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-112.781</ci_lower_limit>
            <ci_upper_limit>-88.551</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 113:Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-109.490</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.054</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-121.519</ci_lower_limit>
            <ci_upper_limit>-97.462</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Non-High Density Lipoprotein- Cholesterol (Non-HDL-C) at Day 85 and Day 113</title>
        <description>Non-HDL-C calculated as total cholesterol minus HDL cholesterol. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value. Percent change from baseline = ([observed value divided by baseline value] minus 1) multiplied by 100.</description>
        <time_frame>Baseline, Day 85, 113</time_frame>
        <population>FAS included all the participants who were randomized and administered at least 1 dose of study treatment. Here, ‘Number analyzed’ = Participants evaluable for this outcome measure at specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin + PF-04950615 50 mg</title>
            <description>Participants with fasting lipoprotein cholesterol (LDL-C) level (greater than or equal to [&gt;=]100 milligram per deciliter [mg/dL]) received atorvastatin along with PF-04950615 50 milligram (mg) subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin + PF-04950615 100 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 100 mg subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin + PF-04950615 150 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 150 mg subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O4">
            <title>Atorvastatin + PF-04950615 Placebo</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 placebo subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O5">
            <title>Atorvastatin + Ezetimibe 10 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with ezetimibe 10 mg tablet orally, once daily from Day 1 up to Day 112. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O6">
            <title>PF-04950615 50 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 50 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O7">
            <title>PF-04950615 100 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 100 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O8">
            <title>PF-04950615 150 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 150 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O9">
            <title>PF-04950615 Placebo</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 placebo, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naive to a treatment by lipid lowering drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Non-High Density Lipoprotein- Cholesterol (Non-HDL-C) at Day 85 and Day 113</title>
          <description>Non-HDL-C calculated as total cholesterol minus HDL cholesterol. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value. Percent change from baseline = ([observed value divided by baseline value] minus 1) multiplied by 100.</description>
          <population>FAS included all the participants who were randomized and administered at least 1 dose of study treatment. Here, ‘Number analyzed’ = Participants evaluable for this outcome measure at specified time points.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="26"/>
                <count group_id="O5" value="22"/>
                <count group_id="O6" value="25"/>
                <count group_id="O7" value="25"/>
                <count group_id="O8" value="24"/>
                <count group_id="O9" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Day 85</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-50.98" spread="15.662"/>
                    <measurement group_id="O2" value="-60.62" spread="17.746"/>
                    <measurement group_id="O3" value="-67.69" spread="14.462"/>
                    <measurement group_id="O4" value="-4.77" spread="11.716"/>
                    <measurement group_id="O5" value="-16.20" spread="16.334"/>
                    <measurement group_id="O6" value="-41.11" spread="16.193"/>
                    <measurement group_id="O7" value="-56.87" spread="14.745"/>
                    <measurement group_id="O8" value="-60.17" spread="10.493"/>
                    <measurement group_id="O9" value="-2.49" spread="12.951"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 113</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="23"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-48.56" spread="12.284"/>
                    <measurement group_id="O2" value="-58.57" spread="17.970"/>
                    <measurement group_id="O3" value="-63.92" spread="15.872"/>
                    <measurement group_id="O4" value="-10.59" spread="11.977"/>
                    <measurement group_id="O5" value="-20.67" spread="15.155"/>
                    <measurement group_id="O6" value="-40.19" spread="17.244"/>
                    <measurement group_id="O7" value="-54.54" spread="13.671"/>
                    <measurement group_id="O8" value="-60.43" spread="11.070"/>
                    <measurement group_id="O9" value="0.88" spread="13.236"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-46.772</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.473</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-53.671</ci_lower_limit>
            <ci_upper_limit>-39.874</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-59.200</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.554</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-66.257</ci_lower_limit>
            <ci_upper_limit>-52.143</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-66.868</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.595</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-74.007</ci_lower_limit>
            <ci_upper_limit>-59.730</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-40.051</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.595</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-47.195</ci_lower_limit>
            <ci_upper_limit>-32.908</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-56.009</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.587</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-63.135</ci_lower_limit>
            <ci_upper_limit>-48.882</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-57.576</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.544</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-64.618</ci_lower_limit>
            <ci_upper_limit>-50.533</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-37.991</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.389</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-44.721</ci_lower_limit>
            <ci_upper_limit>-31.260</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-50.856</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.451</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-57.709</ci_lower_limit>
            <ci_upper_limit>-44.002</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-56.354</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.505</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-63.315</ci_lower_limit>
            <ci_upper_limit>-49.393</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-43.172</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.647</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-50.417</ci_lower_limit>
            <ci_upper_limit>-35.926</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-56.698</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.633</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-63.916</ci_lower_limit>
            <ci_upper_limit>-49.480</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 113:Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-61.305</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.609</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-68.477</ci_lower_limit>
            <ci_upper_limit>-54.134</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio</title>
        <description>Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value.</description>
        <time_frame>Baseline, Day 5, 8, 15, 22, 29, 36, 43, 50, 57, 71, 85, 99, 106, 113, 127, 141, 155, 169</time_frame>
        <population>FAS included all the participants who were randomized and administered at least 1 dose of study treatment. Here, ‘Number analyzed’ = Participants evaluable for this outcome measure at specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin + PF-04950615 50 mg</title>
            <description>Participants with fasting lipoprotein cholesterol (LDL-C) level (greater than or equal to [&gt;=]100 milligram per deciliter [mg/dL]) received atorvastatin along with PF-04950615 50 milligram (mg) subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin + PF-04950615 100 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 100 mg subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin + PF-04950615 150 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 150 mg subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O4">
            <title>Atorvastatin + PF-04950615 Placebo</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 placebo subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O5">
            <title>Atorvastatin + Ezetimibe 10 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with ezetimibe 10 mg tablet orally, once daily from Day 1 up to Day 112. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O6">
            <title>PF-04950615 50 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 50 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O7">
            <title>PF-04950615 100 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 100 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O8">
            <title>PF-04950615 150 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 150 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O9">
            <title>PF-04950615 Placebo</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 placebo, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naive to a treatment by lipid lowering drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio</title>
          <description>Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value.</description>
          <population>FAS included all the participants who were randomized and administered at least 1 dose of study treatment. Here, ‘Number analyzed’ = Participants evaluable for this outcome measure at specified time points.</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="26"/>
                <count group_id="O5" value="22"/>
                <count group_id="O6" value="25"/>
                <count group_id="O7" value="25"/>
                <count group_id="O8" value="24"/>
                <count group_id="O9" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="25"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0118" spread="0.82813"/>
                    <measurement group_id="O2" value="4.0154" spread="0.92478"/>
                    <measurement group_id="O3" value="3.8500" spread="0.72414"/>
                    <measurement group_id="O4" value="3.9629" spread="0.77435"/>
                    <measurement group_id="O5" value="4.0223" spread="0.81145"/>
                    <measurement group_id="O6" value="4.5408" spread="1.11809"/>
                    <measurement group_id="O7" value="4.2558" spread="1.15512"/>
                    <measurement group_id="O8" value="4.2610" spread="1.08481"/>
                    <measurement group_id="O9" value="4.1076" spread="0.88524"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="23"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="25"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1372" spread="0.81529"/>
                    <measurement group_id="O2" value="2.7861" spread="0.57451"/>
                    <measurement group_id="O3" value="2.7500" spread="0.38981"/>
                    <measurement group_id="O4" value="3.9465" spread="0.83527"/>
                    <measurement group_id="O5" value="3.5668" spread="0.77085"/>
                    <measurement group_id="O6" value="3.9264" spread="1.11497"/>
                    <measurement group_id="O7" value="3.5036" spread="0.76250"/>
                    <measurement group_id="O8" value="3.4029" spread="0.86267"/>
                    <measurement group_id="O9" value="4.3259" spread="0.99932"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="21"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="22"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7252" spread="0.63762"/>
                    <measurement group_id="O2" value="2.4100" spread="0.53023"/>
                    <measurement group_id="O3" value="2.3083" spread="0.33483"/>
                    <measurement group_id="O4" value="3.8588" spread="0.92894"/>
                    <measurement group_id="O5" value="3.3510" spread="0.79979"/>
                    <measurement group_id="O6" value="3.6024" spread="1.07004"/>
                    <measurement group_id="O7" value="3.1367" spread="0.80233"/>
                    <measurement group_id="O8" value="3.0941" spread="0.80907"/>
                    <measurement group_id="O9" value="4.3374" spread="0.88617"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="25"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6884" spread="0.58429"/>
                    <measurement group_id="O2" value="2.3754" spread="0.62550"/>
                    <measurement group_id="O3" value="1.9658" spread="0.33815"/>
                    <measurement group_id="O4" value="3.9308" spread="0.89274"/>
                    <measurement group_id="O5" value="3.2700" spread="0.68229"/>
                    <measurement group_id="O6" value="3.4940" spread="1.02033"/>
                    <measurement group_id="O7" value="2.7772" spread="0.71059"/>
                    <measurement group_id="O8" value="2.6050" spread="0.53948"/>
                    <measurement group_id="O9" value="4.3017" spread="0.84316"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2428" spread="0.53640"/>
                    <measurement group_id="O2" value="2.0258" spread="0.49301"/>
                    <measurement group_id="O3" value="1.7730" spread="0.18504"/>
                    <measurement group_id="O4" value="3.8915" spread="0.75155"/>
                    <measurement group_id="O5" value="3.2550" spread="0.66627"/>
                    <measurement group_id="O6" value="3.0676" spread="0.92151"/>
                    <measurement group_id="O7" value="2.4338" spread="0.43218"/>
                    <measurement group_id="O8" value="2.3617" spread="0.35946"/>
                    <measurement group_id="O9" value="4.2822" spread="0.97569"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="25"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4020" spread="0.54386"/>
                    <measurement group_id="O2" value="2.2533" spread="0.64125"/>
                    <measurement group_id="O3" value="1.8296" spread="0.26896"/>
                    <measurement group_id="O4" value="3.8852" spread="0.73498"/>
                    <measurement group_id="O5" value="3.3318" spread="0.70099"/>
                    <measurement group_id="O6" value="3.0260" spread="0.77510"/>
                    <measurement group_id="O7" value="2.5780" spread="0.75738"/>
                    <measurement group_id="O8" value="2.2800" spread="0.37240"/>
                    <measurement group_id="O9" value="4.1023" spread="0.81890"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1924" spread="0.45842"/>
                    <measurement group_id="O2" value="1.9300" spread="0.46830"/>
                    <measurement group_id="O3" value="1.7404" spread="0.18627"/>
                    <measurement group_id="O4" value="3.9496" spread="0.92977"/>
                    <measurement group_id="O5" value="3.2882" spread="0.68375"/>
                    <measurement group_id="O6" value="2.8452" spread="0.78785"/>
                    <measurement group_id="O7" value="2.3000" spread="0.31095"/>
                    <measurement group_id="O8" value="2.2529" spread="0.39114"/>
                    <measurement group_id="O9" value="4.2222" spread="0.97022"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="25"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3688" spread="0.48338"/>
                    <measurement group_id="O2" value="2.1396" spread="0.61972"/>
                    <measurement group_id="O3" value="1.8754" spread="0.39255"/>
                    <measurement group_id="O4" value="3.9338" spread="0.87409"/>
                    <measurement group_id="O5" value="3.3259" spread="0.70739"/>
                    <measurement group_id="O6" value="3.0044" spread="0.77172"/>
                    <measurement group_id="O7" value="2.5124" spread="0.80082"/>
                    <measurement group_id="O8" value="2.3004" spread="0.42044"/>
                    <measurement group_id="O9" value="4.4074" spread="1.03394"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 50</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0280" spread="0.36876"/>
                    <measurement group_id="O2" value="1.9254" spread="0.48864"/>
                    <measurement group_id="O3" value="1.7443" spread="0.15406"/>
                    <measurement group_id="O4" value="3.9419" spread="0.98670"/>
                    <measurement group_id="O5" value="3.3277" spread="0.71213"/>
                    <measurement group_id="O6" value="2.8300" spread="0.81738"/>
                    <measurement group_id="O7" value="2.2883" spread="0.38697"/>
                    <measurement group_id="O8" value="2.2658" spread="0.43915"/>
                    <measurement group_id="O9" value="4.2909" spread="0.97014"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 57</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3148" spread="0.44657"/>
                    <measurement group_id="O2" value="2.0758" spread="0.63508"/>
                    <measurement group_id="O3" value="1.7448" spread="0.12638"/>
                    <measurement group_id="O4" value="3.9596" spread="0.84943"/>
                    <measurement group_id="O5" value="3.2632" spread="0.60608"/>
                    <measurement group_id="O6" value="2.8436" spread="0.67094"/>
                    <measurement group_id="O7" value="2.5708" spread="1.24941"/>
                    <measurement group_id="O8" value="2.2225" spread="0.37721"/>
                    <measurement group_id="O9" value="4.3361" spread="0.97295"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 71</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3925" spread="0.57023"/>
                    <measurement group_id="O2" value="1.9988" spread="0.56686"/>
                    <measurement group_id="O3" value="1.7709" spread="0.19489"/>
                    <measurement group_id="O4" value="4.0085" spread="0.93120"/>
                    <measurement group_id="O5" value="3.3855" spread="0.64850"/>
                    <measurement group_id="O6" value="3.0528" spread="0.77095"/>
                    <measurement group_id="O7" value="2.3258" spread="0.34951"/>
                    <measurement group_id="O8" value="2.1988" spread="0.36789"/>
                    <measurement group_id="O9" value="4.3791" spread="1.15180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3724" spread="0.52972"/>
                    <measurement group_id="O2" value="2.0721" spread="0.54913"/>
                    <measurement group_id="O3" value="1.8561" spread="0.49386"/>
                    <measurement group_id="O4" value="4.0508" spread="0.91154"/>
                    <measurement group_id="O5" value="3.3986" spread="0.73940"/>
                    <measurement group_id="O6" value="3.1204" spread="0.72628"/>
                    <measurement group_id="O7" value="2.2796" spread="0.46691"/>
                    <measurement group_id="O8" value="2.2142" spread="0.37394"/>
                    <measurement group_id="O9" value="4.2613" spread="1.08945"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 99</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="22"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4564" spread="0.54658"/>
                    <measurement group_id="O2" value="2.1417" spread="0.70783"/>
                    <measurement group_id="O3" value="2.0305" spread="0.76914"/>
                    <measurement group_id="O4" value="3.7648" spread="0.83515"/>
                    <measurement group_id="O5" value="3.3073" spread="0.81497"/>
                    <measurement group_id="O6" value="3.0868" spread="0.75654"/>
                    <measurement group_id="O7" value="2.4075" spread="0.70042"/>
                    <measurement group_id="O8" value="2.2121" spread="0.37358"/>
                    <measurement group_id="O9" value="4.4200" spread="1.15874"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 106</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="22"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0476" spread="0.40004"/>
                    <measurement group_id="O2" value="1.8650" spread="0.50620"/>
                    <measurement group_id="O3" value="1.8814" spread="0.56847"/>
                    <measurement group_id="O4" value="3.7912" spread="0.78337"/>
                    <measurement group_id="O5" value="3.2832" spread="0.72097"/>
                    <measurement group_id="O6" value="2.9176" spread="0.75101"/>
                    <measurement group_id="O7" value="2.2517" spread="0.37291"/>
                    <measurement group_id="O8" value="2.1896" spread="0.37808"/>
                    <measurement group_id="O9" value="4.3157" spread="1.01377"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 113</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="23"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4688" spread="0.50001"/>
                    <measurement group_id="O2" value="2.1042" spread="0.55015"/>
                    <measurement group_id="O3" value="1.9691" spread="0.52016"/>
                    <measurement group_id="O4" value="3.8248" spread="0.91875"/>
                    <measurement group_id="O5" value="3.2359" spread="0.65683"/>
                    <measurement group_id="O6" value="3.0760" spread="0.78321"/>
                    <measurement group_id="O7" value="2.3639" spread="0.45213"/>
                    <measurement group_id="O8" value="2.2335" spread="0.42128"/>
                    <measurement group_id="O9" value="4.3570" spread="0.88681"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 127</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3776" spread="0.67839"/>
                    <measurement group_id="O2" value="3.1533" spread="0.98795"/>
                    <measurement group_id="O3" value="2.4822" spread="0.91213"/>
                    <measurement group_id="O4" value="3.7984" spread="0.90030"/>
                    <measurement group_id="O5" value="3.9132" spread="0.79683"/>
                    <measurement group_id="O6" value="3.9896" spread="0.99046"/>
                    <measurement group_id="O7" value="2.9087" spread="0.92317"/>
                    <measurement group_id="O8" value="2.8208" spread="1.08222"/>
                    <measurement group_id="O9" value="4.4717" spread="1.06069"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 141</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5433" spread="0.67339"/>
                    <measurement group_id="O2" value="3.5242" spread="0.96281"/>
                    <measurement group_id="O3" value="3.0078" spread="0.91134"/>
                    <measurement group_id="O4" value="3.7508" spread="0.88092"/>
                    <measurement group_id="O5" value="3.9841" spread="0.87530"/>
                    <measurement group_id="O6" value="4.4256" spread="1.20555"/>
                    <measurement group_id="O7" value="3.6070" spread="1.06034"/>
                    <measurement group_id="O8" value="3.3500" spread="1.37776"/>
                    <measurement group_id="O9" value="4.2843" spread="1.17378"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 155</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="23"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6240" spread="0.63587"/>
                    <measurement group_id="O2" value="3.6392" spread="0.92468"/>
                    <measurement group_id="O3" value="3.2748" spread="0.76307"/>
                    <measurement group_id="O4" value="3.9100" spread="0.92453"/>
                    <measurement group_id="O5" value="3.9205" spread="0.79163"/>
                    <measurement group_id="O6" value="4.5057" spread="1.18175"/>
                    <measurement group_id="O7" value="3.8126" spread="0.99748"/>
                    <measurement group_id="O8" value="3.6450" spread="1.45582"/>
                    <measurement group_id="O9" value="4.1804" spread="1.03516"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 169</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="24"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="23"/>
                    <count group_id="O9" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8140" spread="0.77275"/>
                    <measurement group_id="O2" value="3.7471" spread="0.82852"/>
                    <measurement group_id="O3" value="3.4830" spread="0.67010"/>
                    <measurement group_id="O4" value="3.7436" spread="0.86236"/>
                    <measurement group_id="O5" value="4.0036" spread="0.99761"/>
                    <measurement group_id="O6" value="4.4975" spread="1.25117"/>
                    <measurement group_id="O7" value="4.2000" spread="1.23292"/>
                    <measurement group_id="O8" value="3.8970" spread="1.40230"/>
                    <measurement group_id="O9" value="4.1182" spread="0.81436"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio at Day 85 and Day 113</title>
        <description>Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value. Change from baseline = observed value minus baseline value.</description>
        <time_frame>Baseline, Day 85, 113</time_frame>
        <population>FAS included all the participants who were randomized and administered at least 1 dose of study treatment. Here, ‘Number analyzed’ = Participants evaluable for this outcome measure at specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin + PF-04950615 50 mg</title>
            <description>Participants with fasting lipoprotein cholesterol (LDL-C) level (greater than or equal to [&gt;=]100 milligram per deciliter [mg/dL]) received atorvastatin along with PF-04950615 50 milligram (mg) subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin + PF-04950615 100 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 100 mg subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin + PF-04950615 150 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 150 mg subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O4">
            <title>Atorvastatin + PF-04950615 Placebo</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 placebo subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O5">
            <title>Atorvastatin + Ezetimibe 10 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with ezetimibe 10 mg tablet orally, once daily from Day 1 up to Day 112. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O6">
            <title>PF-04950615 50 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 50 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O7">
            <title>PF-04950615 100 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 100 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O8">
            <title>PF-04950615 150 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 150 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O9">
            <title>PF-04950615 Placebo</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 placebo, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naive to a treatment by lipid lowering drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio at Day 85 and Day 113</title>
          <description>Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value. Change from baseline = observed value minus baseline value.</description>
          <population>FAS included all the participants who were randomized and administered at least 1 dose of study treatment. Here, ‘Number analyzed’ = Participants evaluable for this outcome measure at specified time points.</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="26"/>
                <count group_id="O5" value="22"/>
                <count group_id="O6" value="25"/>
                <count group_id="O7" value="25"/>
                <count group_id="O8" value="24"/>
                <count group_id="O9" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Day 85</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.6394" spread="0.69058"/>
                    <measurement group_id="O2" value="-1.9433" spread="0.90358"/>
                    <measurement group_id="O3" value="-1.9835" spread="0.78766"/>
                    <measurement group_id="O4" value="0.0879" spread="0.43755"/>
                    <measurement group_id="O5" value="-0.6236" spread="0.66072"/>
                    <measurement group_id="O6" value="-1.4204" spread="0.91892"/>
                    <measurement group_id="O7" value="-1.8407" spread="0.85260"/>
                    <measurement group_id="O8" value="-2.0469" spread="0.96230"/>
                    <measurement group_id="O9" value="0.1537" spread="0.47755"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 113</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="23"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5671" spread="0.65875"/>
                    <measurement group_id="O2" value="-1.9113" spread="0.93385"/>
                    <measurement group_id="O3" value="-1.8704" spread="0.73630"/>
                    <measurement group_id="O4" value="-0.1560" spread="0.53286"/>
                    <measurement group_id="O5" value="-0.7864" spread="0.60966"/>
                    <measurement group_id="O6" value="-1.4648" spread="0.83864"/>
                    <measurement group_id="O7" value="-1.7563" spread="0.74752"/>
                    <measurement group_id="O8" value="-2.0461" spread="0.92038"/>
                    <measurement group_id="O9" value="0.2493" spread="0.43772"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-1.69928</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.13216</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.96175</ci_lower_limit>
            <ci_upper_limit>-1.43682</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-2.07922</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.13446</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.34622</ci_lower_limit>
            <ci_upper_limit>-1.81223</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-2.23886</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.13553</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.50795</ci_lower_limit>
            <ci_upper_limit>-1.96978</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-1.43281</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.16311</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.75689</ci_lower_limit>
            <ci_upper_limit>-1.10872</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-2.01501</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.16217</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.33718</ci_lower_limit>
            <ci_upper_limit>-1.69283</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-2.11359</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.16038</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.43230</ci_lower_limit>
            <ci_upper_limit>-1.79489</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-1.35298</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.13609</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.62324</ci_lower_limit>
            <ci_upper_limit>-1.08271</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-1.79615</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.13790</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.07001</ci_lower_limit>
            <ci_upper_limit>-1.52229</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-1.86921</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.13927</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.14575</ci_lower_limit>
            <ci_upper_limit>-1.59266</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-1.57311</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.14333</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.85788</ci_lower_limit>
            <ci_upper_limit>-1.28834</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-2.00256</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.14228</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.28521</ci_lower_limit>
            <ci_upper_limit>-1.71990</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 113:Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-2.20298</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.14142</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.48399</ci_lower_limit>
            <ci_upper_limit>-1.92197</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio at Day 85 and Day 113</title>
        <description>Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value. Percent change from baseline = ([observed value divided by baseline value] minus 1) multiplied by 100.</description>
        <time_frame>Baseline, Day 85, 113</time_frame>
        <population>FAS included all the participants who were randomized and administered at least 1 dose of study treatment. Here, ‘Number analyzed’ = Participants evaluable for this outcome measure at specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin + PF-04950615 50 mg</title>
            <description>Participants with fasting lipoprotein cholesterol (LDL-C) level (greater than or equal to [&gt;=]100 milligram per deciliter [mg/dL]) received atorvastatin along with PF-04950615 50 milligram (mg) subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin + PF-04950615 100 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 100 mg subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin + PF-04950615 150 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 150 mg subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O4">
            <title>Atorvastatin + PF-04950615 Placebo</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 placebo subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O5">
            <title>Atorvastatin + Ezetimibe 10 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with ezetimibe 10 mg tablet orally, once daily from Day 1 up to Day 112. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O6">
            <title>PF-04950615 50 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 50 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O7">
            <title>PF-04950615 100 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 100 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O8">
            <title>PF-04950615 150 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 150 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O9">
            <title>PF-04950615 Placebo</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 placebo, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naive to a treatment by lipid lowering drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio at Day 85 and Day 113</title>
          <description>Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value. Percent change from baseline = ([observed value divided by baseline value] minus 1) multiplied by 100.</description>
          <population>FAS included all the participants who were randomized and administered at least 1 dose of study treatment. Here, ‘Number analyzed’ = Participants evaluable for this outcome measure at specified time points.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="26"/>
                <count group_id="O5" value="22"/>
                <count group_id="O6" value="25"/>
                <count group_id="O7" value="25"/>
                <count group_id="O8" value="24"/>
                <count group_id="O9" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Day 85</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-39.99" spread="12.892"/>
                    <measurement group_id="O2" value="-47.06" spread="15.152"/>
                    <measurement group_id="O3" value="-50.43" spread="13.358"/>
                    <measurement group_id="O4" value="2.19" spread="10.328"/>
                    <measurement group_id="O5" value="-14.65" spread="14.740"/>
                    <measurement group_id="O6" value="-29.51" spread="16.200"/>
                    <measurement group_id="O7" value="-43.25" spread="12.569"/>
                    <measurement group_id="O8" value="-45.74" spread="11.961"/>
                    <measurement group_id="O9" value="3.81" spread="10.643"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 113</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="23"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-38.20" spread="10.463"/>
                    <measurement group_id="O2" value="-46.04" spread="15.705"/>
                    <measurement group_id="O3" value="-47.68" spread="13.195"/>
                    <measurement group_id="O4" value="-3.81" spread="12.537"/>
                    <measurement group_id="O5" value="-18.57" spread="13.541"/>
                    <measurement group_id="O6" value="-31.07" spread="14.770"/>
                    <measurement group_id="O7" value="-41.49" spread="10.520"/>
                    <measurement group_id="O8" value="-45.65" spread="12.114"/>
                    <measurement group_id="O9" value="6.98" spread="12.436"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-41.92915</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.83037</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-47.55052</ci_lower_limit>
            <ci_upper_limit>-36.30778</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-51.08604</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.88356</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-56.81235</ci_lower_limit>
            <ci_upper_limit>-45.35973</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-55.51600</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.91014</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-61.29424</ci_lower_limit>
            <ci_upper_limit>-49.73777</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-33.30375</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.07498</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-39.41376</ci_lower_limit>
            <ci_upper_limit>-27.19373</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-47.85210</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.05746</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-53.92668</ci_lower_limit>
            <ci_upper_limit>-41.77751</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-48.65686</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.02097</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-54.66060</ci_lower_limit>
            <ci_upper_limit>-42.65313</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-33.52920</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.96599</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-39.42015</ci_lower_limit>
            <ci_upper_limit>-27.63826</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-43.85680</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.00531</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-49.82617</ci_lower_limit>
            <ci_upper_limit>-37.88744</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-46.36865</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.03981</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-52.40589</ci_lower_limit>
            <ci_upper_limit>-40.33142</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-38.06019</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.13610</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-44.29176</ci_lower_limit>
            <ci_upper_limit>-31.82863</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-48.57807</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.11350</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-54.76397</ci_lower_limit>
            <ci_upper_limit>-42.39217</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 113:Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-51.87214</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.09363</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-58.01968</ci_lower_limit>
            <ci_upper_limit>-45.72460</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio</title>
        <description>Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value.</description>
        <time_frame>Baseline, Day 5, 8, 15, 22, 29, 36, 43, 50, 57, 71, 85, 99, 106, 113, 127, 141, 155, 169</time_frame>
        <population>FAS included all the participants who were randomized and administered at least 1 dose of study treatment. Here, ‘Number analyzed’ = Participants evaluable for this outcome measure at specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin + PF-04950615 50 mg</title>
            <description>Participants with fasting lipoprotein cholesterol (LDL-C) level (greater than or equal to [&gt;=]100 milligram per deciliter [mg/dL]) received atorvastatin along with PF-04950615 50 milligram (mg) subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin + PF-04950615 100 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 100 mg subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin + PF-04950615 150 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 150 mg subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O4">
            <title>Atorvastatin + PF-04950615 Placebo</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 placebo subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O5">
            <title>Atorvastatin + Ezetimibe 10 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with ezetimibe 10 mg tablet orally, once daily from Day 1 up to Day 112. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O6">
            <title>PF-04950615 50 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 50 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O7">
            <title>PF-04950615 100 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 100 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O8">
            <title>PF-04950615 150 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 150 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O9">
            <title>PF-04950615 Placebo</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 placebo, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naive to a treatment by lipid lowering drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio</title>
          <description>Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value.</description>
          <population>FAS included all the participants who were randomized and administered at least 1 dose of study treatment. Here, ‘Number analyzed’ = Participants evaluable for this outcome measure at specified time points.</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="26"/>
                <count group_id="O5" value="22"/>
                <count group_id="O6" value="25"/>
                <count group_id="O7" value="25"/>
                <count group_id="O8" value="24"/>
                <count group_id="O9" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="25"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6846" spread="0.14145"/>
                    <measurement group_id="O2" value="0.6606" spread="0.13665"/>
                    <measurement group_id="O3" value="0.6567" spread="0.12772"/>
                    <measurement group_id="O4" value="0.6687" spread="0.12269"/>
                    <measurement group_id="O5" value="0.6775" spread="0.14076"/>
                    <measurement group_id="O6" value="0.7890" spread="0.17841"/>
                    <measurement group_id="O7" value="0.7324" spread="0.16556"/>
                    <measurement group_id="O8" value="0.7167" spread="0.16058"/>
                    <measurement group_id="O9" value="0.6980" spread="0.13867"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="23"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="25"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4896" spread="0.14794"/>
                    <measurement group_id="O2" value="0.4135" spread="0.11264"/>
                    <measurement group_id="O3" value="0.4222" spread="0.07116"/>
                    <measurement group_id="O4" value="0.6612" spread="0.12682"/>
                    <measurement group_id="O5" value="0.5968" spread="0.14211"/>
                    <measurement group_id="O6" value="0.6428" spread="0.18885"/>
                    <measurement group_id="O7" value="0.5792" spread="0.11372"/>
                    <measurement group_id="O8" value="0.5300" spread="0.11967"/>
                    <measurement group_id="O9" value="0.7100" spread="0.12642"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="21"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="22"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4044" spread="0.09862"/>
                    <measurement group_id="O2" value="0.3363" spread="0.11305"/>
                    <measurement group_id="O3" value="0.3271" spread="0.06760"/>
                    <measurement group_id="O4" value="0.6660" spread="0.14947"/>
                    <measurement group_id="O5" value="0.5657" spread="0.14552"/>
                    <measurement group_id="O6" value="0.5844" spread="0.18410"/>
                    <measurement group_id="O7" value="0.5017" spread="0.12310"/>
                    <measurement group_id="O8" value="0.4718" spread="0.13900"/>
                    <measurement group_id="O9" value="0.7230" spread="0.11227"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="25"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4308" spread="0.12426"/>
                    <measurement group_id="O2" value="0.3300" spread="0.12322"/>
                    <measurement group_id="O3" value="0.2450" spread="0.05649"/>
                    <measurement group_id="O4" value="0.6712" spread="0.13137"/>
                    <measurement group_id="O5" value="0.5445" spread="0.11164"/>
                    <measurement group_id="O6" value="0.5776" spread="0.16885"/>
                    <measurement group_id="O7" value="0.4216" spread="0.11929"/>
                    <measurement group_id="O8" value="0.3763" spread="0.08293"/>
                    <measurement group_id="O9" value="0.7226" spread="0.13404"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3136" spread="0.10610"/>
                    <measurement group_id="O2" value="0.2463" spread="0.09668"/>
                    <measurement group_id="O3" value="0.2078" spread="0.04572"/>
                    <measurement group_id="O4" value="0.6773" spread="0.13012"/>
                    <measurement group_id="O5" value="0.5564" spread="0.13347"/>
                    <measurement group_id="O6" value="0.4868" spread="0.17148"/>
                    <measurement group_id="O7" value="0.3629" spread="0.10897"/>
                    <measurement group_id="O8" value="0.3283" spread="0.09220"/>
                    <measurement group_id="O9" value="0.7248" spread="0.12409"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="25"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3656" spread="0.12076"/>
                    <measurement group_id="O2" value="0.3058" spread="0.12721"/>
                    <measurement group_id="O3" value="0.2196" spread="0.05943"/>
                    <measurement group_id="O4" value="0.6776" spread="0.12337"/>
                    <measurement group_id="O5" value="0.5609" spread="0.11924"/>
                    <measurement group_id="O6" value="0.4820" spread="0.14437"/>
                    <measurement group_id="O7" value="0.3720" spread="0.11247"/>
                    <measurement group_id="O8" value="0.3254" spread="0.07524"/>
                    <measurement group_id="O9" value="0.7023" spread="0.11439"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2900" spread="0.09278"/>
                    <measurement group_id="O2" value="0.2421" spread="0.10206"/>
                    <measurement group_id="O3" value="0.1983" spread="0.04376"/>
                    <measurement group_id="O4" value="0.6873" spread="0.15278"/>
                    <measurement group_id="O5" value="0.5600" spread="0.13551"/>
                    <measurement group_id="O6" value="0.4428" spread="0.15255"/>
                    <measurement group_id="O7" value="0.3250" spread="0.06093"/>
                    <measurement group_id="O8" value="0.3050" spread="0.08900"/>
                    <measurement group_id="O9" value="0.7048" spread="0.13413"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="25"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3592" spread="0.10723"/>
                    <measurement group_id="O2" value="0.2800" spread="0.12399"/>
                    <measurement group_id="O3" value="0.2142" spread="0.05012"/>
                    <measurement group_id="O4" value="0.6788" spread="0.12944"/>
                    <measurement group_id="O5" value="0.5805" spread="0.11978"/>
                    <measurement group_id="O6" value="0.4696" spread="0.15115"/>
                    <measurement group_id="O7" value="0.3632" spread="0.14522"/>
                    <measurement group_id="O8" value="0.3188" spread="0.09124"/>
                    <measurement group_id="O9" value="0.7548" spread="0.16351"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 50</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2668" spread="0.07669"/>
                    <measurement group_id="O2" value="0.2313" spread="0.10182"/>
                    <measurement group_id="O3" value="0.2048" spread="0.04088"/>
                    <measurement group_id="O4" value="0.6804" spread="0.13489"/>
                    <measurement group_id="O5" value="0.5959" spread="0.13893"/>
                    <measurement group_id="O6" value="0.4472" spread="0.16198"/>
                    <measurement group_id="O7" value="0.3283" spread="0.08917"/>
                    <measurement group_id="O8" value="0.3133" spread="0.09234"/>
                    <measurement group_id="O9" value="0.7465" spread="0.13878"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 57</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3584" spread="0.09715"/>
                    <measurement group_id="O2" value="0.2642" spread="0.13319"/>
                    <measurement group_id="O3" value="0.2026" spread="0.04081"/>
                    <measurement group_id="O4" value="0.6938" spread="0.12747"/>
                    <measurement group_id="O5" value="0.5682" spread="0.13297"/>
                    <measurement group_id="O6" value="0.4616" spread="0.15220"/>
                    <measurement group_id="O7" value="0.3804" spread="0.18286"/>
                    <measurement group_id="O8" value="0.3196" spread="0.07765"/>
                    <measurement group_id="O9" value="0.7630" spread="0.13394"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 71</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3692" spread="0.12402"/>
                    <measurement group_id="O2" value="0.2592" spread="0.11602"/>
                    <measurement group_id="O3" value="0.2157" spread="0.05281"/>
                    <measurement group_id="O4" value="0.6958" spread="0.13840"/>
                    <measurement group_id="O5" value="0.5986" spread="0.12434"/>
                    <measurement group_id="O6" value="0.4976" spread="0.15592"/>
                    <measurement group_id="O7" value="0.3358" spread="0.07678"/>
                    <measurement group_id="O8" value="0.3146" spread="0.08086"/>
                    <measurement group_id="O9" value="0.7500" spread="0.17328"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3768" spread="0.11546"/>
                    <measurement group_id="O2" value="0.2696" spread="0.11705"/>
                    <measurement group_id="O3" value="0.2335" spread="0.10170"/>
                    <measurement group_id="O4" value="0.7023" spread="0.13946"/>
                    <measurement group_id="O5" value="0.6132" spread="0.16069"/>
                    <measurement group_id="O6" value="0.5264" spread="0.14405"/>
                    <measurement group_id="O7" value="0.3435" spread="0.11007"/>
                    <measurement group_id="O8" value="0.3125" spread="0.08125"/>
                    <measurement group_id="O9" value="0.7665" spread="0.18376"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 99</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="22"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3928" spread="0.12458"/>
                    <measurement group_id="O2" value="0.2904" spread="0.12791"/>
                    <measurement group_id="O3" value="0.2491" spread="0.12432"/>
                    <measurement group_id="O4" value="0.6584" spread="0.13120"/>
                    <measurement group_id="O5" value="0.5882" spread="0.15930"/>
                    <measurement group_id="O6" value="0.5164" spread="0.15168"/>
                    <measurement group_id="O7" value="0.3650" spread="0.15223"/>
                    <measurement group_id="O8" value="0.3075" spread="0.07170"/>
                    <measurement group_id="O9" value="0.7883" spread="0.18622"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 106</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="22"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2908" spread="0.08450"/>
                    <measurement group_id="O2" value="0.2267" spread="0.10925"/>
                    <measurement group_id="O3" value="0.2405" spread="0.12187"/>
                    <measurement group_id="O4" value="0.6716" spread="0.12925"/>
                    <measurement group_id="O5" value="0.5877" spread="0.15253"/>
                    <measurement group_id="O6" value="0.4796" spread="0.14386"/>
                    <measurement group_id="O7" value="0.3322" spread="0.09130"/>
                    <measurement group_id="O8" value="0.3142" spread="0.08230"/>
                    <measurement group_id="O9" value="0.7730" spread="0.14455"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 113</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="23"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3888" spread="0.10343"/>
                    <measurement group_id="O2" value="0.2908" spread="0.11858"/>
                    <measurement group_id="O3" value="0.2548" spread="0.10845"/>
                    <measurement group_id="O4" value="0.6556" spread="0.14192"/>
                    <measurement group_id="O5" value="0.5777" spread="0.12976"/>
                    <measurement group_id="O6" value="0.5140" spread="0.15398"/>
                    <measurement group_id="O7" value="0.3557" spread="0.10710"/>
                    <measurement group_id="O8" value="0.3235" spread="0.08804"/>
                    <measurement group_id="O9" value="0.7683" spread="0.14272"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 127</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5772" spread="0.11473"/>
                    <measurement group_id="O2" value="0.5029" spread="0.17571"/>
                    <measurement group_id="O3" value="0.3778" spread="0.19064"/>
                    <measurement group_id="O4" value="0.6692" spread="0.13546"/>
                    <measurement group_id="O5" value="0.6950" spread="0.15732"/>
                    <measurement group_id="O6" value="0.7024" spread="0.18033"/>
                    <measurement group_id="O7" value="0.4730" spread="0.18425"/>
                    <measurement group_id="O8" value="0.4325" spread="0.16469"/>
                    <measurement group_id="O9" value="0.7830" spread="0.15893"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 141</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6233" spread="0.12107"/>
                    <measurement group_id="O2" value="0.5938" spread="0.15786"/>
                    <measurement group_id="O3" value="0.5004" spread="0.19354"/>
                    <measurement group_id="O4" value="0.6580" spread="0.13916"/>
                    <measurement group_id="O5" value="0.7082" spread="0.17595"/>
                    <measurement group_id="O6" value="0.7916" spread="0.20262"/>
                    <measurement group_id="O7" value="0.6352" spread="0.20727"/>
                    <measurement group_id="O8" value="0.5375" spread="0.23022"/>
                    <measurement group_id="O9" value="0.7570" spread="0.17219"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 155</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="23"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6368" spread="0.11957"/>
                    <measurement group_id="O2" value="0.6125" spread="0.15224"/>
                    <measurement group_id="O3" value="0.5574" spread="0.13288"/>
                    <measurement group_id="O4" value="0.6664" spread="0.13225"/>
                    <measurement group_id="O5" value="0.6991" spread="0.17124"/>
                    <measurement group_id="O6" value="0.8148" spread="0.20102"/>
                    <measurement group_id="O7" value="0.6839" spread="0.19315"/>
                    <measurement group_id="O8" value="0.6075" spread="0.24120"/>
                    <measurement group_id="O9" value="0.7452" spread="0.16318"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 169</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="24"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="23"/>
                    <count group_id="O9" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6640" spread="0.14350"/>
                    <measurement group_id="O2" value="0.6321" spread="0.14774"/>
                    <measurement group_id="O3" value="0.6161" spread="0.12493"/>
                    <measurement group_id="O4" value="0.6424" spread="0.14621"/>
                    <measurement group_id="O5" value="0.6845" spread="0.17986"/>
                    <measurement group_id="O6" value="0.8088" spread="0.20105"/>
                    <measurement group_id="O7" value="0.7178" spread="0.18178"/>
                    <measurement group_id="O8" value="0.6639" spread="0.22661"/>
                    <measurement group_id="O9" value="0.7359" spread="0.13397"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio at Day 85 and Day 113</title>
        <description>Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value. Change from baseline = observed value minus baseline value.</description>
        <time_frame>Baseline, Day 85, 113</time_frame>
        <population>FAS included all the participants who were randomized and administered at least 1 dose of study treatment. Here, ‘Number analyzed’ = Participants evaluable for this outcome measure at specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin + PF-04950615 50 mg</title>
            <description>Participants with fasting lipoprotein cholesterol (LDL-C) level (greater than or equal to [&gt;=]100 milligram per deciliter [mg/dL]) received atorvastatin along with PF-04950615 50 milligram (mg) subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin + PF-04950615 100 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 100 mg subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin + PF-04950615 150 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 150 mg subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O4">
            <title>Atorvastatin + PF-04950615 Placebo</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 placebo subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O5">
            <title>Atorvastatin + Ezetimibe 10 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with ezetimibe 10 mg tablet orally, once daily from Day 1 up to Day 112. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O6">
            <title>PF-04950615 50 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 50 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O7">
            <title>PF-04950615 100 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 100 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O8">
            <title>PF-04950615 150 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 150 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O9">
            <title>PF-04950615 Placebo</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 placebo, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naive to a treatment by lipid lowering drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio at Day 85 and Day 113</title>
          <description>Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value. Change from baseline = observed value minus baseline value.</description>
          <population>FAS included all the participants who were randomized and administered at least 1 dose of study treatment. Here, ‘Number analyzed’ = Participants evaluable for this outcome measure at specified time points.</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="26"/>
                <count group_id="O5" value="22"/>
                <count group_id="O6" value="25"/>
                <count group_id="O7" value="25"/>
                <count group_id="O8" value="24"/>
                <count group_id="O9" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Day 85</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3078" spread="0.13144"/>
                    <measurement group_id="O2" value="-0.3910" spread="0.15635"/>
                    <measurement group_id="O3" value="-0.4211" spread="0.16147"/>
                    <measurement group_id="O4" value="0.0337" spread="0.09054"/>
                    <measurement group_id="O5" value="-0.0643" spread="0.11318"/>
                    <measurement group_id="O6" value="-0.2626" spread="0.16341"/>
                    <measurement group_id="O7" value="-0.3748" spread="0.17224"/>
                    <measurement group_id="O8" value="-0.4042" spread="0.14894"/>
                    <measurement group_id="O9" value="0.0685" spread="0.10818"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 113</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="23"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2998" spread="0.12105"/>
                    <measurement group_id="O2" value="-0.3698" spread="0.16194"/>
                    <measurement group_id="O3" value="-0.3998" spread="0.15163"/>
                    <measurement group_id="O4" value="-0.0170" spread="0.10303"/>
                    <measurement group_id="O5" value="-0.0998" spread="0.09487"/>
                    <measurement group_id="O6" value="-0.2750" spread="0.15604"/>
                    <measurement group_id="O7" value="-0.3626" spread="0.14553"/>
                    <measurement group_id="O8" value="-0.3965" spread="0.15431"/>
                    <measurement group_id="O9" value="0.0702" spread="0.09306"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-0.33157</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.02639</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.38399</ci_lower_limit>
            <ci_upper_limit>-0.27916</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-0.44402</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.02682</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.49727</ci_lower_limit>
            <ci_upper_limit>-0.39077</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-0.48314</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.02698</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.53671</ci_lower_limit>
            <ci_upper_limit>-0.42956</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-0.30542</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.03230</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.36960</ci_lower_limit>
            <ci_upper_limit>-0.24124</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-0.44143</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.03183</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.50466</ci_lower_limit>
            <ci_upper_limit>-0.37821</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-0.46235</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.03148</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.52491</ci_lower_limit>
            <ci_upper_limit>-0.39980</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-0.26949</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.02615</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.32142</ci_lower_limit>
            <ci_upper_limit>-0.21755</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-0.37493</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.02649</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.42754</ci_lower_limit>
            <ci_upper_limit>-0.32231</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-0.41199</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.02676</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.46512</ci_lower_limit>
            <ci_upper_limit>-0.35886</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-0.31806</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.02979</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.37723</ci_lower_limit>
            <ci_upper_limit>-0.25888</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-0.42583</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.02932</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.48409</ci_lower_limit>
            <ci_upper_limit>-0.36758</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-0.45501</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.02912</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.51287</ci_lower_limit>
            <ci_upper_limit>-0.39715</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio at Day 85 and Day 113</title>
        <description>Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value. Percent change from baseline = ([observed value divided by baseline value] minus 1) multiplied by 100.</description>
        <time_frame>Baseline, Day 85, 113</time_frame>
        <population>FAS included all the participants who were randomized and administered at least 1 dose of study treatment. Here, ‘Number analyzed’ = Participants evaluable for this outcome measure at specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin + PF-04950615 50 mg</title>
            <description>Participants with fasting lipoprotein cholesterol (LDL-C) level (greater than or equal to [&gt;=]100 milligram per deciliter [mg/dL]) received atorvastatin along with PF-04950615 50 milligram (mg) subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin + PF-04950615 100 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 100 mg subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin + PF-04950615 150 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 150 mg subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O4">
            <title>Atorvastatin + PF-04950615 Placebo</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 placebo subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O5">
            <title>Atorvastatin + Ezetimibe 10 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with ezetimibe 10 mg tablet orally, once daily from Day 1 up to Day 112. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O6">
            <title>PF-04950615 50 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 50 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O7">
            <title>PF-04950615 100 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 100 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O8">
            <title>PF-04950615 150 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 150 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O9">
            <title>PF-04950615 Placebo</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 placebo, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naive to a treatment by lipid lowering drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio at Day 85 and Day 113</title>
          <description>Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value. Percent change from baseline = ([observed value divided by baseline value] minus 1) multiplied by 100.</description>
          <population>FAS included all the participants who were randomized and administered at least 1 dose of study treatment. Here, ‘Number analyzed’ = Participants evaluable for this outcome measure at specified time points.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="26"/>
                <count group_id="O5" value="22"/>
                <count group_id="O6" value="25"/>
                <count group_id="O7" value="25"/>
                <count group_id="O8" value="24"/>
                <count group_id="O9" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Day 85</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-44.37" spread="16.358"/>
                    <measurement group_id="O2" value="-58.47" spread="19.271"/>
                    <measurement group_id="O3" value="-63.09" spread="16.240"/>
                    <measurement group_id="O4" value="5.51" spread="12.823"/>
                    <measurement group_id="O5" value="-9.13" spread="16.695"/>
                    <measurement group_id="O6" value="-32.09" spread="18.463"/>
                    <measurement group_id="O7" value="-50.97" spread="16.380"/>
                    <measurement group_id="O8" value="-55.16" spread="11.927"/>
                    <measurement group_id="O9" value="10.41" spread="15.319"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 113</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="23"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-43.21" spread="13.147"/>
                    <measurement group_id="O2" value="-55.05" spread="19.756"/>
                    <measurement group_id="O3" value="-60.32" spread="15.924"/>
                    <measurement group_id="O4" value="-2.03" spread="14.326"/>
                    <measurement group_id="O5" value="-14.00" spread="14.205"/>
                    <measurement group_id="O6" value="-34.11" spread="18.505"/>
                    <measurement group_id="O7" value="-49.84" spread="13.744"/>
                    <measurement group_id="O8" value="-53.65" spread="13.386"/>
                    <measurement group_id="O9" value="11.47" spread="16.250"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-49.42411</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.72907</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-56.83019</ci_lower_limit>
            <ci_upper_limit>-42.01803</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-66.63383</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.79050</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-74.16086</ci_lower_limit>
            <ci_upper_limit>-59.10681</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-71.72901</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.81541</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-79.30431</ci_lower_limit>
            <ci_upper_limit>-64.15371</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-43.56596</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.92236</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-51.35899</ci_lower_limit>
            <ci_upper_limit>-35.77293</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-62.34926</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.86432</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-70.02607</ci_lower_limit>
            <ci_upper_limit>-54.67245</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-65.06617</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.82052</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-72.65818</ci_lower_limit>
            <ci_upper_limit>-57.47415</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-40.52435</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.66973</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-47.81299</ci_lower_limit>
            <ci_upper_limit>-33.23571</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-56.14495</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.71641</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-63.52668</ci_lower_limit>
            <ci_upper_limit>-48.76322</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-61.56370</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.75690</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-69.02510</ci_lower_limit>
            <ci_upper_limit>-54.10230</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-46.34109</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.16385</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-54.61427</ci_lower_limit>
            <ci_upper_limit>-38.06792</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-61.37890</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.09957</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-69.52338</ci_lower_limit>
            <ci_upper_limit>-53.23443</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>One-sided p-values (unadjusted for multiplicity) was derived from the MMRM model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-64.67274</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.06866</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-72.75728</ci_lower_limit>
            <ci_upper_limit>-56.58820</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving Low-density Lipoprotein Cholesterol (LDL-C) Less Than (&lt;) 10, 25, 40, 70 and 100 Milligram Per Deciliter</title>
        <description>LDL-C is cholesterol in the bloodstream that is carried by low density lipoprotein. Fasting was required at least 10 hours before blood sample collection.</description>
        <time_frame>Baseline up to Day 113</time_frame>
        <population>FAS included all the participants who were randomized and administered at least 1 dose of study treatment. The outcome measure was planned to be analyzed for all the reporting groups except Atorvastatin + Ezetimibe 10 mg.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin + PF-04950615 50 mg</title>
            <description>Participants with fasting lipoprotein cholesterol (LDL-C) level (greater than or equal to [&gt;=]100 milligram per deciliter [mg/dL]) received atorvastatin along with PF-04950615 50 milligram (mg) subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin + PF-04950615 100 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 100 mg subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin + PF-04950615 150 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 150 mg subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O4">
            <title>Atorvastatin + PF-04950615 Placebo</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 placebo subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O5">
            <title>PF-04950615 50 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 50 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O6">
            <title>PF-04950615 100 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 100 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O7">
            <title>PF-04950615 150 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 150 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O8">
            <title>PF-04950615 Placebo</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 placebo, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naive to a treatment by lipid lowering drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Low-density Lipoprotein Cholesterol (LDL-C) Less Than (&lt;) 10, 25, 40, 70 and 100 Milligram Per Deciliter</title>
          <description>LDL-C is cholesterol in the bloodstream that is carried by low density lipoprotein. Fasting was required at least 10 hours before blood sample collection.</description>
          <population>FAS included all the participants who were randomized and administered at least 1 dose of study treatment. The outcome measure was planned to be analyzed for all the reporting groups except Atorvastatin + Ezetimibe 10 mg.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="26"/>
                <count group_id="O5" value="25"/>
                <count group_id="O6" value="25"/>
                <count group_id="O7" value="24"/>
                <count group_id="O8" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>LDL-C &lt;10 mg/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="4.2"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="0.0"/>
                    <measurement group_id="O6" value="0.0"/>
                    <measurement group_id="O7" value="0.0"/>
                    <measurement group_id="O8" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL-C &lt;25 mg/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.0"/>
                    <measurement group_id="O2" value="66.7"/>
                    <measurement group_id="O3" value="58.3"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="0.0"/>
                    <measurement group_id="O6" value="0.0"/>
                    <measurement group_id="O7" value="20.8"/>
                    <measurement group_id="O8" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL-C &lt;40 mg/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.0"/>
                    <measurement group_id="O2" value="91.7"/>
                    <measurement group_id="O3" value="95.8"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="12.0"/>
                    <measurement group_id="O6" value="36.0"/>
                    <measurement group_id="O7" value="41.7"/>
                    <measurement group_id="O8" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL-C &lt;70 mg/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.0"/>
                    <measurement group_id="O2" value="100.0"/>
                    <measurement group_id="O3" value="100.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="64.0"/>
                    <measurement group_id="O6" value="92.0"/>
                    <measurement group_id="O7" value="87.5"/>
                    <measurement group_id="O8" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL-C &lt;100 mg/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                    <measurement group_id="O3" value="100.0"/>
                    <measurement group_id="O4" value="23.1"/>
                    <measurement group_id="O5" value="92.0"/>
                    <measurement group_id="O6" value="100.0"/>
                    <measurement group_id="O7" value="100.0"/>
                    <measurement group_id="O8" value="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment-Emergent Adverse Events (TEAEs) or Serious Adverse Events (SAEs)</title>
        <description>An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. TEAEs are events between first dose of study drug and up to Day 169 that were absent before treatment or that worsened relative to pretreatment state. Adverse events included treatment emergent injection site adverse events and any clinically significant abnormal laboratory value.</description>
        <time_frame>Baseline up to Day 169</time_frame>
        <population>Safety analysis set included all randomized and non-randomized participants who were administered at least 1 dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin + PF-04950615 50 mg</title>
            <description>Participants with fasting lipoprotein cholesterol (LDL-C) level (greater than or equal to [&gt;=]100 milligram per deciliter [mg/dL]) received atorvastatin along with PF-04950615 50 milligram (mg) subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin + PF-04950615 100 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 100 mg subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin + PF-04950615 150 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 150 mg subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O4">
            <title>Atorvastatin + PF-04950615 Placebo</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 placebo subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O5">
            <title>Atorvastatin + Ezetimibe 10 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with ezetimibe 10 mg tablet orally, once daily from Day 1 up to Day 112. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O6">
            <title>PF-04950615 50 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 50 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O7">
            <title>PF-04950615 100 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 100 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O8">
            <title>PF-04950615 150 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 150 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O9">
            <title>PF-04950615 Placebo</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 placebo, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naive to a treatment by lipid lowering drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-Emergent Adverse Events (TEAEs) or Serious Adverse Events (SAEs)</title>
          <description>An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. TEAEs are events between first dose of study drug and up to Day 169 that were absent before treatment or that worsened relative to pretreatment state. Adverse events included treatment emergent injection site adverse events and any clinically significant abnormal laboratory value.</description>
          <population>Safety analysis set included all randomized and non-randomized participants who were administered at least 1 dose of study treatment.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="26"/>
                <count group_id="O5" value="22"/>
                <count group_id="O6" value="25"/>
                <count group_id="O7" value="25"/>
                <count group_id="O8" value="24"/>
                <count group_id="O9" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="13"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="16"/>
                    <measurement group_id="O7" value="16"/>
                    <measurement group_id="O8" value="15"/>
                    <measurement group_id="O9" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Anti-Drug Antibody (ADA) Response</title>
        <description>Participants tested positive for ADA response on at least one post-baseline visit were reported. Participants with ADA titer level &gt;=6.23 for PF-04950615 were considered ADA positive.</description>
        <time_frame>Baseline up to Day 169</time_frame>
        <population>Safety analysis set included all randomized and non-randomized participants who were administered at least 1 dose of study treatment. This outcome measure was planned to be analyzed for all the reporting groups except for Atorvastatin + Ezetimibe 10 mg.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin + PF-04950615 50 mg</title>
            <description>Participants with fasting lipoprotein cholesterol (LDL-C) level (greater than or equal to [&gt;=]100 milligram per deciliter [mg/dL]) received atorvastatin along with PF-04950615 50 milligram (mg) subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin + PF-04950615 100 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 100 mg subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin + PF-04950615 150 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 150 mg subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O4">
            <title>Atorvastatin + PF-04950615 Placebo</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 placebo subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O5">
            <title>PF-04950615 50 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 50 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O6">
            <title>PF-04950615 100 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 100 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O7">
            <title>PF-04950615 150 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 150 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O8">
            <title>PF-04950615 Placebo</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 placebo, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naive to a treatment by lipid lowering drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Anti-Drug Antibody (ADA) Response</title>
          <description>Participants tested positive for ADA response on at least one post-baseline visit were reported. Participants with ADA titer level &gt;=6.23 for PF-04950615 were considered ADA positive.</description>
          <population>Safety analysis set included all randomized and non-randomized participants who were administered at least 1 dose of study treatment. This outcome measure was planned to be analyzed for all the reporting groups except for Atorvastatin + Ezetimibe 10 mg.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="25"/>
                <count group_id="O6" value="25"/>
                <count group_id="O7" value="24"/>
                <count group_id="O8" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O5" value="13"/>
                    <measurement group_id="O6" value="16"/>
                    <measurement group_id="O7" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of PF-04950615</title>
        <description>Area under the plasma concentration time-curve from time zero to end of dosing interval (tau). This outcome measure was to be analyzed in participants who received at least 1 dose of the PF-04950615.</description>
        <time_frame>Single dose (Day 1: pre-dose, 24, 48, 72, 96, 120, 144, 168 hour (hr) post-dose), Multiple dose (Day 99: pre-dose, 24, 72, 120, 168, 336, 504, 672, 1008 hr post-dose)</time_frame>
        <population>The pharmacokinetic (PK) parameter analysis population included participants with full PK sampling in FAS who had at least 1 of the PF-04950615 PK parameters of interest. Here, ‘Number analyzed’ = Participants evaluable for this outcome measure at specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin + PF-04950615 50 mg</title>
            <description>Participants with fasting lipoprotein cholesterol (LDL-C) level (greater than or equal to [&gt;=]100 milligram per deciliter [mg/dL]) received atorvastatin along with PF-04950615 50 milligram (mg) subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin + PF-04950615 100 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 100 mg subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin + PF-04950615 150 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 150 mg subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O4">
            <title>PF-04950615 50 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 50 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O5">
            <title>PF-04950615 100 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 100 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O6">
            <title>PF-04950615 150 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 150 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of PF-04950615</title>
          <description>Area under the plasma concentration time-curve from time zero to end of dosing interval (tau). This outcome measure was to be analyzed in participants who received at least 1 dose of the PF-04950615.</description>
          <population>The pharmacokinetic (PK) parameter analysis population included participants with full PK sampling in FAS who had at least 1 of the PF-04950615 PK parameters of interest. Here, ‘Number analyzed’ = Participants evaluable for this outcome measure at specified time points.</population>
          <units>microgram*day per milliliter(mcg*day/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="11"/>
                <count group_id="O5" value="12"/>
                <count group_id="O6" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Single dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="11"/>
                    <count group_id="O5" value="12"/>
                    <count group_id="O6" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.98" spread="57"/>
                    <measurement group_id="O2" value="52.33" spread="49"/>
                    <measurement group_id="O3" value="77.11" spread="43"/>
                    <measurement group_id="O4" value="32.97" spread="42"/>
                    <measurement group_id="O5" value="51.49" spread="46"/>
                    <measurement group_id="O6" value="82.05" spread="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Multiple dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="11"/>
                    <count group_id="O6" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.54" spread="40"/>
                    <measurement group_id="O2" value="92.46" spread="127"/>
                    <measurement group_id="O3" value="242.5" spread="81"/>
                    <measurement group_id="O4" value="63.74" spread="57"/>
                    <measurement group_id="O5" value="136.6" spread="32"/>
                    <measurement group_id="O6" value="273.5" spread="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] of PF-04950615</title>
        <description>Area under the plasma concentration-time profile from time zero extrapolated to infinite time. This outcome measure was to be analyzed in participants who received at least 1 dose of the PF-04950615.</description>
        <time_frame>Multiple dose (Day 99: pre-dose, 24, 72, 120, 168, 336, 504, 672, 1008 hr post-dose)</time_frame>
        <population>The PK parameter analysis population included participants with full PK sampling in FAS who had at least 1 of the PF-04950615 PK parameters of interest. Here, number of participants analyzed (N) signifies participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin + PF-04950615 50 mg</title>
            <description>Participants with fasting lipoprotein cholesterol (LDL-C) level (greater than or equal to [&gt;=]100 milligram per deciliter [mg/dL]) received atorvastatin along with PF-04950615 50 milligram (mg) subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin + PF-04950615 100 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 100 mg subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin + PF-04950615 150 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 150 mg subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O4">
            <title>PF-04950615 50 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 50 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O5">
            <title>PF-04950615 100 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 100 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O6">
            <title>PF-04950615 150 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 150 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] of PF-04950615</title>
          <description>Area under the plasma concentration-time profile from time zero extrapolated to infinite time. This outcome measure was to be analyzed in participants who received at least 1 dose of the PF-04950615.</description>
          <population>The PK parameter analysis population included participants with full PK sampling in FAS who had at least 1 of the PF-04950615 PK parameters of interest. Here, number of participants analyzed (N) signifies participants evaluable for this outcome measure.</population>
          <units>mcg*day/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.83" spread="46"/>
                    <measurement group_id="O2" value="176.9" spread="144"/>
                    <measurement group_id="O3" value="469.5" spread="90"/>
                    <measurement group_id="O4" value="111.7" spread="63"/>
                    <measurement group_id="O5" value="237.4" spread="41"/>
                    <measurement group_id="O6" value="248.4" spread="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of PF-04950615</title>
        <description>Area under the plasma concentration-time profile from time zero to the time of the last quantifiable concentration. This outcome measure was to be analyzed in participants who received at least 1 dose of the PF-04950615.</description>
        <time_frame>Multiple dose (Day 99: pre-dose, 24, 72, 120, 168, 336, 504, 672, 1008 hr post-dose)</time_frame>
        <population>The PK parameter analysis population included participants with full PK sampling in FAS who had at least 1 of the PF-04950615 PK parameters of interest. Here, N signifies participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin + PF-04950615 50 mg</title>
            <description>Participants with fasting lipoprotein cholesterol (LDL-C) level (greater than or equal to [&gt;=]100 milligram per deciliter [mg/dL]) received atorvastatin along with PF-04950615 50 milligram (mg) subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin + PF-04950615 100 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 100 mg subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin + PF-04950615 150 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 150 mg subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O4">
            <title>PF-04950615 50 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 50 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O5">
            <title>PF-04950615 100 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 100 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O6">
            <title>PF-04950615 150 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 150 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of PF-04950615</title>
          <description>Area under the plasma concentration-time profile from time zero to the time of the last quantifiable concentration. This outcome measure was to be analyzed in participants who received at least 1 dose of the PF-04950615.</description>
          <population>The PK parameter analysis population included participants with full PK sampling in FAS who had at least 1 of the PF-04950615 PK parameters of interest. Here, N signifies participants evaluable for this outcome measure.</population>
          <units>mcg*day/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.86" spread="49"/>
                    <measurement group_id="O2" value="140.3" spread="145"/>
                    <measurement group_id="O3" value="434.2" spread="91"/>
                    <measurement group_id="O4" value="96.32" spread="65"/>
                    <measurement group_id="O5" value="220.9" spread="39"/>
                    <measurement group_id="O6" value="486.7" spread="143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Observed Plasma Concentration (Cmax) of PF-04950615</title>
        <description>This outcome measure was to be analyzed in participants who received at least 1 dose of the PF-04950615.</description>
        <time_frame>Single dose (Day 1: pre-dose, 24, 48, 72, 96, 120, 144, 168 hr post-dose), Multiple dose (Day 99: pre-dose, 24, 72, 120, 168, 336, 504, 672, 1008 hr post-dose)</time_frame>
        <population>The PK parameter analysis population included participants with full PK sampling in FAS who had at least 1 of the PF-04950615 PK parameters of interest. Here, ‘Number analyzed’ = Participants evaluable for this outcome measure at specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin + PF-04950615 50 mg</title>
            <description>Participants with fasting lipoprotein cholesterol (LDL-C) level (greater than or equal to [&gt;=]100 milligram per deciliter [mg/dL]) received atorvastatin along with PF-04950615 50 milligram (mg) subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin + PF-04950615 100 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 100 mg subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin + PF-04950615 150 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 150 mg subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O4">
            <title>PF-04950615 50 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 50 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O5">
            <title>PF-04950615 100 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 100 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O6">
            <title>PF-04950615 150 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 150 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Plasma Concentration (Cmax) of PF-04950615</title>
          <description>This outcome measure was to be analyzed in participants who received at least 1 dose of the PF-04950615.</description>
          <population>The PK parameter analysis population included participants with full PK sampling in FAS who had at least 1 of the PF-04950615 PK parameters of interest. Here, ‘Number analyzed’ = Participants evaluable for this outcome measure at specified time points.</population>
          <units>microgram per milliliter (mcg/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="11"/>
                <count group_id="O5" value="12"/>
                <count group_id="O6" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Single dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="11"/>
                    <count group_id="O5" value="12"/>
                    <count group_id="O6" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.173" spread="61"/>
                    <measurement group_id="O2" value="5.074" spread="50"/>
                    <measurement group_id="O3" value="7.382" spread="45"/>
                    <measurement group_id="O4" value="2.994" spread="44"/>
                    <measurement group_id="O5" value="4.744" spread="47"/>
                    <measurement group_id="O6" value="7.726" spread="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Multiple dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="11"/>
                    <count group_id="O6" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.197" spread="36"/>
                    <measurement group_id="O2" value="8.343" spread="119"/>
                    <measurement group_id="O3" value="21.91" spread="76"/>
                    <measurement group_id="O4" value="5.874" spread="55"/>
                    <measurement group_id="O5" value="12.22" spread="29"/>
                    <measurement group_id="O6" value="23.64" spread="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Minimum Observed Plasma Trough Concentration (Cmin) of PF-04950615</title>
        <description>This outcome measure was to be analyzed in participants who received at least 1 dose of the PF-04950615.</description>
        <time_frame>Multiple dose (Day 99: pre-dose, 24, 72, 120, 168, 336, 504, 672, 1008 hr post-dose)</time_frame>
        <population>The PK parameter analysis population included participants with full PK sampling in FAS who had at least 1 of the PF-04950615 PK parameters of interest. Here, N signifies participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin + PF-04950615 50 mg</title>
            <description>Participants with fasting lipoprotein cholesterol (LDL-C) level (greater than or equal to [&gt;=]100 milligram per deciliter [mg/dL]) received atorvastatin along with PF-04950615 50 milligram (mg) subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin + PF-04950615 100 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 100 mg subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin + PF-04950615 150 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 150 mg subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O4">
            <title>PF-04950615 50 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 50 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O5">
            <title>PF-04950615 100 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 100 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O6">
            <title>PF-04950615 150 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 150 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Minimum Observed Plasma Trough Concentration (Cmin) of PF-04950615</title>
          <description>This outcome measure was to be analyzed in participants who received at least 1 dose of the PF-04950615.</description>
          <population>The PK parameter analysis population included participants with full PK sampling in FAS who had at least 1 of the PF-04950615 PK parameters of interest. Here, N signifies participants evaluable for this outcome measure.</population>
          <units>mcg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.176" spread="65"/>
                    <measurement group_id="O2" value="4.041" spread="147"/>
                    <measurement group_id="O3" value="12.95" spread="94"/>
                    <measurement group_id="O4" value="2.858" spread="64"/>
                    <measurement group_id="O5" value="6.571" spread="40"/>
                    <measurement group_id="O6" value="13.47" spread="139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-04950615</title>
        <description>This outcome measure was to be analyzed in participants who received at least 1 dose of the PF-04950615.</description>
        <time_frame>Single dose (Day 1: pre-dose, 24, 48, 72, 96, 120, 144, 168 hour (hr) post-dose), Multiple dose (Day 99: pre-dose, 24, 72, 120, 168, 336, 504, 672, 1008 hr post-dose)</time_frame>
        <population>The PK parameter analysis population included participants with full PK sampling in FAS who had at least 1 of the PF-04950615 PK parameters of interest. Here, ‘Number analyzed’ = Participants evaluable for this outcome measure at specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin + PF-04950615 50 mg</title>
            <description>Participants with fasting lipoprotein cholesterol (LDL-C) level (greater than or equal to [&gt;=]100 milligram per deciliter [mg/dL]) received atorvastatin along with PF-04950615 50 milligram (mg) subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin + PF-04950615 100 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 100 mg subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin + PF-04950615 150 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 150 mg subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O4">
            <title>PF-04950615 50 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 50 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O5">
            <title>PF-04950615 100 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 100 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O6">
            <title>PF-04950615 150 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 150 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-04950615</title>
          <description>This outcome measure was to be analyzed in participants who received at least 1 dose of the PF-04950615.</description>
          <population>The PK parameter analysis population included participants with full PK sampling in FAS who had at least 1 of the PF-04950615 PK parameters of interest. Here, ‘Number analyzed’ = Participants evaluable for this outcome measure at specified time points.</population>
          <units>day</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="11"/>
                <count group_id="O5" value="12"/>
                <count group_id="O6" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Single dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="11"/>
                    <count group_id="O5" value="12"/>
                    <count group_id="O6" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.01" lower_limit="3.00" upper_limit="5.96"/>
                    <measurement group_id="O2" value="4.97" lower_limit="3.94" upper_limit="7.00"/>
                    <measurement group_id="O3" value="5.94" lower_limit="1.94" upper_limit="7.00"/>
                    <measurement group_id="O4" value="5.94" lower_limit="3.94" upper_limit="6.95"/>
                    <measurement group_id="O5" value="5.45" lower_limit="2.95" upper_limit="6.94"/>
                    <measurement group_id="O6" value="6.94" lower_limit="2.96" upper_limit="14.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Multiple dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="11"/>
                    <count group_id="O6" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.03" lower_limit="2.92" upper_limit="6.98"/>
                    <measurement group_id="O2" value="2.98" lower_limit="1.00" upper_limit="4.97"/>
                    <measurement group_id="O3" value="2.97" lower_limit="0.964" upper_limit="4.99"/>
                    <measurement group_id="O4" value="2.99" lower_limit="0.985" upper_limit="7.06"/>
                    <measurement group_id="O5" value="2.98" lower_limit="0.988" upper_limit="4.98"/>
                    <measurement group_id="O6" value="4.98" lower_limit="2.97" upper_limit="7.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Elimination Half-Life (t1/2) of PF-04950615</title>
        <description>Terminal elimination half-life is the time measured for the plasma concentration to decrease by one half. This outcome measure was to be analyzed in participants who received at least 1 dose of the PF-04950615.</description>
        <time_frame>Multiple dose (Day 99: pre-dose, 24, 72, 120, 168, 336, 504, 672, 1008 hr post-dose)</time_frame>
        <population>The PK parameter analysis population included participants with full PK sampling in FAS who had at least 1 of the PF-04950615 PK parameters of interest. Here, N signifies participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin + PF-04950615 50 mg</title>
            <description>Participants with fasting lipoprotein cholesterol (LDL-C) level (greater than or equal to [&gt;=]100 milligram per deciliter [mg/dL]) received atorvastatin along with PF-04950615 50 milligram (mg) subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin + PF-04950615 100 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 100 mg subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin + PF-04950615 150 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 150 mg subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O4">
            <title>PF-04950615 50 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 50 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O5">
            <title>PF-04950615 100 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 100 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O6">
            <title>PF-04950615 150 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 150 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Elimination Half-Life (t1/2) of PF-04950615</title>
          <description>Terminal elimination half-life is the time measured for the plasma concentration to decrease by one half. This outcome measure was to be analyzed in participants who received at least 1 dose of the PF-04950615.</description>
          <population>The PK parameter analysis population included participants with full PK sampling in FAS who had at least 1 of the PF-04950615 PK parameters of interest. Here, N signifies participants evaluable for this outcome measure.</population>
          <units>day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.716" spread="1.7594"/>
                    <measurement group_id="O2" value="9.471" spread="2.2889"/>
                    <measurement group_id="O3" value="10.56" spread="1.5934"/>
                    <measurement group_id="O4" value="9.404" spread="2.1454"/>
                    <measurement group_id="O5" value="9.570" spread="2.2338"/>
                    <measurement group_id="O6" value="9.333" spread="2.7535"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)</title>
        <description>Concentration versus time summary was calculated by setting concentration values below the lower limit of quantification (LLQ =6.99 nanogram per milliliter [ng/mL]) to zero. Summary statistics were not to be presented if number of observations above lower limit of quantification (NALQ) =0. Here, 'Number analyzed' = Participants evaluable for this outcome measure at specified time points.</description>
        <time_frame>Day 1, 5, 8, 15, 22, 29, 36, 43, 50, 57, 71, 85, 99, 106, 113, 127, 141</time_frame>
        <population>PK concentration population included participants in FAS who have at least 1 concentration of either PF-04950615, PCSK9 or atorvastatin or its active metabolites. This outcome measure was planned to be analyzed for all the reporting groups except for Atorvastatin + Ezetimibe 10 mg.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin + PF-04950615 50 mg</title>
            <description>Participants with fasting lipoprotein cholesterol (LDL-C) level (greater than or equal to [&gt;=]100 milligram per deciliter [mg/dL]) received atorvastatin along with PF-04950615 50 milligram (mg) subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin + PF-04950615 100 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 100 mg subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin + PF-04950615 150 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 150 mg subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O4">
            <title>Atorvastatin + PF-04950615 Placebo</title>
            <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 placebo subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
          </group>
          <group group_id="O5">
            <title>PF-04950615 50 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 50 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O6">
            <title>PF-04950615 100 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 100 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O7">
            <title>PF-04950615 150 mg</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 150 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
          </group>
          <group group_id="O8">
            <title>PF-04950615 Placebo</title>
            <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 placebo, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naive to a treatment by lipid lowering drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)</title>
          <description>Concentration versus time summary was calculated by setting concentration values below the lower limit of quantification (LLQ =6.99 nanogram per milliliter [ng/mL]) to zero. Summary statistics were not to be presented if number of observations above lower limit of quantification (NALQ) =0. Here, 'Number analyzed' = Participants evaluable for this outcome measure at specified time points.</description>
          <population>PK concentration population included participants in FAS who have at least 1 concentration of either PF-04950615, PCSK9 or atorvastatin or its active metabolites. This outcome measure was planned to be analyzed for all the reporting groups except for Atorvastatin + Ezetimibe 10 mg.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="26"/>
                <count group_id="O5" value="25"/>
                <count group_id="O6" value="25"/>
                <count group_id="O7" value="24"/>
                <count group_id="O8" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="25"/>
                    <count group_id="O6" value="24"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="266.64" spread="61.5494"/>
                    <measurement group_id="O2" value="261.23" spread="72.3625"/>
                    <measurement group_id="O3" value="285.96" spread="75.7940"/>
                    <measurement group_id="O4" value="269.19" spread="66.8377"/>
                    <measurement group_id="O5" value="228.80" spread="49.9983"/>
                    <measurement group_id="O6" value="215.50" spread="43.0086"/>
                    <measurement group_id="O7" value="234.42" spread="77.5410"/>
                    <measurement group_id="O8" value="210.22" spread="48.5536"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="23"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="25"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2292.2" spread="676.414"/>
                    <measurement group_id="O2" value="2152.6" spread="451.749"/>
                    <measurement group_id="O3" value="1997.7" spread="563.722"/>
                    <measurement group_id="O4" value="291.77" spread="65.8011"/>
                    <measurement group_id="O5" value="1952.5" spread="527.661"/>
                    <measurement group_id="O6" value="1775.4" spread="531.225"/>
                    <measurement group_id="O7" value="1712.0" spread="458.574"/>
                    <measurement group_id="O8" value="240.41" spread="63.093"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="25"/>
                    <count group_id="O6" value="23"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2711.2" spread="614.649"/>
                    <measurement group_id="O2" value="2701.9" spread="568.958"/>
                    <measurement group_id="O3" value="2539.5" spread="587.196"/>
                    <measurement group_id="O4" value="292.19" spread="62.5108"/>
                    <measurement group_id="O5" value="2490.4" spread="573.777"/>
                    <measurement group_id="O6" value="2297.7" spread="521.003"/>
                    <measurement group_id="O7" value="2306.7" spread="594.409"/>
                    <measurement group_id="O8" value="240.22" spread="53.5842"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="25"/>
                    <count group_id="O6" value="23"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2539.8" spread="558.369"/>
                    <measurement group_id="O2" value="3198.1" spread="897.565"/>
                    <measurement group_id="O3" value="3291.9" spread="624.935"/>
                    <measurement group_id="O4" value="303.42" spread="47.9418"/>
                    <measurement group_id="O5" value="2590.6" spread="601.052"/>
                    <measurement group_id="O6" value="3030.8" spread="715.193"/>
                    <measurement group_id="O7" value="2966.7" spread="713.934"/>
                    <measurement group_id="O8" value="224.43" spread="57.6903"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="22"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="16"/>
                    <count group_id="O6" value="21"/>
                    <count group_id="O7" value="21"/>
                    <count group_id="O8" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3451.7" spread="872.597"/>
                    <measurement group_id="O2" value="3297.3" spread="701.137"/>
                    <measurement group_id="O3" value="3166.5" spread="663.295"/>
                    <measurement group_id="O4" value="295" spread="71.6996"/>
                    <measurement group_id="O5" value="3117.4" spread="582.258"/>
                    <measurement group_id="O6" value="2971.6" spread="669.215"/>
                    <measurement group_id="O7" value="2726.7" spread="616.409"/>
                    <measurement group_id="O8" value="218.82" spread="41.2647"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="23"/>
                    <count group_id="O3" value="22"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="24"/>
                    <count group_id="O6" value="23"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2844.2" spread="684.693"/>
                    <measurement group_id="O2" value="3224.8" spread="868.760"/>
                    <measurement group_id="O3" value="3419.8" spread="715.001"/>
                    <measurement group_id="O4" value="275" spread="57.6888"/>
                    <measurement group_id="O5" value="3050.0" spread="534.176"/>
                    <measurement group_id="O6" value="3095.5" spread="647.481"/>
                    <measurement group_id="O7" value="2955.6" spread="678.703"/>
                    <measurement group_id="O8" value="230.09" spread="44.1742"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="21"/>
                    <count group_id="O4" value="24"/>
                    <count group_id="O5" value="23"/>
                    <count group_id="O6" value="22"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3446.2" spread="825.704"/>
                    <measurement group_id="O2" value="3310.7" spread="732.706"/>
                    <measurement group_id="O3" value="3248.5" spread="660.213"/>
                    <measurement group_id="O4" value="304.75" spread="48.529"/>
                    <measurement group_id="O5" value="3237.0" spread="694.727"/>
                    <measurement group_id="O6" value="3011.2" spread="578.469"/>
                    <measurement group_id="O7" value="2761.4" spread="601.567"/>
                    <measurement group_id="O8" value="233.09" spread="56.7693"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="23"/>
                    <count group_id="O3" value="22"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="24"/>
                    <count group_id="O6" value="23"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2900.9" spread="653.572"/>
                    <measurement group_id="O2" value="3406.3" spread="765.437"/>
                    <measurement group_id="O3" value="3391.9" spread="717.922"/>
                    <measurement group_id="O4" value="303.54" spread="81.0823"/>
                    <measurement group_id="O5" value="3278.9" spread="693.207"/>
                    <measurement group_id="O6" value="3302.5" spread="584.658"/>
                    <measurement group_id="O7" value="3016.9" spread="772.615"/>
                    <measurement group_id="O8" value="239.13" spread="43.8782"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 50</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="22"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="24"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="22"/>
                    <count group_id="O7" value="21"/>
                    <count group_id="O8" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3394.8" spread="750.557"/>
                    <measurement group_id="O2" value="3297.2" spread="654.384"/>
                    <measurement group_id="O3" value="3230.9" spread="716.416"/>
                    <measurement group_id="O4" value="293.38" spread="66.9138"/>
                    <measurement group_id="O5" value="3148.5" spread="541.230"/>
                    <measurement group_id="O6" value="3001.3" spread="696.256"/>
                    <measurement group_id="O7" value="2820.3" spread="693.130"/>
                    <measurement group_id="O8" value="237.40" spread="68.2421"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 57</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="23"/>
                    <count group_id="O3" value="21"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="23"/>
                    <count group_id="O6" value="22"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2779.2" spread="698.727"/>
                    <measurement group_id="O2" value="3204.8" spread="699.490"/>
                    <measurement group_id="O3" value="3390.6" spread="1149.17"/>
                    <measurement group_id="O4" value="277.69" spread="70.6132"/>
                    <measurement group_id="O5" value="2910.6" spread="531.493"/>
                    <measurement group_id="O6" value="3026.4" spread="708.490"/>
                    <measurement group_id="O7" value="2791.9" spread="633.717"/>
                    <measurement group_id="O8" value="220.13" spread="66.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 71</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="23"/>
                    <count group_id="O3" value="21"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="23"/>
                    <count group_id="O6" value="22"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2889.6" spread="542.831"/>
                    <measurement group_id="O2" value="3241.2" spread="724.363"/>
                    <measurement group_id="O3" value="3280.5" spread="727.932"/>
                    <measurement group_id="O4" value="285.81" spread="45.5315"/>
                    <measurement group_id="O5" value="3066.8" spread="693.445"/>
                    <measurement group_id="O6" value="3197.1" spread="575.162"/>
                    <measurement group_id="O7" value="2887.6" spread="684.734"/>
                    <measurement group_id="O8" value="355.17" spread="556.079"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="23"/>
                    <count group_id="O3" value="21"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="23"/>
                    <count group_id="O6" value="22"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2727.0" spread="635.595"/>
                    <measurement group_id="O2" value="3166.3" spread="736.216"/>
                    <measurement group_id="O3" value="3198.9" spread="827.313"/>
                    <measurement group_id="O4" value="276.31" spread="72.3396"/>
                    <measurement group_id="O5" value="2898.7" spread="551.114"/>
                    <measurement group_id="O6" value="2934.1" spread="548.311"/>
                    <measurement group_id="O7" value="2787.9" spread="812.792"/>
                    <measurement group_id="O8" value="269.61" spread="201.161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 99</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="23"/>
                    <count group_id="O6" value="22"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2915.1" spread="711.932"/>
                    <measurement group_id="O2" value="3242.9" spread="684.758"/>
                    <measurement group_id="O3" value="3259.6" spread="754.730"/>
                    <measurement group_id="O4" value="326.08" spread="78.8759"/>
                    <measurement group_id="O5" value="3119.2" spread="665.408"/>
                    <measurement group_id="O6" value="3149.3" spread="590.228"/>
                    <measurement group_id="O7" value="2918.9" spread="752.647"/>
                    <measurement group_id="O8" value="252.13" spread="72.1011"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 106</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="24"/>
                    <count group_id="O5" value="23"/>
                    <count group_id="O6" value="23"/>
                    <count group_id="O7" value="21"/>
                    <count group_id="O8" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3326.7" spread="611.790"/>
                    <measurement group_id="O2" value="3138.9" spread="604.177"/>
                    <measurement group_id="O3" value="2864.0" spread="596.757"/>
                    <measurement group_id="O4" value="283.67" spread="58.9079"/>
                    <measurement group_id="O5" value="3165.7" spread="786.665"/>
                    <measurement group_id="O6" value="2755.7" spread="549.755"/>
                    <measurement group_id="O7" value="2566.5" spread="483.133"/>
                    <measurement group_id="O8" value="242.23" spread="59.4266"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 113</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="24"/>
                    <count group_id="O5" value="23"/>
                    <count group_id="O6" value="23"/>
                    <count group_id="O7" value="19"/>
                    <count group_id="O8" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2727.3" spread="710.746"/>
                    <measurement group_id="O2" value="2919.0" spread="511.959"/>
                    <measurement group_id="O3" value="2910.3" spread="609.380"/>
                    <measurement group_id="O4" value="267.71" spread="68.1498"/>
                    <measurement group_id="O5" value="2908.4" spread="639.771"/>
                    <measurement group_id="O6" value="3009.8" spread="685.462"/>
                    <measurement group_id="O7" value="2683.9" spread="574.842"/>
                    <measurement group_id="O8" value="222.05" spread="46.0574"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 127</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="23"/>
                    <count group_id="O6" value="23"/>
                    <count group_id="O7" value="21"/>
                    <count group_id="O8" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1429.8" spread="599.406"/>
                    <measurement group_id="O2" value="2148.7" spread="1062.32"/>
                    <measurement group_id="O3" value="3030.7" spread="607.610"/>
                    <measurement group_id="O4" value="281.40" spread="95.7562"/>
                    <measurement group_id="O5" value="1778.9" spread="872.368"/>
                    <measurement group_id="O6" value="2556.0" spread="772.015"/>
                    <measurement group_id="O7" value="2769.7" spread="736.453"/>
                    <measurement group_id="O8" value="249.87" spread="63.2113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 141</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="23"/>
                    <count group_id="O6" value="23"/>
                    <count group_id="O7" value="21"/>
                    <count group_id="O8" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="736.63" spread="297.087"/>
                    <measurement group_id="O2" value="1382.8" spread="892.457"/>
                    <measurement group_id="O3" value="2851.0" spread="1373.69"/>
                    <measurement group_id="O4" value="290.16" spread="84.2168"/>
                    <measurement group_id="O5" value="1056.5" spread="545.337"/>
                    <measurement group_id="O6" value="1477.0" spread="816.342"/>
                    <measurement group_id="O7" value="2368.7" spread="1106.62"/>
                    <measurement group_id="O8" value="20.043" spread="68.7012"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Atorvastatin + PF-04950615 50 mg</title>
          <description>Participants with fasting lipoprotein cholesterol (LDL-C) level (greater than or equal to [&gt;=]100 milligram per deciliter [mg/dL]) received atorvastatin along with PF-04950615 50 milligram (mg) subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
        </group>
        <group group_id="E2">
          <title>Atorvastatin + PF-04950615 100 mg</title>
          <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 100 mg subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
        </group>
        <group group_id="E3">
          <title>Atorvastatin + PF-04950615 150 mg</title>
          <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 150 mg subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
        </group>
        <group group_id="E4">
          <title>Atorvastatin + PF-04950615 Placebo</title>
          <description>Participants with fasting LDL-C level (&gt;=100 [mg/dL]) received atorvastatin along with PF-04950615 placebo subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.</description>
        </group>
        <group group_id="E5">
          <title>Atorvastatin + Ezetimibe 10 mg QD PO</title>
          <description>Participants received Atorvastatin plus Ezetimibe 10 mg oral administration once daily for 16 week (open).</description>
        </group>
        <group group_id="E6">
          <title>PF-04950615 50 mg</title>
          <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 50 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
        </group>
        <group group_id="E7">
          <title>PF-04950615 100 mg</title>
          <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 100 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
        </group>
        <group group_id="E8">
          <title>PF-04950615 150 mg</title>
          <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 150 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naïve to a treatment by lipid lowering drug.</description>
        </group>
        <group group_id="E9">
          <title>PF-04950615 Placebo</title>
          <description>Participants with fasting LDL-C level (&gt;=130 [mg/dL]) received PF-04950615 placebo, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naive to a treatment by lipid lowering drug.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 17.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 17.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="25"/>
                <counts group_id="E7" subjects_affected="11" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="11" subjects_at_risk="24"/>
                <counts group_id="E9" subjects_affected="9" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="24"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Injection site haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="24"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="24"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ejaculation disorder</sub_title>
                <description>Gender specific adverse event.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract inflammation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

